TW202140504A - Boron-containing cyclic emissive compounds and color conversion film containing the same - Google Patents

Abstract

The present disclosure relates to novel photoluminescent complex comprising a BODIPY moiety covalently bonded to a blue light absorbing naphthalic acid derivative, and a color conversion film, a back‐light unit using the same.

Description

Boron-containing cyclic luminescent compound and color conversion film containing the boron-containing cyclic luminescent compound

The present invention relates to a compound used in a color conversion film, a backlight unit including the color conversion film, and a display device including the backlight unit.

In color reproduction, the color gamut (gamut/color gamut) is a specific complete subset of the colors available on the device (such as a TV or monitor). For example, Adobe ^TM Red, Green, and Blue (RGB) was developed to provide a wider color gamut and provide a more realistic representation of the visible colors viewed by the monitor. The Adobe™ RGB is a wide color gamut realized by using pure spectral primary colors. Color space. It is believed that devices that can provide a wider color gamut may enable the display to depict more vivid colors.

As high-definition large-screen displays become increasingly popular, the demand for higher-efficiency, thinner, and more powerful displays is also growing. The current light emitting diode (LED) is obtained by exciting a green phosphor, a red phosphor or a yellow phosphor by a blue light source to obtain a white light source. However, the current full width at half width (FWHM) of the emission peaks of the current green phosphors and red phosphors is very large, usually greater than 40 nm, which causes the green spectrum and the red spectrum to overlap and makes the color indistinguishable from the other. This overlap can lead to poor color performance and color gamut degradation.

In order to correct the color gamut degradation, a method of using a film containing quantum dots in combination with an LED has been developed. However, there are problems with the use of quantum dots. First, cadmium-based quantum dots are extremely toxic and are banned in many countries due to health and safety issues. Second, non-cadmium-based quantum dots have very low efficiency in converting blue LED light into green and red light. Third, quantum dots require expensive packaging processes to protect against moisture and oxygen. Finally, since it is difficult to control size uniformity during the production process, the cost of using quantum dots is high.

The photoluminescent composite described herein can be used to improve the contrast between distinguishable colors in televisions, computer monitors, smart devices, and any other devices that utilize color displays. The photoluminescence composite of the present invention provides a novel color conversion dye composite, which has good blue light absorbance and narrow emission bandwidth, wherein the full width at half width [FWHM] of the emission band is less than 40 nm. In some embodiments, the photoluminescent composite absorbs light having a first wavelength and emits light having a second wavelength higher than the first wavelength. The photoluminescent composite disclosed herein can be used in a light-emitting device together with a color conversion film. The color conversion film of the present invention reduces the color degradation by reducing the overlap in the chromatogram, thereby producing high-quality color performance.

Some embodiments include a photoluminescent composite, wherein the photoluminescent composite may include: a blue light absorbing moiety; a linking group including a substituted ester; and a boron dipyrromethene (BODIPY) moiety. In some embodiments, the blue light absorbing portion may include a naphthalenedicarboxylic acid derivative. In some embodiments, the linking group can covalently link the naphthalenedicarboxylic acid derivative to the BODIPY moiety. In some embodiments, the naphthalenedicarboxylic acid derivative absorbs light at the first excitation wavelength and transfers energy to the BODIPY moiety. In some embodiments, the BODIPY partially absorbs energy from the naphthalenedicarboxylic acid derivative and emits light energy at a second higher wavelength. In some embodiments, the emission quantum yield of the photoluminescent composite is greater than 80%.

In some embodiments, the photoluminescent composite may have an emission band with a full width at half width [FWHM] of at most 40 nm.

In some embodiments, the photoluminescent composite may have a Stokes shift equal to or greater than 45 nm, that is, the difference between the excitation peak of the blue absorption part and the emission peak of the BODIPY part.

。In some embodiments, the naphthalenedicarboxylic acid derivative may have the following general formula:

.

In some embodiments, X may be substituted nitrogen (NR ⁹ ). In some embodiments, X may be oxygen (O). In some embodiments, n may be an integer of 0 or 1. In some embodiments, R ⁹ may be selected from H, substituted aryl, substituted aryl linker, or substituted ester linker. In some embodiments, R ¹⁰ may be selected from H, a methyl group, a direct bond to an adjacent benzene ring to form a carbazole, or a substituted ester linker, and R ¹¹ may be H or a methyl group;

； 其中X為NR⁹ 或O；其中R⁹ 為氫、經取代之芳基、或連接基團；其中n 為0或1；其中R¹⁰ 為H、甲基、至相鄰苯環以形成咔唑的直接鍵、或連接基團；其中R¹¹ 為H、或甲基；其中該連接基團為經取代之酯基團或經取代之芳烷基；其中萘二甲酸衍生物吸收第一激發波長的光能並將能量轉移至BODIPY部分，其中該BODIPY部分吸收來自萘二甲酸衍生物的能量並發射第二更高波長的光能；並且其中該光致發光複合物具有大於80%的發射量子產率。Some embodiments include a photoluminescent composite comprising: a blue light-absorbing naphthalenedicarboxylic acid derivative; a boron dipyrromethene (BODIPY) moiety; and a linking group, wherein the linking group is naphthalene The dicarboxylic acid derivative is covalently attached to the BODIPY moiety; wherein the blue light-absorbing naphthalenedicarboxylic acid derivative is represented by the following formula:

; Wherein X is NR ⁹ or O; where R ⁹ is hydrogen, a substituted aryl group, or a linking group; where n is 0 or 1; where R ¹⁰ is H, methyl, to the adjacent benzene ring to form a carbohydrate A direct bond or linking group of an azole; wherein R ¹¹ is H or methyl; wherein the linking group is a substituted ester group or a substituted aralkyl group; wherein the naphthalenedicarboxylic acid derivative absorbs the first excitation Wavelength of light energy and transfer the energy to the BODIPY part, wherein the BODIPY part absorbs the energy from the naphthalenedicarboxylic acid derivative and emits the second higher wavelength light energy; and wherein the photoluminescent composite has greater than 80% emission Quantum yield.

Some examples include a color conversion film, wherein the color conversion film may include: a color conversion layer, wherein the color conversion layer includes a resin matrix; and at least one photoluminescent composite as described herein, the at least one photoluminescent composite The substance is dispersed in the resin matrix. In some embodiments, the thickness of the color conversion film may be between 1 µm and about 200 µm. In some embodiments, the color conversion film of the present invention can absorb blue light in the range of 400 nm to about 480 nm, and emit light in the wavelength range of 510 nm to about 560 nm. Another embodiment describes a color conversion film that can absorb blue light in the range of 400 nm to about 480 nm and emit light in the wavelength range of 575 nm to about 645 nm. In some embodiments, the color conversion film may also include a transparent substrate layer. In some embodiments, the transparent substrate layer includes two opposing surfaces, wherein the color conversion layer is disposed on one of the opposing surfaces.

Some embodiments include a method of preparing the color conversion film, the method comprising: dissolving at least one of the aforementioned photoluminescent composite and binder resin in a solvent; and applying the mixture on one of the opposite surfaces of the transparent substrate .

Some embodiments include a backlight unit including the color conversion film described herein.

Some embodiments include a display device including the backlight unit described herein.

This application provides a photoluminescent composite with excellent color gamut and light-emitting characteristics; a method for manufacturing a color conversion film using the photoluminescence composite, and a backlight unit including the color conversion film. These and other embodiments are described in more detail below.

Cross references to related applications

This application claims the rights and interests of U.S. Provisional Application No. 62/992,761 filed on March 20, 2020, and the entire content of the U.S. Provisional Application is incorporated herein by reference.

The present invention describes a photoluminescent composite and the use of the photoluminescent composite in a color conversion film. The photoluminescent composite can be used to improve and enhance the transmission with one or more desired emission bandwidths in the color conversion film. In some embodiments, the photoluminescent composite can enhance the transmission with the desired first emission bandwidth and reduce the transmission with the second emission bandwidth. For example, the color conversion film can enhance the contrast or intensity between two or more colors, thereby increasing the difference between each other. In some embodiments, a photoluminescent composite can enhance the contrast or intensity between two colors, thereby increasing the difference between them.

As used herein, when a compound or chemical structure is referred to as "substituted," it can contain one or more substituents. A substituted group is derived from an unsubstituted parent structure, wherein one or more hydrogen atoms on the parent structure have been independently replaced by one or more substituents. The substituent may have one or more substituents on the structure of the parent group. In one or more forms, the substituents can be independently selected from optionally substituted alkyl, alkenyl, or C ₃ -C ₇ heterocycloalkyl.

The term "alkyl" group as used herein refers to a hydrocarbon group without carbon-carbon double or triple bonds. The "alkene" part refers to a hydrocarbon group with at least one carbon-carbon double bond (-C=C-), and the "alkyne" part refers to a group with at least one carbon-carbon triple bond (-C≡C-) . The alkyl moiety, alkene moiety, or alkyne moiety can be branched, linear, or cyclic.

The alkyl moiety can have 1 to 6 carbon atoms (regardless of whether it appears in this document, a numerical range such as "1 to 6" refers to each integer in the given range: for example, "1 to 6 carbon atoms" It means that an alkyl group can have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms, but this definition also covers the term "alkane" without a specified numerical range. Occurrence of the group". The alkyl group of the compound specified herein may be referred to as "C ₁ -C ₆ alkyl" or similar names. For example only, "C ₁ -C ₆ alkyl" means in the alkyl chain There are one to six carbon atoms, that is, the alkyl chain is selected from methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, secondary butyl, tertiary butyl, etc. Therefore, C ₁ The -C ₆ alkyl group includes a C ₁ -C ₂ alkyl group, a C ₁ -C ₃ alkyl group, a C ₁ -C ₄ alkyl group, a C ₁ -C ₅ alkyl group. The alkyl group may be substituted or unsubstituted. Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, Cyclohexyl and so on.

Typical olefin groups include, but are not limited to, vinyl, propenyl, butenyl, and the like.

The term "aromatic" refers to a planar ring with a delocalized π electron system containing 4n+2 π electrons, where n is an integer. Aromatic rings can be formed by five, six, seven, eight, nine, or more than nine atoms. The aromatic ring may be substituted as appropriate. The term "aromatic" includes carbocyclic aryl (e.g., phenyl) and heterocyclic aryl (or "heteroaryl" or "heteroaromatic") groups (e.g., pyridine). The term includes monocyclic or fused-ring polycyclic (ie, rings that share adjacent pairs of carbon atoms) groups.

等。多環基的說明性實例包括以下部分：

[二環辛烷]、

[二環戊烷]、

[二環庚烷]、

[二環庚烷]、

[二環癸烷]、

[十氫化萘]、

[八氫并環戊二烯]、

[八氫茚]、

[六氫茚]、

[1,2,3,4-四氫化萘]、

[2,3-二氫-1H -茚]、

[1,1-二甲基-2,3-二氫-1H -茚]、或

[1,2,3,3a-四氫并環戊二烯]。The term "hydrocarbon ring" refers to a monocyclic or polycyclic group containing only carbon and hydrogen. The hydrocarbon ring can be saturated or unsaturated. The monocyclic hydrocarbon ring may have 3 to 12 carbon atoms. Illustrative examples of monocyclic groups include the following:

Wait. Illustrative examples of polycyclic groups include the following:

[Dicyclooctane],

[Dicyclopentane],

[Dicycloheptane],

[Dicycloheptane],

[Dicyclodecane],

[Decahydronaphthalene],

[Octahydrocyclopentadiene],

[Octahydroindene],

[Hexahydroindene],

[1,2,3,4-Tetrahydronaphthalene],

[2,3-Dihydro-1 H -indene],

[1,1-Dimethyl-2,3-dihydro-1 H -indene], or

[1,2,3,3a-Tetrahydrocyclopentadiene].

The term "aryl" as used herein refers to an aromatic ring in which every atom forming the ring is a carbon atom. Aromatic rings can be formed by five, six, seven, eight, or more than eight carbon atoms. Aryl groups can be substituted or unsubstituted. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, phenanthryl, and the like.

The term "aralkyl" refers to an alkyl group as defined herein substituted with an aryl group as defined herein. Non-limiting aralkyl groups include benzyl, 2-phenethyl, 3-phenylpropyl; and the like.

The term "heteroaryl" refers to an aryl group containing one or more ring heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group has 4 to 10 atoms in its ring system, provided that the group The ring of the group does not contain two adjacent oxygen or sulfur atoms. It should be understood that the heteroaromatic ring may have other heteroatoms in the ring. In a heteroaromatic ring having two or more heteroatoms, the two or more heteroatoms may be the same or different from each other. The heteroaromatic ring can be optionally substituted. The N-containing heteroaryl moiety refers to an aryl group in which at least one backbone atom of the ring is a nitrogen atom. Illustrative examples of heteroaryl groups include the following: pyrrole, imidazole, pyridine, and the like.

The term "halogen" as used herein refers to fluorine, chlorine, bromine and iodine.

As used herein, the terms "bond", "bonded", "direct bond" or "single bond" refer to the connection between or between two atoms when the atoms connected by a bond are considered part of a larger structure The chemical bond of the two parts.

The term "portion" as used herein refers to a specific segment or functional group of a molecule. A chemical moiety is often thought of as a chemical entity embedded in or attached to a molecule.

As used herein, the term "cyano" or "nitrile" refers to any organic compound containing a -CN functional group.

The term "ester" refers to a chemical moiety having the formula -COOR, where R is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded by ring carbon) and heterocycle (bonded by ring carbon) . Any hydroxyl or carboxyl side chain on the compounds described herein can be esterified. Such esters can be prepared by any suitable method, which can be easily found in cited sources.

As described herein, the term "ether" refers to a chemical moiety containing an oxygen atom connecting two alkyl or aryl groups, and its general formula is R-O-R', where the terms alkyl and aryl are as defined herein.

As used herein, the term "ketone" refers to a chemical moiety containing a carbonyl group (carbon-oxygen double bond) connecting two alkyl or aryl groups, with the general formula RC(=O)R', where the terms alkyl and aryl The base is as defined herein.

。The term "BODIPY" as used herein refers to a chemical moiety having the following formula:

.

The BODIPY moiety may consist of a dipyrromethene group complexed with a disubstituted boron atom (usually a BF _{2 unit).} The IUPAC name of BODIPY core is 4,4-difluoro-4-bora-3a,4a-diaza-s-dicyclopentacene.

The term "naphthalenedicarboxylic acid" or "naphthalenedicarboxylic acid derivative" as used herein refers to a chemical moiety having the following formula:

The use of the term "can" or "can be" should be interpreted as a shorthand for "being" or "not being", or alternatively "doing" or "not doing" or "will" or "will not" etc. Shorthand. For example, the expression "the color conversion film may further include a transparent substrate layer" should be interpreted as, for example, "in some embodiments, the color conversion film also includes a transparent substrate layer" or "in some embodiments, the color conversion film does not further include a transparent substrate layer." Floor".

The present invention relates to a photoluminescence composite that absorbs light energy at a first wavelength and emits light energy at a second, higher wavelength. The photoluminescence composite of the present invention includes an absorbing light-emitting portion and an emitting light-emitting portion, and the absorbing light-emitting portion and the emitting light-emitting portion are connected by a linking group, so that their energy is adjusted for the absorbing light-emitting portion to transfer its energy to the acceptor light-emitting portion Distance in which the light-emitting portion of the acceptor then emits at a second wavelength greater than the first wavelength absorbed.

In some embodiments, the photoluminescent composite comprises: a blue light-absorbing naphthalenedicarboxylic acid derivative; a linking group; and a boron dipyrromethene (BODIPY) moiety. In some embodiments, the linking group can covalently link the naphthalenedicarboxylic acid derivative to the BODIPY moiety. In some embodiments, the naphthalenedicarboxylic acid derivative absorbs the light of the first excitation wavelength and transfers the energy to the BODIPY part, and then the BODIPY part emits light energy of a second wavelength, wherein the light energy of the second wavelength is higher than the light energy of the first wavelength. One wavelength. It is believed that the energy transfer from the excited naphthalene dicarboxylic acid derivative to the BODIPY moiety occurs through Forster resonance energy transfer (FRET). This idea is due to the absorption/emission spectrum of the photoluminescent complex, in which there are two main absorption bands, one at the blue absorption band (naphthalene dicarboxylic acid derivative) and one at the BODIPY absorption band, And only one emission band is located at the emission wavelength of the BODIPY part (see Figure 1 and Figure 2).

In one embodiment, the photoluminescent composite may have a high emission quantum yield. In some embodiments, the emission quantum yield may be greater than 50%, 60%, 70%, 80%, or 90%, up to 100%. In some embodiments, the emission quantum yield may be greater than 50%, or 55%, or 60%, or 65%, or 70%, or 75%, or 80%, or 85%, or 90%, or 95% , Up to 100%, 50-60%, 60-70%, 70-80%, 80-90%, 90-100%. The emission quantum yield can be measured by dividing the number of emitted photons by the number of absorbed photons, which is equivalent to the emission efficiency of the light-emitting part. In some embodiments, the emission quantum yield of the absorbing light-emitting part may be greater than 80%. In some embodiments, the quantum yield may be greater than 0.8 (80%), greater than 0.81 (81%), greater than 0.82 (82%), greater than 0.83 (83%), greater than 0.84 (84%), greater than 0.85 (85%) ), greater than 0.86 (86%), greater than 0.87 (87%), greater than 0.88 (88%), greater than 0.89 (89%), greater than 0.9 (90%), greater than 0.91 (91%), greater than 0.92 (92%) , Greater than 0.93 (93%), greater than 0.94 (94%), or greater than 0.95 (95%). The quantum yield in the film can be measured by a spectrophotometer, such as a Quantaurus-QY spectrophotometer (Humamatsu, Inc., Campbell, CA, USA).

In some embodiments, the photoluminescent composite has an emission band, which may have a full width at half width (FWHM) less than 40 nm. FWHM is the width (in nanometers) of the emission band at half the maximum emission intensity of the band. In some embodiments, the photoluminescent composite has an emission band FWHM value less than or equal to about 35 nm, less than or equal to about 30 nm, less than or equal to about 25 nm, or less than or equal to about 20 nm.

In some embodiments, the Stokes shift of the photoluminescent composite may be equal to or greater than 45 nm. As used herein, the term "Stokes shift" refers to the distance between the excitation peak of the blue absorption part and the emission peak of the BODIPY part.

The photoluminescent composite of the present invention may have a tunable emission wavelength. By substituting different substituents for the BODIPY moiety, the emission wavelength can be tuned between 510 nm and about 560 nm, or between about 610 nm and about 645 nm, or roughly any of these equivalent values. Any wavelength within the range defined by the value.

In some embodiments, the blue absorbing portion may have a peak absorption maximum between about 400 nm and about 470 nm wavelength. In some embodiments, the peak absorption may be at about 400 nm to about 405 nm, about 405 nm to about 410 nm, about 410 nm to about 415 nm, about 415 nm to about 420 nm, about 420 nm to about 425 nm, About 425 nm to about 430 nm, about 430 nm to about 435 nm, about 435 nm to about 440 nm, about 440 nm to about 445 nm, about 445 nm to about 450 nm, about 450 nm to about 455 nm, about 455 nm to about 460 nm, about 460 nm to about 465 nm, about 465 nm to about 470 nm, or approximately any wavelength within the range defined by any of these equivalent values.

In some embodiments, the photoluminescent composite may have an emission peak between 510 nm and 560 nm. In some embodiments, the emission peak may be between about 510 nm to about 515 nm, about 515 nm to about 520 nm, about 520 nm to about 525 nm, about 525 nm to about 530 nm, and about 530 nm to about 535 nm. Between about 535 nm to about 540 nm, about 540 nm to about 545 nm, about 545 nm to about 550 nm, about 550 nm to about 555 nm, about 555 nm to about 560 nm, or roughly the same Any wavelength within the range defined by any of the values.

In another embodiment, the photoluminescent composite may have an emission peak between 610 nm and 645 nm. In some embodiments, the emission peak may be between 610 nm to about 615 nm, about 615 nm to about 620 nm, about 620 nm to about 625 nm, about 625 nm to about 630 nm, about 630 nm to about 635 nm, Between about 635 nm and about 640 nm, between about 640 nm and about 645 nm, or roughly any wavelength within the range defined by any of these equivalent values.

Other embodiments include photoluminescent composites in which the spatial distance between the blue light-absorbing naphthalenedicarboxylic acid derivative and the BODIPY moiety is tuned by a linking group for transferring the energy of the blue light-absorbing naphthalenedicarboxylic acid derivative to the BODIPY moiety.

The present invention describes a photoluminescent composite, wherein the photoluminescent composite may include a blue light-absorbing naphthalenedicarboxylic acid derivative; a linking group; and a BODIPY moiety. The linking group covalently links the blue light-absorbing naphthalenedicarboxylic acid derivative to the BODIPY moiety. In some embodiments, the naphthalenedicarboxylic acid derivative absorbs light energy at a first excitation wavelength and transfers energy to the BODIPY moiety, wherein the BODIPY moiety absorbs the energy from the naphthalenedicarboxylic acid derivative and emits a second higher Wavelength of light energy; and wherein the emission quantum yield of the photoluminescent composite is greater than 80%.

， 其中X可為NR⁹ 或O；n 為0或1；R⁹ 為H、經取代之芳基、經取代之芳基連接基、或經取代之酯連接基；R¹⁰ 為H、甲基、至相鄰苯環以形成咔唑的直接鍵、或經取代之酯連接基；並且R¹¹ 為H或甲基。Some embodiments include a blue light absorbing naphthalenedicarboxylic acid derivative, wherein the blue light absorbing naphthalenedicarboxylic acid derivative may have the following general formula:

, Where X can be NR ⁹ or O; n is 0 or 1; R ⁹ is H, substituted aryl, substituted aryl linker, or substituted ester linker; R ¹⁰ is H, methyl , To the adjacent benzene ring to form a direct bond of carbazole, or a substituted ester linking group; and R ¹¹ is H or methyl.

In some embodiments, X is NR ⁹ . In some embodiments, X is O.

In some embodiments, n is zero. In some embodiments, n is 1.

In some embodiments, R ⁹ is substituted H. In some embodiments, R ⁹ is substituted phenyl. In some embodiments, R ⁹ is a linking group.

In some embodiments, R ¹⁰ is methyl. In some embodiments, R ¹⁰ is H. In some embodiments, R ¹⁰ is a linking group. In some embodiments, R ¹⁰ is a direct bond to the adjacent benzene ring to form a carbazole.

In some embodiments, R ¹¹ is methyl. In some embodiments, R ¹¹ is H.

In some embodiments, X can be NR ⁹ , n can be 0, R ⁹ can be a substituted ester linker, R ¹⁰ can be H, and R ¹¹ can be H.

In some embodiments, X can be NR ⁹ , n can be 1, R ⁹ can be a substituted ester linker, R ¹⁰ can be H, and R ¹¹ can be H.

In some embodiments, X can be NR ⁹ , n can be 1, R ⁹ can be a substituted ester linker, R ¹⁰ can be a methyl group, and R ¹¹ can be a methyl group.

In some embodiments, X may be NR ⁹ , n may be 1, R ⁹ may be a substituted ester linker, R ¹⁰ may be a direct bond to the adjacent benzene ring to form a carbazole, and R ¹¹ may For H.

In some embodiments, X can be NR ⁹ , n can be 0, R ⁹ can be a substituted aryl group, R ¹⁰ can be a substituted ester linker, and R ¹¹ can be H.

In some embodiments, X can be NR ⁹ , n can be 1, R ⁹ can be an aralkyl linker, R ¹⁰ can be H, and R ¹¹ can be H.

In some embodiments, X can be O, n can be 1, R ¹⁰ can be a substituted ester linker, and R ¹¹ can be H.

。In some embodiments, R ⁹ is a substituted aryl group, wherein the substituted aryl group can be

.

Those familiar with the art will also recognize that the R ¹⁰ and R ¹¹ substituents can be substituted at any position on their corresponding benzene ring. Although the structural formula provided herein can describe one of many possible positional isomers, it should be understood that these structures are only illustrative, and the present invention is not limited to any specific isomeric state, and naphthalene dicarboxylic acid derivatives Any and all possible positional isomers of are intended to fall within the scope of the present invention.

In some embodiments, the linking group covalently connects the blue light-absorbing naphthalenedicarboxylic acid derivative and the BODIPY moiety. The linking group can be changed to adjust the spatial distance between the blue light-absorbing naphthalenedicarboxylic acid derivative and the BODIPY moiety. By optimizing the spatial distance between the naphthalenedicarboxylic acid derivative and the BODIPY part, the quantum yield can be tuned.

。In some embodiments, L may represent a linking group. The linking group may include a substituted ester linking group. The substituted ester linker can include one of the following structures:

.

。In some embodiments, the linking group may include a substituted aralkyl linking group. In some embodiments, the substituted aralkyl linking group can be

.

， 其中R¹ 和R⁶ 獨立地為氫(H)、烷基、烯基、或炔基； R³ 和R⁴ 獨立地為H或C₁ -C₂ 烷基； R² 和R⁵ 獨立地為氫(H)、烷基、烯基、炔基、氰基(-CN)、酯(-COOCH₂ CH₃ )、或芳基酯(-COOCH₂ Ar)； R² 和R³ 可以連接在一起以形成另一單環烴環結構或多環烴環結構； R⁴ 和R⁵ 可以連接在一起以形成另一單環烴環結構或多環烴環結構； G⁷ 可為以下結構的芳烷基連接基、或經取代之芳基部分：

； R⁷ 和R⁸ 獨立地為H、甲基、氟、氯、或烷氧基(例如甲氧基)；並且 L表示連接基團。The photoluminescent composite of the present invention may include a BODIPY moiety. The BODIPY part may have the following chemical formula:

, Wherein R ¹ and R ^{6 are} independently hydrogen (H), alkyl, alkenyl, or alkynyl; R ³ and R ^{4 are} independently H or C ₁ -C ₂ alkyl; R ² and R ^{5 are} independently Is hydrogen (H), alkyl, alkenyl, alkynyl, cyano (-CN), ester (-COOCH ₂ CH ₃ ), or aryl ester (-COOCH ₂ Ar); R ² and R ³ can be connected to Together to form another monocyclic hydrocarbon ring structure or polycyclic hydrocarbon ring structure; R ⁴ and R ⁵ can be joined together to form another monocyclic hydrocarbon ring structure or polycyclic hydrocarbon ring structure; G ⁷ may be an aromatic of the following structure Alkyl linker, or substituted aryl moiety:

; R ⁷ and R ^{8 are} independently H, methyl, fluorine, chlorine, or alkoxy (for example, methoxy); and L represents a linking group.

In some embodiments, R ¹ is methyl. In some embodiments, R ¹ is H.

In some embodiments, R ³ is methyl. In some embodiments, R ³ is H.

In some embodiments, R ⁴ is methyl. In some embodiments, R ⁴ is H.

In some embodiments, R ⁶ is methyl. In some embodiments, R ⁶ is H.

In some embodiments, R ¹ , R ³ , R ⁴ and R ⁶ are all methyl groups.

In some embodiments, R ² is cyano. In some embodiments, R ² is an alkyl ester or an aryl ester. In some embodiments, R ² is an aryl ester. In some embodiments, R ² is an alkyl ester.

In some embodiments, R ⁵ is cyano. In some embodiments, R ⁵ is an alkyl ester or an aryl ester. In some embodiments, R ⁵ is an aryl ester. In some embodiments, R ⁵ is an alkyl ester.

In some embodiments, R ² and R ⁵ are both cyano. In some embodiments, R ² and R ⁵ are alkyl esters or aryl esters. In some embodiments, R ² and R ⁵ are aryl esters. In some embodiments, R ² and R ⁵ are alkyl esters.

In some embodiments, R ¹ and R ^{2 are} joined together to form a polycyclic hydrocarbon ring structure.

In some embodiments, R ⁵ and R ^{6 are} joined together to form a polycyclic hydrocarbon ring structure.

In some embodiments, R ⁷ is H, methyl, halo, or methoxy. In some embodiments, R ⁷ is methyl, fluorine, chlorine, or methoxy. In some embodiments, R ⁷ is methyl.

In some embodiments, R ⁸ is H, methyl, halo, or methoxy. In some embodiments, R ⁸ is methyl, fluorine, chlorine, or methoxy. In some embodiments, R ⁸ is methyl.

In some embodiments, R ⁷ and R ⁸ are H, methyl, halo, or methoxy. In some embodiments, R ⁷ and R ^{8 are} independently methyl, fluoro, chloro, or methoxy. In some embodiments, R ⁷ and R ⁸ are both methyl.

The BODIPY part of the present invention may be the following BODIPY part, wherein R ¹ , R ³ , R ⁴ and R ⁶ are each a methyl group; R ² and R ⁵ are both cyano ^{groups; R 7} and R ⁸ are each a methyl group; and G ⁷ Contains a substituted aryl moiety containing a substituted ester linker.

In some embodiments, the BODIPY portion of the present invention may be the following BODIPY portion, wherein R ¹ , R ³ , R ⁴ and R ⁶ are each a methyl group; R ² and R ⁵ are both substituted ester groups, wherein the The substituted ester group contains an alkyl chain; R ⁷ and R ⁸ are each methyl; and G ⁷ contains a substituted aryl moiety containing a substituted ester linker.

In some embodiments, R ¹ , R ³ , R ⁴ and R ⁶ are each a methyl group; R ² and R ⁵ are both substituted ester groups, wherein the substituted ester group contains an aryl group; R ⁷ And R ⁸ are each selected from methyl, fluorine, chlorine, or alkoxy; and G ⁷ includes a substituted aryl moiety containing a substituted ester linker.

In some embodiments, R ¹ and R ² can be connected together to form a polycyclic hydrocarbon ring structure; R ³ and R ⁴ are both methyl; R ⁵ and R ⁶ can be connected together to form a polycyclic hydrocarbon ring structure; R ⁷ and R ⁸ may be selected from H, methyl, or alkoxy; and G ⁷ includes a substituted aryl moiety containing a substituted ester linker.

。In some embodiments, R ² and R ⁵ may be substituted esters, where the substituted ester is an aryl ester. The aryl ester may have the following structure:

.

。In some embodiments, R ² and R ⁵ may be substituted esters, wherein the substituted ester is an alkyl ester. The alkyl ester may have the following structure:

.

， 其中R¹ 和R² 可以連接在一起以形成另一單環烴環結構或多環烴環結構； R³ 和R⁴ 可為H； R⁵ 和R⁶ 可以連接在一起以形成另一單環烴環結構或多環烴環結構； R⁷ 和R⁸ 可以獨立地為H、鹵基、甲基、或烷氧基；並且 L代表連接基團，該連接基團包含經取代之酯連接基。The photoluminescent composite of the present invention may include a BODIPY moiety. The BODIPY part may have the following chemical formula:

, Wherein R ¹ and R ² can be joined together to form another monocyclic hydrocarbon ring structure or a polycyclic hydrocarbon ring structure; R ³ and R ⁴ can be H; R ⁵ and R ⁶ can be joined together to form another single Cyclic hydrocarbon ring structure or polycyclic hydrocarbon ring structure; R ⁷ and R ⁸ may independently be H, halo, methyl, or alkoxy; and L represents a linking group that includes a substituted ester link base.

[環丁烷]、

[環戊烷]、

[環己烷]、

[環庚烷]、

[環辛烷]、

[環己烯]、

[環己-1,4-二烯]、

[環戊烯]、

[環己-1,3二烯]、或

[環十二烷]。在一些實施例中，在R¹ 和R² 連接在一起以形成多環烴環結構的情況下，該結構可選自以下：

[二環辛烷]、

[二環戊烷]、

[二環庚烷]、

{二環[4.1.0]庚烷]、

[1s,5s二環[3.3.1]壬烷]、

[十氫化萘]、

[八氫并環戊二烯]、

[八氫茚]、

[六氫茚]、

[1,2,3,4-四氫化萘]、

[2,3-二氫-1H -茚]、

[1,1-二甲基-2,3-二氫-1H -茚]、或

[1,2,3,3a-四氫并環戊二烯]。In some embodiments, R ¹ and R ² may be joined together to form another monocyclic hydrocarbon ring structure or a polycyclic hydrocarbon ring structure. In an embodiment, in the case where R ¹ and R ^{2 are} connected together to form a monocyclic hydrocarbon ring structure, the structure may be selected from the following:

[Cyclobutane],

[Cyclopentane],

[Cyclohexane],

[Cycloheptane],

[Cyclooctane],

[Cyclohexene],

[Cyclohexa-1,4-diene],

[Cyclopentene],

[Cyclohexa-1,3diene], or

[Cyclododecane]. In some embodiments, where R ¹ and R ^{2 are} connected together to form a polycyclic hydrocarbon ring structure, the structure may be selected from the following:

[Dicyclooctane],

[Dicyclopentane],

[Dicycloheptane],

{Bicyclo[4.1.0]heptane],

[1s,5s bicyclo[3.3.1]nonane],

[Decahydronaphthalene],

[Octahydrocyclopentadiene],

[Octahydroindene],

[Hexahydroindene],

[1,2,3,4-Tetrahydronaphthalene],

[2,3-Dihydro-1 H -indene],

[1,1-Dimethyl-2,3-dihydro-1 H -indene], or

[1,2,3,3a-Tetrahydrocyclopentadiene].

[環丁烷]、

[環戊烷]、

[環己烷]、

[環庚烷]、

[環辛烷]、

[環己烯]、

[環己-1,4二烯]、

[環戊烯]、

[環己-1,3二烯]、或

[環十二烷]。在一些實施例中，在R⁵ 和R⁶ 連接在一起以形成多環烴環結構的情況下，該結構可選自以下：

[二環辛烷]、

[二環戊烷]、

[二環庚烷]、

[二環[4.1.0]庚烷]、

[1s,5s二環[3.3.1]壬烷]、

[十氫化萘]、

[八氫并環戊二烯]、

[八氫茚]、

[六氫茚]、

[1,2,3,4-四氫化萘]、

[2,3-二氫-1H -茚]、

[1,1-二甲基-2,3-二氫-1H -茚]、或

[1,2,3,3a-四氫并環戊二烯]。In some embodiments, R ⁵ and R ⁶ may be joined together to form another monocyclic hydrocarbon ring structure or a polycyclic hydrocarbon ring structure. In some embodiments, where R ⁵ and R ^{6 are} connected together to form a monocyclic hydrocarbon ring structure, the structure may be selected from the following:

[Cyclobutane],

[Cyclopentane],

[Cyclohexane],

[Cycloheptane],

[Cyclooctane],

[Cyclohexene],

[Cyclohexa-1,4-diene],

[Cyclopentene],

[Cyclohexa-1,3diene], or

[Cyclododecane]. In some embodiments, where R ⁵ and R ^{6 are} connected together to form a polycyclic hydrocarbon ring structure, the structure may be selected from the following:

[Dicyclooctane],

[Dicyclopentane],

[Dicycloheptane],

[Bicyclo[4.1.0]heptane],

[1s,5s bicyclo[3.3.1]nonane],

[Decahydronaphthalene],

[Octahydrocyclopentadiene],

[Octahydroindene],

[Hexahydroindene],

[1,2,3,4-Tetrahydronaphthalene],

[2,3-Dihydro-1 H -indene],

[1,1-Dimethyl-2,3-dihydro-1 H -indene], or

[1,2,3,3a-Tetrahydrocyclopentadiene].

In some embodiments, the distance separating the blue light-absorbing naphthalenedicarboxylic acid derivative and the BODIPY moiety may be about 8 Å or more. The linking group can maintain the required distance between the blue light-absorbing naphthalenedicarboxylic acid derivative and the BODIPY moiety.

。In some embodiments, the photoluminescent composite includes a linking group, wherein the linking group covalently links the blue light-absorbing naphthalenedicarboxylic acid derivative to the BODIPY moiety. In some embodiments, the linking group may include an optionally substituted C ₂ -C ₁₆ ester group. When the linking group includes a substituted ester group, the linking group can be selected from one of the following:

.

，其中R¹ -R⁶ 如上所述，並且其中L'可為芳烷基連接基。在一些實施例中，該芳烷基連接基可為

。In some embodiments, the BODIPY portion may have the following chemical formula:

, Wherein R ¹ -R ^{6 are} as described above, and wherein L'may be an aralkyl linking group. In some embodiments, the aralkyl linking group can be

.

。The photoluminescent composite of the present invention can be represented by the following structure, which is provided for illustrative purposes and in no way should be construed as limiting:

.

In some embodiments, the photoluminescent composite comprises a blue light absorbing naphthalenedicarboxylic acid derivative. The blue light-absorbing naphthalenedicarboxylic acid derivative may include an organic luminescent group. In some embodiments, the naphthalene dicarboxylic acid derivative can be used in the range of 400 nm to about 480 nm, about 400 nm to about 410 nm, about 410 nm to about 420 nm, about 420 nm to about 430 nm, and about 430 nm to about 430 nm. In the range of about 440 nm, about 440 nm to about 450 nm, about 450 nm to about 460 nm, about 460 nm to about 470 nm, about 470 nm to about 480 nm, or a range defined by any of these values The light within roughly any wavelength has the maximum absorbance. In some embodiments, the maximum absorbance peak of the photoluminescent composite may be about 450 nm. In other embodiments, the blue light-absorbing naphthalenedicarboxylic acid derivative may have a maximum peak absorbance of about 405 nm. In other embodiments, the blue light-absorbing naphthalenedicarboxylic acid derivative may have a maximum peak absorbance of about 480 nm.

Some embodiments include a color conversion film, wherein the color conversion film includes: a color conversion layer, wherein the color conversion layer includes a resin matrix and the photoluminescence composite as described above, and the photoluminescence composite is dispersed in the resin matrix Inside. In some embodiments, the color conversion film can be described as comprising one or more of the composites described herein.

In some embodiments, the color conversion film may be about 1 µm to about 200 µm thick, about 1 µm to about 5 µm thick, about 5 µm to about 10 µm thick, about 10 µm to about 15 µm thick, about 15 µm To about 20 µm thick, about 20 µm to about 40 µm thick, about 40 µm to about 80 µm thick, about 80 µm to about 120 µm thick, about 120 µm to about 160 µm thick, about 160 µm to about 200 µm thick , Or roughly any thickness within the range defined by any of these equivalent values.

In some embodiments, the color conversion film may absorb light in a wavelength range of 400 nm to about 480 nm, and may emit light in a range of about 510 nm to about 560 nm and/or about 610 nm to about 645 nm. In other embodiments, the color conversion film may emit light in a range of 510 nm to about 560 nm, a range of 610 nm to about 645 nm, or any combination thereof.

In some embodiments, the color conversion film may also include a transparent substrate layer. The transparent substrate layer may have two opposing surfaces, wherein the color conversion layer may be disposed on the surface of the transparent layer that will be adjacent to the light-emitting source and be in physical contact with the surface. There is no particular limitation on the transparent substrate, and those skilled in the art will be able to select a transparent substrate from those transparent substrates used in the art. Some non-limiting examples of transparent substrates include PE (polyethylene), PP (polypropylene), PEN (polyethylene naphthalate), PC (polycarbonate), PMA (polymethyl acrylate), PMMA ( Polymethyl methacrylate), CAB (cellulose acetate butyrate), PVC (polyvinyl chloride), PET (polyethylene terephthalate), PETG (ethylene glycol modified polyethylene terephthalate) Glycol formate), PDMS (polydimethylsiloxane), COC (cycloolefin copolymer), PGA (polyglycolide or polyglycolic acid), PLA (polylactic acid), PCL (polycaprolactone) ), PEA (polyethylene adipate), PHA (polyhydroxyalkanoate), PHBV (poly(3-hydroxybutyrate-co-poly-3-hydroxyvalerate)), PBE (poly Butylene phthalate), PTT (polytrimethylene terephthalate). Any of the aforementioned resins may be corresponding/corresponding monomers and/or polymers.

In some embodiments, the transparent substrate may have two opposite surfaces. In some embodiments, the color conversion film may be disposed on and in physical contact with one of the opposing surfaces. In some embodiments, the side on which the color conversion film is not provided on the transparent substrate may be adjacent to the light source. The substrate can be used as a support during the preparation of the color conversion film. There is no particular limitation on the type of substrate used, and there is no limitation on the material and/or thickness, as long as the substrate is transparent and can be used as a support. Those skilled in the art can determine which material and thickness to use as the supporting substrate.

Some embodiments include a method for preparing a color conversion film, wherein the method includes: dissolving the photoluminescent compound and the binder resin described herein in a solvent; and applying the mixture to the surface of the transparent substrate.

Binder resins that can be used with the photoluminescent composite include, for example, the following resins: acrylic resins, polycarbonate resins, ethylene-vinyl alcohol copolymer resins, ethylene-vinyl acetate copolymer resins and their saponification products, AS resins, Polyester resin, vinyl chloride-vinyl acetate copolymer resin, polyvinyl butyral resin, polyvinyl phosphonic acid (PVPA), polystyrene resin, phenolic resin, phenoxy resin, polyvinyl, nylon, fiber Plain resin and cellulose acetate resin. In some embodiments, the binder resin may be polyester resin and/or acrylic resin.

Solvents that can be used to dissolve or disperse compounds and resins can include alkanes, such as butane, pentane, hexane, heptane, and octane; cycloalkanes, such as cyclopentane, cyclohexane, cycloheptane, and cyclooctane ; Alcohols, such as ethanol, propanol, butanol, pentanol, hexanol, heptanol, octanol, decanol, undecyl alcohol, diacetone alcohol and furfuryl alcohol; Cellosolves™, such as methyl Cellosolve™, ethyl Cellosolve™ , Butyl Cellosolve™, Methyl Cellosolve™ Acetate and Ethyl Cellosolve™ Acetate; Propylene glycol and its derivatives, such as propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monobutyl ether, propylene glycol monomethyl ether acetate , Propylene glycol monoethyl ether acetate, propylene glycol monobutyl ether acetate and dipropylene glycol dimethyl ether; ketones such as acetone, methyl amyl ketone, cyclohexanone, and acetophenone; ethers such as diethylene and Tetrahydrofuran; esters, such as butyl acetate, pentyl acetate, ethyl butyrate, butyl butyrate, diethyl oxalate, ethyl pyruvate, ethyl 2-hydroxybutyrate, ethyl acetate, methyl lactate , Ethyl lactate and methyl 3-methoxypropionate; halogenated hydrocarbons such as chloroform, dichloromethane and tetrachloroethane; aromatic hydrocarbons such as benzene, toluene, xylene and cresol; and/or high Polar solvents such as dimethylformamide, dimethylacetamide and N-methylpyrrolidone.

Some embodiments include a backlight unit, wherein the backlight unit may include the above-mentioned color conversion film.

Other embodiments may describe a display device, which may include the following backlight unit.

Unless otherwise specified, all numbers used in the specification and examples to indicate the amounts of ingredients, properties (such as molecular weight), reaction conditions, etc. should be understood as being modified by the term "about" in all cases. Therefore, unless there are instructions to the contrary, the numerical parameters listed in the specification and the appended embodiments are approximate values, and the approximate values may vary according to the desired properties sought to be obtained. In any case, it is not an attempt to limit the application of the principle of equivalents. For the scope of the embodiment, each numerical parameter should be explained at least based on the number of significant digits reported and by applying ordinary rounding techniques.

For the disclosed process and/or method, the functions performed in the process and method can be implemented in a different order, as the context dictates. In addition, the outlined steps and operations are only provided as examples, and some of the steps and operations may be present as appropriate, combined into fewer steps and operations, or expanded into other steps and operations.

The present invention may sometimes describe different components included in or connected to different other components. This type of depicted architecture is only an example, and many other architectures that achieve the same or similar functionality can be implemented.

The terms used in the present invention and the appended embodiments (for example, the main body of the appended embodiments) are generally intended as "open" terms (for example, the term "including" should be interpreted as "including but not limited to", and the term "having" Should be interpreted as "at least with", the term "including" should be interpreted as "including but not limited to" etc.). In addition, if a specific number of elements is introduced, this can be interpreted as including at least the recited number, as can be dictated by the context (for example, the expression "two narrative items" without other modifiers means two Or at least two of the more narrative items). As used in the present invention, transitional words and/or phrases that present two or more alternatives should be understood to include one of these items, any one or all of these items, etc. The possibility of the item. For example, the phrase "A or B": should be understood to include the possibility of "A" or "B" or "A and B".

Unless otherwise indicated herein or clearly contradictory to the context, the terms "a", "an", "the" and similar indicators used in the context of describing the present invention (especially in the context of the following embodiments) Should be interpreted as covering both the singular and the plural. The use of any and all examples or representative language (such as "for example") provided herein is only intended to better illustrate the present invention, and does not limit the scope of any embodiment. Any language in the specification should not be construed as indicating that any unrepresented element is indispensable for the implementation of the present invention.

The grouping of alternative elements or embodiments disclosed herein should not be construed as limiting. Each group member can be mentioned and embodied individually or in any combination with other members of the group or other elements found in this document. It is contemplated that one or more members of the group may be included in or deleted from the group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, this specification is deemed to include the modified group so as to satisfy the written description of all Markush groups used in the appended embodiments.

Certain embodiments are described herein, including the best mode known to the inventors for carrying out the invention. Of course, for those familiar with the art, after reading the foregoing description, the variations of the described embodiments will become obvious. The present inventor hopes that the skilled person appropriately adopts such modifications, and the present inventor hopes to implement the present invention in a manner different from that specifically described herein. Therefore, the embodiment includes all modifications and equivalents of the subject matter described in the embodiment permitted by applicable laws. In addition, unless otherwise stated herein or clearly contradicting the context, any combination of all possible variations of the aforementioned elements is contemplated. Finally, it should be understood that the embodiments disclosed herein are illustrative of the principles of the embodiments. Other modifications that can be adopted are within the scope of the embodiment. Therefore, by way of example (and not limitation), alternative embodiments may be utilized in accordance with the teachings herein. Therefore, the embodiments are not limited to exactly as shown and described.

， 其中X為NR⁹ 或O；n 為0或1的整數；R⁹ 選自H、經取代之芳基、經取代之芳基連接基、或經取代之酯連接基；R¹⁰ 選自H、甲基、連至相鄰苯環以形成咔唑的直接鍵、或經取代之酯連接基；並且R¹¹ 為H或甲基； 連接基團，其中該連接基團為經取代之酯；以及 二吡咯亞甲基硼(BODIPY)部分； 其中該連接基團將該萘二甲酸衍生物共價地連接至該BODIPY部分，其中該萘二甲酸衍生物吸收第一激發波長的光能並將能量轉移至該BODIPY部分，其中該BODIPY部分吸收來自該萘二甲酸衍生物的該能量並發射第二更高波長的光能；並且其中該光致發光複合物的發射量子產率大於80%。實施例 2 根據實施例1所述的萘二甲酸衍生物，其中X為N，n 為0，R⁹ 為經取代之酯連接基，R¹⁰ 為H，並且R¹¹ 為H。實施例 3 根據實施例1所述的萘二甲酸衍生物，其中X為N，n 為1，R⁹ 為經取代之酯連接基，R¹⁰ 為H，並且R¹¹ 為H。實施例 4 根據實施例1所述的萘二甲酸衍生物，其中X為N，n 為1，R⁹ 為經取代之酯連接基，R¹⁰ 為甲基，並且R¹¹ 為甲基。實施例 5 根據實施例1所述的萘二甲酸衍生物，其中X為N，n 為1，R⁹ 為經取代之酯連接基，R¹⁰ 是連至相鄰苯環以形成咔唑的直接鍵，並且R¹¹ 為H。實施例 6 根據實施例1所述的萘二甲酸衍生物，其中X為N，n 為0，R⁹ 為經取代之芳基，R¹⁰ 為經取代之酯連接基，並且R¹¹ 為H。實施例 7 根據實施例1所述的萘二甲酸衍生物，其中X為O，n 為1，R⁹ 為H，R¹⁰ 為經取代之酯連接基，並且R¹¹ 為H。實施例 8 根據實施例6所述的萘二甲酸衍生物，其中該經取代之芳基選自以下結構中的一者：

。實施例 9 根據實施例1所述的光致發光複合物，其中該BODIPY部分具有以下通式：

， 其中R¹ 和R⁶ 獨立地選自氫(H)、烷基、烯基、或炔基； R³ 和R⁴ 獨立地選自H或C₁ -C₂ 烷基； R² 和R⁵ 獨立地選自氫(H)、烷基、烯基、炔基、氰基(-CN)、酯(-COOCH₂ CH₃ )、或芳基酯(-COOCH₂ Ar)； R² 和R³ 可以連接在一起以形成另一單環烴環結構或多環烴環結構； R⁴ 和R⁵ 可以連接在一起以形成另一單環烴環結構或多環烴環結構； R⁷ 和R⁸ 可獨立地選自H、甲基、氟、氯、或烷氧基；並且 L代表連接基團，該連接基團包含經取代之酯連接基。實施例 10 根據實施例9所述的BODIPY部分，其中R¹ 、R³ 、R⁴ 和R⁶ 均為甲基，R² 和R⁵ 選自經取代之酯，R⁷ 和R⁸ 均為甲基，並且L為連接基團。實施例 11 根據實施例9所述的BODIPY部分，其中R¹ 、R³ 、R⁴ 和R⁶ 均為甲基，R² 和R⁵ 均為氰基，R⁷ 和R⁸ 均為甲基，並且L為連接基團。實施例 12 根據實施例9所述的BODIPY部分，其中R¹ 、R³ 、R⁴ 和R⁶ 均為甲基，R² 和R⁵ 均為芳基酯，R⁷ 和R⁸ 選自甲基、氟、氯、或醚基團，並且L為連接基團。實施例 13 根據實施例1所述的光致發光複合物，其中該BODIPY部分具有以下通式：

， R¹ 和R² 連接在一起以形成另一多環烴環結構； R³ 和R⁴ 均為甲基； R⁵ 和R⁶ 連接在一起以形成另一多環烴環結構； R⁷ 和R⁸ 可以獨立地選自H、甲基或烷氧基；並且 L代表連接基團，該連接基團包含經取代之酯連接基。實施例 14 根據實施例13所述的BODIPY部分，其中R¹ 和R² 連接在一起以形成烴環結構，R³ 和R⁴ 均為甲基，R⁵ 和R⁶ 可連接在一起以形成多環烴環結構，R⁷ 和R⁸ 選自H、甲基、或醚基團，並且L為連接基團。實施例 15 根據實施例1、2、3、4、5、6、7、8、9、10、11、12、13和14所述的光致發光複合物，其中該連接基團的該經取代之酯選自以下結構中的一者：

。實施例 16 根據實施例1、2、3、4、5、6、7、8、9、10、11、12、13和14所述的光致發光複合物，其中該連接基團可包含經取代之芳基連接基。在一些實施例中，該經取代之烷基連接基可為

。實施例 17 根據實施例1、2、3、4、5、6、7、8、9、10、11、12、13和14所述的光致發光複合物，其中該複合物選自以下結構中的任一者：

。實施例 18 一種色轉換膜，該色轉換膜包括： 透明基板層； 色轉換層，其中該色轉換層包括樹脂基質，以及 至少一種光致發光複合物，其中該至少一種光致發光化合物包含根據實施例1、2、3、4、5、6、7、8、9、10、11、12、13或14所述的光致發光化合物，該光致發光化合物分散在該樹脂基質中。實施例 19 根據實施例18所述的色轉換膜，該色轉換膜還包含單線態氧淬滅劑。實施例 20 根據實施例18所述的色轉換膜，該色轉換膜還包含自由基清除劑。實施例 21 根據實施例18所述的色轉換膜，其中該膜的厚度介於10 µm與200 μm之間。實施例 22 根據實施例17所述的色轉換膜，其中該膜吸收在約400 nm至約480 nm波長範圍內的光並且發射在510 nm至約560 nm和575 nm至約645 nm波長範圍內的光。實施例 23 一種製備根據實施例18、19、20和21所述的色轉換膜的方法，該方法包括： 將根據實施例1、2、3、4、5、6、7、8、9、10、11、12、13和14所述的光致發光複合物和黏合劑樹脂溶於溶劑中；以及 將混合物施加至透明基板的相對表面中的一者上。實施例 24 一種背光單元，該背光單元包括根據技術方案18、19、20、21或22所述的色轉換膜。實施例 25 一種顯示設備，該顯示設備包括根據實施例24所述的背光單元。 Examples Example 1 A photoluminescent composite, the photoluminescent composite comprising: a blue light-absorbing naphthalenedicarboxylic acid derivative having the following general formula:

, Wherein X is NR ⁹ or O; n is an integer of 0 or 1; R ^{9 is} selected from H, substituted aryl, substituted aryl linker, or substituted ester linker; R ^{10 is} selected from H , A methyl group, a direct bond to the adjacent benzene ring to form a carbazole, or a substituted ester linking group; and R ¹¹ is H or a methyl group; a linking group, wherein the linking group is a substituted ester; And a boron dipyrromethene (BODIPY) moiety; wherein the linking group covalently connects the naphthalenedicarboxylic acid derivative to the BODIPY moiety, wherein the naphthalenedicarboxylic acid derivative absorbs the light energy of the first excitation wavelength and Energy is transferred to the BODIPY part, wherein the BODIPY part absorbs the energy from the naphthalenedicarboxylic acid derivative and emits light energy of a second higher wavelength; and wherein the emission quantum yield of the photoluminescent composite is greater than 80%. Embodiment 2 The naphthalenedicarboxylic acid derivative according to embodiment 1, wherein X is N, n is 0, R ⁹ is a substituted ester linker, R ¹⁰ is H, and R ¹¹ is H. Embodiment 3 The naphthalenedicarboxylic acid derivative according to embodiment 1, wherein X is N, n is 1, R ⁹ is a substituted ester linker, R ¹⁰ is H, and R ¹¹ is H. Embodiment 4 The naphthalenedicarboxylic acid derivative described in embodiment 1, wherein X is N, n is 1, R ⁹ is a substituted ester linker, R ¹⁰ is a methyl group, and R ¹¹ is a methyl group. Embodiment 5 The naphthalenedicarboxylic acid derivative according to embodiment 1, wherein X is N, n is 1, R ⁹ is a substituted ester linker, and R ¹⁰ is a direct link to the adjacent benzene ring to form a carbazole Bond, and R ¹¹ is H. Embodiment 6 The naphthalenedicarboxylic acid derivative according to embodiment 1, wherein X is N, n is 0, R ⁹ is a substituted aryl group, R ¹⁰ is a substituted ester linker, and R ¹¹ is H. Embodiment 7 The naphthalenedicarboxylic acid derivative according to embodiment 1, wherein X is O, n is 1, R ⁹ is H, R ¹⁰ is a substituted ester linker, and R ¹¹ is H. Embodiment 8 The naphthalenedicarboxylic acid derivative according to embodiment 6, wherein the substituted aryl group is selected from one of the following structures:

. Embodiment 9 The photoluminescent composite according to embodiment 1, wherein the BODIPY part has the following general formula:

, Wherein R ¹ and R ^{6 are} independently selected from hydrogen (H), alkyl, alkenyl, or alkynyl; R ³ and R ^{4 are} independently selected from H or C ₁ -C ₂ alkyl; R ² and R ⁵ Independently selected from hydrogen (H), alkyl, alkenyl, alkynyl, cyano (-CN), ester (-COOCH ₂ CH ₃ ), or aryl ester (-COOCH ₂ Ar); R ² and R ³ May be connected together to form another monocyclic hydrocarbon ring structure or polycyclic hydrocarbon ring structure; R ⁴ and R ⁵ may be connected together to form another monocyclic hydrocarbon ring structure or polycyclic hydrocarbon ring structure; R ⁷ and R ⁸ It may be independently selected from H, methyl, fluorine, chlorine, or alkoxy; and L represents a linking group that includes a substituted ester linking group. Embodiment 10 The BODIPY portion according to embodiment 9, wherein R ¹ , R ³ , R ⁴ and R ⁶ are all methyl groups, R ² and R ^{5 are} selected from substituted esters, and R ⁷ and R ⁸ are both methyl Group, and L is a linking group. Embodiment 11 According to the BODIPY portion of embodiment 9, wherein R ¹ , R ³ , R ⁴ and R ⁶ are all methyl groups, R ² and R ⁵ are both cyano groups, and R ^{7 and R 8} are both methyl groups, And L is a linking group. Embodiment 12 The BODIPY part according to embodiment 9, wherein R ¹ , R ³ , R ⁴ and R ⁶ are all methyl groups, R ² and R ⁵ are all aryl esters, and R ⁷ and R ^{8 are} selected from methyl groups , Fluorine, chlorine, or ether groups, and L is a linking group. Embodiment 13 The photoluminescent composite of embodiment 1, wherein the BODIPY part has the following general formula:

, R ¹ and R ^{2 are} connected together to form another polycyclic hydrocarbon ring structure; R ³ and R ⁴ are both methyl groups; R ⁵ and R ^{6 are} connected together to form another polycyclic hydrocarbon ring structure; R ⁷ and R ⁸ may be independently selected from H, methyl, or alkoxy; and L represents a linking group including a substituted ester linking group. Embodiment 14 The BODIPY portion according to embodiment 13, wherein R ¹ and R ^{2 are} connected together to form a hydrocarbon ring structure, R ³ and R ⁴ are both methyl groups, and R ⁵ and R ⁶ can be connected together to form a poly In the cyclic hydrocarbon ring structure, R ⁷ and R ^{8 are} selected from H, methyl, or ether groups, and L is a linking group. Embodiment 15 The photoluminescent composite according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14, wherein the effect of the linking group is The substituted ester is selected from one of the following structures:

. Embodiment 16 The photoluminescent composite according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14, wherein the linking group may comprise Substituted aryl linker. In some embodiments, the substituted alkyl linker can be

. Embodiment 17 The photoluminescent composite according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14, wherein the composite is selected from the following structures Any of:

. Embodiment 18 A color conversion film, the color conversion film comprising: a transparent substrate layer; a color conversion layer, wherein the color conversion layer includes a resin matrix, and at least one photoluminescence compound, wherein the at least one photoluminescence compound comprises The photoluminescent compound described in embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14, wherein the photoluminescent compound is dispersed in the resin matrix. Embodiment 19 According to the color conversion film of embodiment 18, the color conversion film further contains a singlet oxygen quencher. Embodiment 20 According to the color conversion film of embodiment 18, the color conversion film further contains a radical scavenger. Embodiment 21 The color conversion film of embodiment 18, wherein the thickness of the film is between 10 μm and 200 μm. Embodiment 22 The color conversion film of embodiment 17, wherein the film absorbs light in the wavelength range of about 400 nm to about 480 nm and emits light in the wavelength range of 510 nm to about 560 nm and 575 nm to about 645 nm Of light. Embodiment 23 A method for preparing the color conversion film according to Embodiments 18, 19, 20, and 21, the method comprising: The photoluminescent composite and the binder resin described in 10, 11, 12, 13, and 14 are dissolved in a solvent; and the mixture is applied to one of the opposite surfaces of the transparent substrate. Embodiment 24 is a backlight unit including the color conversion film according to technical solutions 18, 19, 20, 21 or 22. Embodiment 25 A display device including the backlight unit according to Embodiment 24.

Examples It has been found that the embodiments of the photoluminescent composite described herein have improved performance compared to other forms of dyes used in color conversion films. The following examples further demonstrate these benefits, which are only intended to illustrate the present invention, and are not intended to limit the scope or basic principles in any way.

CE-1 ： 將0.75 g的4-羥基-2,6-二甲基苯甲醛(5 mmol)和1.04 g的2,4-二甲基吡咯(11 mmol)溶於100 mL的無水二氯甲烷中。將溶液除氣30分鐘。接著添加一滴三氟乙酸。將溶液在氬氣氛圍下在室溫下攪拌隔夜。向所得溶液中添加DDQ(2.0 g)，並將混合物攪拌隔夜。第二天將溶液過濾，接著用二氯甲烷洗滌，得到二吡咯甲烷(1.9 g)。接下來，將1.0 g的二吡咯甲烷溶於60 mL的THF中。將5 mL的三甲胺添加至溶液中，接著除氣10分鐘。在除氣後，緩慢添加5 mL三氟硼-二乙醚，接著在70℃加熱30分鐘。將所得溶液裝載到矽膠上，並藉由使用二氯甲烷作為溶離劑的快速層析法純化。收集所需溶離份，並減壓乾燥，得到0.9 g的橙色固體(76%產率)。LCMS (APCI+)：C₂₁ H₂₄ BF₂ N₂ O (M+H)的計算值=369；實測值：369。¹ H NMR (400 MHz，氯仿-d ) δ 6.64 (s, 2H), 5.97 (s, 2H), 4.73 (s, 1H), 2.56 (s, 6H), 2.09 (s, 6H), 1.43 (s, 6H)。 Example 1.1 Comparative Example 1 (CE-1) :

CE-1 : Dissolve 0.75 g of 4-hydroxy-2,6-dimethylbenzaldehyde (5 mmol) and 1.04 g of 2,4-dimethylpyrrole (11 mmol) in 100 mL of anhydrous dichloromethane middle. The solution was degassed for 30 minutes. Then add one drop of trifluoroacetic acid. The solution was stirred overnight at room temperature under an argon atmosphere. To the resulting solution was added DDQ (2.0 g), and the mixture was stirred overnight. The solution was filtered the next day, followed by washing with dichloromethane to obtain dipyrromethene (1.9 g). Next, 1.0 g of dipyrromethene was dissolved in 60 mL of THF. Add 5 mL of trimethylamine to the solution, then degas for 10 minutes. After degassing, 5 mL of trifluoroboron-diethyl ether was slowly added, followed by heating at 70°C for 30 minutes. The resulting solution was loaded on silica gel and purified by flash chromatography using dichloromethane as the eluent. The required fractions were collected and dried under reduced pressure to obtain 0.9 g of an orange solid (76% yield). LCMS (APCI+): _{calculated value of C 21} H ₂₄ BF ₂ N ₂ O (M+H)=369; actually measured value: 369. ¹ H NMR (400 MHz, chloroform- d ) δ 6.64 (s, 2H), 5.97 (s, 2H), 4.73 (s, 1H), 2.56 (s, 6H), 2.09 (s, 6H), 1.43 (s , 6H).

Example 1.2 : Comparative Example 2 (CE-2) : Synthesis according to the description of Wakamiya, Atsushi et al., Chemistry Letters, 37(10), 1094-1095; 2008

Instance 2 : Synthetic photoluminescence compound:

化合物 1.1 ： 將4-溴-1,8-萘二甲酸酐(5.5 g，20 mmol)、4-丁基-苯胺(3.58 g，25 mmol)在乙醇(20 mL)中的混合物除氣並回流加熱隔夜(16小時)。冷卻至室溫後，將混合物過濾，並將固體用甲醇洗滌，風乾，得到灰白色固體(7.48 g，產率為92%)。LCMS (APCI-)：C₂₂ H₁₈ BrNO₂ (M-)的計算值：408；實測值：408。化合物 1.2 ：將化合物1.1(1.0 g，2.45 mmol)、N,N'-二苯胺(0.62 g，3.7 mmol)、Pd(dppf)Cl₂ (0.15 g，0.2 mmol)和三級丁醇鈉(0.36 g，3.7 mmol)在無水甲苯(25 mL)中的混合物除氣並在110℃下加熱隔夜。將所得混合物裝載到矽膠上，並藉由使用二氯甲烷/己烷(0%à90%二氯甲烷)溶離劑進行快速層析法來純化。收集主要橙色溶離份，並且在移除溶劑後，獲得了0.6 g橙色固體(產率為50%)。LCMS (APCI)：C₃₄ H₂₈ N₂ O₂ (M-)的計算值：496；實測值：496。¹ H NMR (400 MHz, TCE) δ 8.48-8.37 (m, 2H), 8.15 (dd,J = 8.6, 1.2 Hz, 1H), 7.46 (dd,J = 8.6, 7.2 Hz, 1H), 7.31 (dd,J = 8.2, 6.6 Hz, 3H), 7.25-7.17 (m, 4H), 7.16-7.10 (m, 2H), 7.06-6.95 (m, 6H), 2.69-2.60 (m, 2H), 1.67-1.55 (m, 2H), 1.36 (dt,J = 14.8, 7.3 Hz, 2H), 0.86 (dt,J = 24.8, 7.3 Hz, 3H)。化合物 1.3 和 1.4 ：向化合物1.2 (200 mg，0.40 mmol)和4-氯-4-側氧基丁酸甲酯(120 mg，0.8 mmol)在10 mL二氯乙烷中的溶液中添加0.8 mL的1.0 M ZnCl₂ 的乙醚溶液。將整體除氣30分鐘，接著在66℃加熱隔夜。冷卻至室溫後，將混合物溶於100 mL二氯甲烷中，用NH₄ Cl水溶液洗滌，接著用鹽水洗滌。收集有機相並經Na₂ SO₄ 乾燥，裝載到矽膠上，並藉由使用二氯甲烷/乙酸乙酯(0%à100%乙酸乙酯)溶離劑進行快速層析法而純化。收集所需溶離份(最極性的溶離份)，並且在移除溶劑後，獲得了橙色固體(100 mg，產率為42%)。LCMS (APCI)：C₃₈ H₃₁ N₂ O₅ (M-H)的計算值：595；實測值：595。PLC-1 ：將化合物1.4(40 mg，0.067 mmol)、5,5-二氟-10-(4-羥基-2,6-二甲基苯基)-1,3,7,9-四甲基-5H -4λ⁴ ,5λ⁴ -二吡咯并[1,2-c :2',1'-f ][1,3,2]二氮雜環己硼烷-2,8-二甲酸二苯甲酯)(38 mg，0.06 mmol)、DMAP/TsOH鹽(29 mg，0.1 mmol)和DIC (30 mg，0.2 mmol)在二氯甲烷(5 mL)中的混合物在室溫下攪拌隔夜。將所得混合物裝載到矽膠上，並藉由使用DCM/乙酸乙酯(0%à30%乙酸乙酯)溶離劑進行快速層析法來純化。收集所需溶離份，並且在移除溶劑後，獲得了橙色固體(5 mg，產率為7%)。LCMS (APCI)：C₇₅ H₆₅ BF₂ N₄ O₉ (M-)的計算值：1214；實測值：1214。 Example 2.1 : PLC-1

Compound 1.1 : The mixture of 4-bromo-1,8-naphthalenedicarboxylic acid anhydride (5.5 g, 20 mmol) and 4-butyl-aniline (3.58 g, 25 mmol) in ethanol (20 mL) was degassed and refluxed Heat overnight (16 hours). After cooling to room temperature, the mixture was filtered, and the solid was washed with methanol and air-dried to obtain an off-white solid (7.48 g, 92% yield). LCMS (APCI- _{): calculated value of C 22} H _{18 BrNO 2} (M-): 408; actually measured value: 408. Compound 1.2 : Combine compound 1.1 (1.0 g, 2.45 mmol), N,N'-diphenylamine (0.62 g, 3.7 mmol), Pd(dppf)Cl ₂ (0.15 g, 0.2 mmol) and sodium tertiary butoxide (0.36 g, 3.7 mmol) in anhydrous toluene (25 mL) was degassed and heated at 110°C overnight. The resulting mixture was loaded on silica gel and purified by flash chromatography using dichloromethane/hexane (0%→90% dichloromethane) eluent. The main orange eluates were collected, and after removing the solvent, 0.6 g of orange solid was obtained (50% yield). LCMS (APCI): _{calculated value for C 34} H ₂₈ N ₂ O ₂ (M-): 496; actually measured value: 496. ¹ H NMR (400 MHz, TCE) δ 8.48-8.37 (m, 2H), 8.15 (dd, J = 8.6, 1.2 Hz, 1H), 7.46 (dd, J = 8.6, 7.2 Hz, 1H), 7.31 (dd , J = 8.2, 6.6 Hz, 3H), 7.25-7.17 (m, 4H), 7.16-7.10 (m, 2H), 7.06-6.95 (m, 6H), 2.69-2.60 (m, 2H), 1.67-1.55 (m, 2H), 1.36 (dt, J = 14.8, 7.3 Hz, 2H), 0.86 (dt, J = 24.8, 7.3 Hz, 3H). Compounds 1.3 and 1.4 : To a solution of compound 1.2 (200 mg, 0.40 mmol) and methyl 4-chloro-4-oxobutyrate (120 mg, 0.8 mmol) in 10 mL of dichloroethane, 0.8 mL 1.0 M ZnCl ₂ in ether solution. The whole was degassed for 30 minutes, and then heated at 66°C overnight. After cooling to room temperature, the mixture was dissolved in 100 mL of dichloromethane and washed with _{aqueous NH 4} Cl, followed by brine. The organic phase was collected and _{dried over Na 2} SO ₄ , loaded onto silica gel, and purified by flash chromatography using dichloromethane/ethyl acetate (0%→100% ethyl acetate) eluent. The required fractions (the most polar fractions) were collected, and after the solvent was removed, an orange solid was obtained (100 mg, 42% yield). LCMS (APCI): _{calculated value for C 38} H ₃₁ N ₂ O ₅ (MH): 595; found value: 595. PLC-1 : Compound 1.4 (40 mg, 0.067 mmol), 5,5-difluoro-10-(4-hydroxy-2,6-dimethylphenyl)-1,3,7,9-tetramethyl Group -5 H ^{-4λ 4} ,5λ ⁴ -dipyrrolo[1,2- c :2',1'- f ][1,3,2]diazepine-2,8-dicarboxylic acid A mixture of diphenylmethyl ester) (38 mg, 0.06 mmol), DMAP/TsOH salt (29 mg, 0.1 mmol) and DIC (30 mg, 0.2 mmol) in dichloromethane (5 mL) was stirred at room temperature overnight . The resulting mixture was loaded on silica gel and purified by flash chromatography using DCM/ethyl acetate (0%→30% ethyl acetate) eluent. The required fractions were collected, and after removing the solvent, an orange solid was obtained (5 mg, 7% yield). LCMS (APCI): _{calculated value of C 75} H ₆₅ BF ₂ N ₄ O ₉ (M-): 1214; actually measured value: 1214.

化合物 2.1 [5,5-二氟-10-(4-羥基-2,6-二甲基苯基)-1,3,7,9-四甲基-5H -4λ⁴ ,5λ⁴ -二吡咯并[1,2-c :2',1'-f ][1,3,2]二氮雜環己硼烷-2,8-二腈]：如美國臨時專利申請案62/986,462中所述合成化合物2.1。PLC-2 ： 將化合物1.4 (40 mg，0.067 mmol)、5,5-二氟-10-(4-羥基-2,6-二甲基苯基)-1,3,7,9-四甲基-5H -4λ⁴ ,5λ⁴ -二吡咯并[1,2-c :2',1'-f ][1,3,2]二氮雜環己硼烷-2,8-二腈(25 mg，0.06 mmol)、DMAP/p-TsOH鹽(30 mg，0.1 mmol)和DIC (30 mg，0.24 mmol)在DCM(5 mL)中的混合物在室溫下攪拌隔夜。將所得混合物裝載到矽膠上，並藉由使用DCM/乙酸乙酯(0%à35%乙酸乙酯)溶離劑進行快速層析法來純化。收集所需溶離份，並且在移除溶劑後，獲得了橙色固體(5 mg，產率為8%)。LCMS (APCI)：C₆₁ H₅₁ BF₂ N₆ O₅ (M-)的計算值：996；實測值：996。¹ H NMR (400 MHz，氯仿-d ) δ 8.66-8.58 (m, 2H), 8.19 (dd,J = 8.6, 1.1 Hz, 1H), 7.93-7.85 (m, 2H), 7.61 (dd,J = 8.5, 7.2 Hz, 1H), 7.52 (d,J = 7.9 Hz, 1H), 7.36 (dt,J = 8.4, 3.7 Hz, 4H), 7.25-7.14 (m, 6H), 7.09-7.04 (m, 2H), 7.01-6.93 (m, 2H), 3.37 (t,J = 6.3 Hz, 2H), 3.00 (t,J = 6.2 Hz, 2H), 2.73 (s, 6H), 2.69 (d,J = 7.8 Hz, 2H), 2.12 (d,J = 0.8 Hz, 6H), 1.73-1.64 (m, 2H), 1.62 (s, 6H), 1.47-1.35 (m, 2H), 0.96 (t, 3H)。 Example 2.2 : PLC-2

Compound 2.1 [5,5-difluoro-10-(4-hydroxy-2,6-dimethylphenyl)-1,3,7,9-tetramethyl-5 H -4λ ⁴ ,5λ ^{4 -two} Pyrrolo[1,2- c :2',1'- f ][1,3,2]diazaborane-2,8-dinitrile]: as in U.S. Provisional Patent Application 62/986,462 The synthesis of compound 2.1. PLC-2 : Compound 1.4 (40 mg, 0.067 mmol), 5,5-difluoro-10-(4-hydroxy-2,6-dimethylphenyl)-1,3,7,9-tetramethyl Group -5 H ^{-4λ 4} ,5λ ⁴ -dipyrrolo[1,2- c :2',1'- f ][1,3,2]diazepine-2,8-dinitrile (25 mg, 0.06 mmol), a mixture of DMAP/p-TsOH salt (30 mg, 0.1 mmol) and DIC (30 mg, 0.24 mmol) in DCM (5 mL) was stirred at room temperature overnight. The resulting mixture was loaded on silica gel and purified by flash chromatography using DCM/ethyl acetate (0%→35% ethyl acetate) eluent. The required fractions were collected, and after the solvent was removed, an orange solid was obtained (5 mg, 8% yield). LCMS (APCI): _{calculated value of C 61} H ₅₁ BF ₂ N ₆ O ₅ (M-): 996; actually measured value: 996. ¹ H NMR (400 MHz, chloroform- d ) δ 8.66-8.58 (m, 2H), 8.19 (dd, J = 8.6, 1.1 Hz, 1H), 7.93-7.85 (m, 2H), 7.61 (dd, J = 8.5, 7.2 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.36 (dt, J = 8.4, 3.7 Hz, 4H), 7.25-7.14 (m, 6H), 7.09-7.04 (m, 2H ), 7.01-6.93 (m, 2H), 3.37 (t, J = 6.3 Hz, 2H), 3.00 (t, J = 6.2 Hz, 2H), 2.73 (s, 6H), 2.69 (d, J = 7.8 Hz , 2H), 2.12 (d, J = 0.8 Hz, 6H), 1.73-1.64 (m, 2H), 1.62 (s, 6H), 1.47-1.35 (m, 2H), 0.96 (t, 3H).

化合物 3.1 ： 將化合物1.1 (816 mg，2 mmol)、(4-(二苯基胺基)苯基)

酸(580 mg，2 mmol)、Pd(PPh₃ )₄ (115 mg，0.1 mmol)、K₂ CO₃ (414 mg，3 mmol)在二㗁烷/水(10 mL/2 mL)中的混合物除氣並在100℃加熱隔夜。在冷卻至室溫之後，形成了黃色沈澱物。在過濾，並用水、甲醇洗滌，並真空乾燥後收集固體。將固體溶於DCM中，並進一步藉由使用DCM/己烷(0%à80% DCM)溶離劑進行快速層析法來純化。收集主要橙色溶離份，並且在移除溶劑後，獲得了黃色固體(1.0 g，產率為87.4%)。LCMS (APCI)：C₄₀ H₃₃ N₂ O₂ (M+H)的計算值：573；實測值：573。化合物 3.2 ： 向化合物3.1 (458 mg，0.8 mmol)、4-氯-4-側氧基丁酸甲酯(240 mg，1.6 mmol)在20 mL DCE中的混合物中添加1.0 M ZnCl₂ 的二乙醚溶液(1.0 mL，1.0 mmol)。將整體除氣，接著在氬氣氛圍下在50℃加熱隔夜。冷卻至室溫後，將混合物用DCM/水處理。收集有機相並經Na₂ SO₄ 乾燥，濃縮並裝載到矽膠上，接著藉由使用DCM/乙酸乙酯(0%à8%乙酸乙酯)溶離劑進行快速層析法而純化。將所需溶離份收集，並移除溶劑，得到為橙色固體的所需產物(0.30 g，產率為50%)。LCMS (APCI)：C₄₅ H₃₉ N₂ O₅ (M+H)的計算值：687；實測值：687。化合物 3.3 ： 在10小時內分10份向化合物3.2在DCM/TFA (10 mL/4 mL)中的溶液中添加三乙基矽烷(1.5 g，13 mmol)。在移除溶劑後，將剩餘油性固體再溶於10 mL DCM中，並藉由使用己烷/乙酸乙酯(0%à20%乙酸乙酯)溶離劑進行快速層析法來純化。收集主溶離份並移除溶劑，得到橙色固體(0.23 g，產率為78%)。LCMS (APCI)：C₄₅ H₄₀ N₂ O₄ (M-)的計算值：672；實測值：672。¹ H NMR (400 MHz, TCE) δ 8.59-8.52 (m, 2H), 8.43 (dd,J = 8.7, 1.1 Hz, 1H), 7.70 (t,J = 7.6 Hz, 2H), 7.32 (d,J = 8.1 Hz, 4H), 7.25 (dd,J = 8.4, 7.2 Hz, 2H), 7.18-7.09 (m, 6H), 7.07 (s, 4H), 7.01 (t,J = 7.3 Hz, 1H), 3.59 (s, 3H), 2.65 (t,J = 7.8 Hz, 2H), 2.56 (t,J = 7.5 Hz, 2H), 2.29 (q,J = 7.0, 6.6 Hz, 2H), 1.89 (p,J = 7.4 Hz, 2H), 1.36 (h,J = 7.5 Hz, 2H), 0.90 (t,J = 7.3 Hz, 3H)。化合物 3.4 ： 向3.3 (0.23 g，0.34 mol)在1-丁醇(8 mL)中的混合物中添加5M KOH水溶液(0.7 mL，3.4 mmol)，將整體在90℃加熱1小時。將反應混合物減壓濃縮至1 mL，接著用10 mL甲醇稀釋，並滴入至 20 mL 1N HCl水溶液中。形成了橙色沈澱物，過濾收集固體並用水洗滌，真空乾燥，得到180 mg紅色固體(以定量產率計)。LCMS (APCI)：C₃₄ H₂₅ NO₅ (M-)的計算值：527；實測值：527。

化合物 3.5 (5,5- 二氟 -10-(4- 羥基 -2,6- 二甲基苯基 )-1,3,7,9- 四甲基 -5H -4λ⁴ ,5λ⁴ - 二吡咯并 [[1,2-c :2',1'-f ][1,3,2] 二氮雜環己硼烷 -2,8- 二甲酸二苯甲酯 ) ： 向250 mL圓底燒瓶中添加溶於80 mL乙酸中的40 mL (241 mmol) 3-側氧基丁酸三級丁酯。將混合物在冰水浴中冷卻至約10℃。在1小時內添加亞硝酸鈉(18 g，262 mmol)，同時將溫度保持低於15℃。移除冷浴，並將混合物在室溫下攪拌3.5小時。將不溶物濾除，得到肟的粗製溶液，該粗製溶液無需進一步純化即用於下一步驟。接著，將50 g鋅粉(0.76 mol)分批添加至13.7 mL (79 mmol) 3-側氧基丁酸苯甲酯和100 mL乙酸的混合物中。將所得混合物在油浴中攪拌並加熱至60℃。緩慢添加固化的2-(羥基亞胺基-3-側氧基丁酸三級丁酯溶液。接著將溫度升至75℃並攪拌1小時。接著，將反應混合物倒入水(4 L)中。將沈澱物收集並過濾，得到2,4-二甲基-1H- 吡咯-3-甲酸苯甲酯，將其從MeOH中重結晶為白色固體，得到15 g，產率基於3-側氧基丁酸苯甲酯為65%。¹ H NMR (400 MHz, CDCl₃ ): 8.88 (br, s, 1H, NH), 7.47-7.33 (m, 5H, C=CH), 5.29 (s, 2H, CH₂ ), 2.53, 2.48 (2s, 6H, 2CH₃ ), 1.56 (s, 9H, 3CH₃ )。 接著，在25 mL小瓶中，將1 g (4.36 mmol) 2,4-二甲基-1H- 吡咯-3-甲酸苯甲酯、0.524 g (4.36 mmol) MgSO₄ 的混合物溶於8 mL無水DCE中，並在氬氣存在下在室溫下攪拌15分鐘。分多個小份添加0.327 g的2,6-二甲基4-羥基苯甲醛(2.18 mmol)；將小瓶用特氟龍蓋封閉。將所得混合物繼續用氬氣淨化15分鐘，並且添加TFA (3滴，催化量)。將反應混合物在65℃下攪拌16小時。TLC和LCMS顯示原料已被消耗。向粗產物中一次性添加0.544 g (2.398 mmol)的DDQ。將所得混合物在室溫下攪拌½小時。TLC和LCMS顯示起始材料已被消耗。將所得混合物濾過短路徑矽藻土；將濾液濃縮至乾，將殘餘物與三甲胺(1.4 mL，19 mmol)一起再溶於50 mL DCE中，在室溫下攪拌15分鐘，接著冷卻至0℃。緩慢添加3 mL的BF₃ -OEt₂ (18.36 mmol)。將所得混合物在室溫下攪拌½ h，接著加熱至86℃持續45 min。接著將反應混合物用150 mL的CHCl₃ 稀釋，並用50 mL鹽水淬滅。將有機層分離並經MgSO₄ 乾燥，並藉由旋轉蒸發移除溶劑。將殘餘物在矽膠柱上使用CH₂ Cl₂ /EtOAc作為溶離劑進行層析分離，得到1 g純的5,5-二氟-10-(4-羥基-2,6-二甲基苯基)-1,3,7,9-四甲基-5H-414,514-二吡咯并[1,2-c:2',1'-f][1,3,2]二氮雜環己硼烷-2,8-二甲酸二苯甲酯)，為橙紅色固體，基於2,6-二甲基4-羥基苯甲醛的產率為72%。LCMS (APCI-)，針對C₃₇ H₃₅ BF₂ N₂ O₅ 的M-的計算值：636.26；實測值：636。¹ H NMR (400 MHz，氯仿-d ) δ 7.42-7.28 (m, 4H), 6.66 (d,J = 0.7 Hz, 1H), 5.29 (d,J = 11.3 Hz, 2H), 2.82 (s, 3H), 2.04 (d,J = 5.4 Hz, 3H), 1.72 (s, 3H)。PLC-3 ： 將化合物3.4 (72 mg，0.136 mmol)、化合物3.5 [5,5-二氟-10-(4-羥基-2,6-二甲基苯基)-1,3,7,9-四甲基-5H -4λ⁴ ,5λ⁴ -二吡咯并[1,2-c :2',1'-f ][1,3,2]二氮雜環己硼烷-2,8-二甲酸二苯甲酯](64 mg，0.1 mmol)、DMAP/p-TsOH鹽(59 mg，0.2 mmol)和DIC (63 mg，0.5 mmol)在DCM(5 mL)中的混合物在室溫下攪拌隔夜。所得混合物藉由使用DCM/乙酸乙酯(0%à5%)溶離劑進行快速層析法來純化。收集所需溶離份並濃縮，固體藉由在DCM/甲醇中再沈澱進一步純化，得到橙色固體(70 mg，產率為61%)。LCMS (APCI)：C₇₁ H₅₈ BF₂ N₃ O₉ (M-)的計算值：1146；實測值：1146。 Example 2.3 : PLC-3

Compound 3.1 : Compound 1.1 (816 mg, 2 mmol), (4-(diphenylamino)phenyl)

A mixture of acid (580 mg, 2 mmol), Pd(PPh ₃ ) ₄ (115 mg, 0.1 mmol), K ₂ CO ₃ (414 mg, 3 mmol) in diethane/water (10 mL/2 mL) Degas and heat at 100°C overnight. After cooling to room temperature, a yellow precipitate formed. The solid was collected after filtration, washing with water, methanol, and vacuum drying. The solid was dissolved in DCM and further purified by flash chromatography using DCM/hexane (0%→80% DCM) eluent. The main orange eluates were collected, and after the solvent was removed, a yellow solid (1.0 g, yield 87.4%) was obtained. LCMS (APCI): _{calculated value for C 40} H ₃₃ N ₂ O ₂ (M+H): 573; found value: 573. Compound 3.2 : To a mixture of compound 3.1 (458 mg, 0.8 mmol) and methyl 4-chloro-4-oxobutanoate (240 mg, 1.6 mmol) in 20 mL of DCE, add 1.0 M ZnCl ₂ in diethyl ether Solution (1.0 mL, 1.0 mmol). The whole was degassed, and then heated at 50°C overnight under an argon atmosphere. After cooling to room temperature, the mixture was treated with DCM/water. The organic phase was collected and _{dried over Na 2} SO ₄ , concentrated and loaded on silica gel, and then purified by flash chromatography using DCM/ethyl acetate (0%→8% ethyl acetate) eluent. The desired fractions were collected, and the solvent was removed to obtain the desired product (0.30 g, yield 50%) as an orange solid. LCMS (APCI): _{calculated value for C 45} H ₃₉ N ₂ O ₅ (M+H): 687; found value: 687. Compound 3.3 : To a solution of compound 3.2 in DCM/TFA (10 mL/4 mL) was added triethylsilane (1.5 g, 13 mmol) in 10 portions over 10 hours. After removing the solvent, the remaining oily solid was redissolved in 10 mL DCM and purified by flash chromatography using hexane/ethyl acetate (0%→20% ethyl acetate) eluent. The main fractions were collected and the solvent was removed to obtain an orange solid (0.23 g, yield 78%). LCMS (APCI): _{calculated value of C 45} H ₄₀ N ₂ O ₄ (M-): 672; actually measured value: 672. ¹ H NMR (400 MHz, TCE) δ 8.59-8.52 (m, 2H), 8.43 (dd, J = 8.7, 1.1 Hz, 1H), 7.70 (t, J = 7.6 Hz, 2H), 7.32 (d, J = 8.1 Hz, 4H), 7.25 (dd, J = 8.4, 7.2 Hz, 2H), 7.18-7.09 (m, 6H), 7.07 (s, 4H), 7.01 (t, J = 7.3 Hz, 1H), 3.59 (s, 3H), 2.65 (t, J = 7.8 Hz, 2H), 2.56 (t, J = 7.5 Hz, 2H), 2.29 (q, J = 7.0, 6.6 Hz, 2H), 1.89 (p, J = 7.4 Hz, 2H), 1.36 (h, J = 7.5 Hz, 2H), 0.90 (t, J = 7.3 Hz, 3H). Compound 3.4 : To a mixture of 3.3 (0.23 g, 0.34 mol) in 1-butanol (8 mL) was added 5M KOH aqueous solution (0.7 mL, 3.4 mmol), and the whole was heated at 90°C for 1 hour. The reaction mixture was concentrated under reduced pressure to 1 mL, then diluted with 10 mL methanol, and dropped into 20 mL 1N HCl aqueous solution. An orange precipitate formed, and the solid was collected by filtration, washed with water, and dried under vacuum to obtain 180 mg of a red solid (in quantitative yield). LCMS (APCI): _{calculated value of C 34} H ₂₅ NO ₅ (M-): 527; found value: 527.

Compound 3.5 (5,5-Difluoro-10- (4-hydroxy-2,6-dimethylphenyl) -1,3,7,9- tetramethyl -5 H -4λ ^4, 5λ ⁴ - two Pyrrolo [[1,2- c :2',1'- f ][1,3,2] diazepine- 2,8 -diphenylmethyl dicarboxylate ) : To 250 mL round bottom 40 mL (241 mmol) tertiary butyl 3-oxobutyrate dissolved in 80 mL acetic acid was added to the flask. The mixture was cooled to about 10°C in an ice water bath. Sodium nitrite (18 g, 262 mmol) was added over 1 hour while keeping the temperature below 15°C. The cold bath was removed, and the mixture was stirred at room temperature for 3.5 hours. The insoluble matter was filtered off to obtain a crude oxime solution, which was used in the next step without further purification. Next, 50 g of zinc powder (0.76 mol) was added in batches to a mixture of 13.7 mL (79 mmol) of benzyl 3-oxobutyrate and 100 mL of acetic acid. The resulting mixture was stirred in an oil bath and heated to 60°C. The solidified 2-(hydroxyimino-3-oxobutyric acid tertiary butyl ester solution was slowly added. Then the temperature was raised to 75°C and stirred for 1 hour. Then, the reaction mixture was poured into water (4 L) The precipitate was collected and filtered to obtain benzyl 2,4-dimethyl-1H- pyrrole-3-carboxylate, which was recrystallized from MeOH as a white solid to obtain 15 g, and the yield was based on 3-oxo Benzyl butyrate is 65%. ¹ H NMR (400 MHz, CDCl ₃ ): 8.88 (br, s, 1H, NH), 7.47-7.33 (m, 5H, C=CH), 5.29 (s, 2H) , CH ₂ ), 2.53, 2.48 (2s, 6H, 2CH ₃ ), 1.56 (s, 9H, 3CH ₃ ). Then, in a 25 mL vial, add 1 g (4.36 mmol) of 2,4-dimethyl- A mixture of 1 benzyl H -pyrrole-3-carboxylate and 0.524 g (4.36 mmol) MgSO ₄ was dissolved in 8 mL of anhydrous DCE and stirred at room temperature in the presence of argon for 15 minutes. Add in several small portions 0.327 g of 2,6-dimethyl 4-hydroxybenzaldehyde (2.18 mmol); the vial was sealed with a Teflon cap. The resulting mixture was continued to be purged with argon for 15 minutes, and TFA (3 drops, catalytic amount) was added The reaction mixture was stirred at 65°C for 16 hours. TLC and LCMS showed that the starting material had been consumed. To the crude product was added 0.544 g (2.398 mmol) of DDQ at one time. The resulting mixture was stirred at room temperature for ½ hour. TLC and LCMS showed that the starting material had been consumed. The resulting mixture was filtered through short-path diatomaceous earth; the filtrate was concentrated to dryness, and the residue was redissolved in 50 mL of DCE together with trimethylamine (1.4 mL, 19 mmol) at room temperature Stir for 15 minutes, then cool to 0°C. Slowly add 3 mL of BF ₃ -OEt ₂ (18.36 mmol). The resulting mixture was stirred at room temperature for ½ h, and then heated to 86°C for 45 min. Then the reaction mixture was added Dilute with 150 mL of CHCl ₃ and quench with 50 mL of brine. The organic layer was separated and dried over MgSO ₄ , and the solvent was removed by rotary evaporation. The residue was eluted on a silica gel column using CH ₂ Cl ₂ /EtOAc Chromatographic separation of the reagent to obtain 1 g of pure 5,5-difluoro-10-(4-hydroxy-2,6-dimethylphenyl)-1,3,7,9-tetramethyl-5H- 414,514-Dipyrrolo[1,2-c:2',1'-f][1,3,2]diazepine-2,8-diphenylmethyl dicarboxylate), orange-red As a solid, the yield based on 2,6-dimethyl 4-hydroxybenzaldehyde was 72%. LCMS (APCI-), _{calculated value of M- for C 37} H ₃₅ BF ₂ N ₂ O ₅ : 636.26; found value: 636. ¹ H NMR (400 MHz, chloroform- d ) δ 7.42-7.28 (m, 4H), 6.66 (d, J = 0.7 Hz, 1H), 5.29 (d, J = 11.3 Hz, 2H), 2.82 (s, 3H ), 2.04 (d, J = 5.4 Hz, 3H), 1.72 (s, 3H). PLC-3 : Compound 3.4 (72 mg, 0.136 mmol), compound 3.5 [5,5-difluoro-10-(4-hydroxy-2,6-dimethylphenyl)-1,3,7,9 -Tetramethyl-5 H ^{-4λ 4} ,5λ ⁴ -Dipyrrolo[1,2- c :2',1'- f ][1,3,2]diazepine-2,8 -Diphenylmethyl dicarboxylate] (64 mg, 0.1 mmol), a mixture of DMAP/p-TsOH salt (59 mg, 0.2 mmol) and DIC (63 mg, 0.5 mmol) in DCM (5 mL) at room temperature Stir overnight. The resulting mixture was purified by flash chromatography using DCM/ethyl acetate (0%→5%) eluent. The required fractions were collected and concentrated. The solid was further purified by reprecipitation in DCM/methanol to obtain an orange solid (70 mg, 61% yield). LCMS (APCI): _{Calculated value of C 71} H ₅₈ BF ₂ N ₃ O ₉ (M-): 1146; found value: 1146.

化合物 4.1 ：將化合物3.4 (95 mg，0.18 mmol)、4-丁基苯胺(30 mg，0.2 mmol)在3 mL乙醇中的溶液在85℃加熱隔夜。向所得溶液中添加0.1 mL的35% HCl水溶液，並將混合物冷卻至室溫。過濾並風乾，得到淺黃色固體(90 mg，產率為76%)。LCMS (APCI)：C₄₄ H₃₈ N₂ O₄ (M-)的計算值：658；實測值：658。¹ H NMR (400 MHz，氯仿-d ) δ 8.70-8.63 (m, 2H), 8.46 (dd,J = 8.5, 1.2 Hz, 1H), 7.75 (dd,J = 9.3, 7.5 Hz, 2H), 7.40 (d,J = 2.0 Hz, 1H), 7.39-7.27 (m, 5H), 7.26-7.17 (m, 6H), 7.15 (s, 4H), 7.13-7.05 (m, 1H), 2.75-2.64 (m, 4H), 2.43 (t,J = 7.4 Hz, 2H), 2.00 (p,J = 7.5 Hz, 2H), 1.68 (p,J = 7.6 Hz, 2H), 1.42 (h,J = 7.3 Hz, 2H), 0.96 (t,J = 7.3 Hz, 3H)。化合物 PLC-4 ： 將化合物4.1(50 mg，0.076 mmol)、5,5-二氟-10-(4-羥基-2,6-二甲基苯基)-1,3,7,9-四甲基-5H -4λ⁴ ,5λ⁴ -二吡咯并[1,2-c :2',1'-f ][1,3,2]二氮雜環己硼烷-2,8-二甲酸二苯甲酯)(40 mg，0.063 mmol)、DMAP/p-TsOH鹽(60 mg，0.2 mmol)、DIC(63 mg，0.5 mmol)在2 mL DCM中的混合物在室溫下攪拌隔夜。將所得混合物藉由使用DCM/乙酸乙酯(0%à5%)溶離劑進行快速層析法來純化。將所需溶離份收集並濃縮，藉由在DCM/甲醇中再沈澱進一步純化，得到橙色固體(66 mg，產率為82%)。LCMA (APCI)：C₈₁ H₇₁ BF₂ N₄ O₈ (M-)的計算值：1277；實測值：1277。 Example 2.4 : PLC-4

Compound 4.1 : A solution of compound 3.4 (95 mg, 0.18 mmol), 4-butylaniline (30 mg, 0.2 mmol) in 3 mL ethanol was heated at 85°C overnight. To the resulting solution was added 0.1 mL of 35% HCl aqueous solution, and the mixture was cooled to room temperature. It was filtered and air-dried to obtain a pale yellow solid (90 mg, yield 76%). LCMS (APCI): _{calculated value for C 44} H ₃₈ N ₂ O ₄ (M-): 658; found value: 658. ¹ H NMR (400 MHz, chloroform- d ) δ 8.70-8.63 (m, 2H), 8.46 (dd, J = 8.5, 1.2 Hz, 1H), 7.75 (dd, J = 9.3, 7.5 Hz, 2H), 7.40 (d, J = 2.0 Hz, 1H), 7.39-7.27 (m, 5H), 7.26-7.17 (m, 6H), 7.15 (s, 4H), 7.13-7.05 (m, 1H), 2.75-2.64 (m , 4H), 2.43 (t, J = 7.4 Hz, 2H), 2.00 (p, J = 7.5 Hz, 2H), 1.68 (p, J = 7.6 Hz, 2H), 1.42 (h, J = 7.3 Hz, 2H ), 0.96 (t, J = 7.3 Hz, 3H). Compound PLC-4 : Compound 4.1 (50 mg, 0.076 mmol), 5,5-difluoro-10-(4-hydroxy-2,6-dimethylphenyl)-1,3,7,9-tetra Methyl-5 H -4λ ⁴ ,5λ ⁴ -dipyrrolo[1,2- c :2',1'- f ][1,3,2]diazepine-2,8-di A mixture of diphenylmethyl formate) (40 mg, 0.063 mmol), DMAP/p-TsOH salt (60 mg, 0.2 mmol), DIC (63 mg, 0.5 mmol) in 2 mL DCM was stirred at room temperature overnight. The resulting mixture was purified by flash chromatography using DCM/ethyl acetate (0%→5%) eluent. The desired fractions were collected and concentrated, and further purified by reprecipitation in DCM/methanol to obtain an orange solid (66 mg, 82% yield). LCMA (APCI): _{Calculated value of C 81} H ₇₁ BF ₂ N ₄ O ₈ (M-): 1277; actually measured value: 1277.

化合物 5.1 ：將4-溴-1,8-萘二甲酸酐(2.5 g，9 mmol)、2,5-二異丙基苯胺(5 mL，27 mmol)在30 mL丙酸中的混合物在氬氣氛圍下加熱至回流隔夜。將所得混合物冷卻至室溫，接著過濾，用甲醇洗滌並風乾，得到白色固體(3.9 g，產率為99%)。LCMS (APCI)：C₂₄ H₂₂ BrNO₂ (M-)的計算值：435；實測值：435。¹ H NMR (400 MHz) δ 8.64-8.54 (m, 2H), 8.36 (d,J = 7.8 Hz, 1H), 8.04 (d,J = 7.8 Hz, 1H), 7.84 (dd,J = 8.5, 7.3 Hz, 1H), 7.39 (t,J = 7.7 Hz, 1H), 7.23 (d,J = 7.7 Hz, 2H), 2.59 (p,J = 6.8 Hz, 2H), 1.04 (d,J = 6.9 Hz, 12H)。化合物 5.2 ： 將化合物5.1 (1.0 g，2.29 mmol)、N,N'-二苯胺(0.62 g，3.7 mmol)、Pd(dppf)Cl₂ (0.15 g，0.2 mmol)和三級丁醇鈉(0.36 g，3.8 mmol)在無水甲苯(25 mL)中的混合物除氣並在110℃下加熱隔夜。將所得混合物裝載到矽膠上，並藉由使用己烷/DCM(0%à20% DCM)溶離劑進行快速層析法來純化。收集所需溶離份並移除溶劑，得到固體(0.75 g，產率為62%)。LCMS (APCI)：C₃₆ H₃₃ N₂ O₂ (M+H)的計算值：525；實測值：525。化合物 5.3.1 和5.3.2 ：向化合物5.2 (0.4 g，0.76 mmol)在DCE(20 mL)中的溶液中添加4-氯-4-側氧基丁酸甲酯(0.24 g，1.6 mmol)和1.0 M ZnCl₂ 的乙醚溶液(1.0 mL，1.0 mmol)。將所得混合物除氣並在50℃加熱，接著使用己烷/DCM(50%à100% DCM)和DCM/乙酸乙酯(0%à60%乙酸乙酯)溶離劑進行快速層析法純化。收集兩種所需溶離份，濃縮極性較低的溶離份，得到紅色固體，該紅色固體表徵為酯化合物5.3.1 (250 mg，產率為52%)。LCMS (APCI)：C₄₁ H₃₉ N₂ O₅ (M+H)的計算值：639；實測值：639。將極性最高的溶離份濃縮，得到另一種紅色固體，該紅色固體表徵為酸，即化合物5.3.2 (62 mg，產率為12.6%)。LCMS (APCI)：C₄₀ H₃₆ N₂ O₅ (M-)的計算值：624；實測值：624。PLC-5 ：將化合物5.3.1 (62 mg，0.1 mmol)、化合物3.5 [5,5-二氟-10-(4-羥基-2,6-二甲基苯基)-1,3,7,9-四甲基-5H -4λ⁴ ,5λ⁴ -二吡咯并[1,2-c :2',1'-f ][1,3,2]二氮雜環己硼烷-2,8-二甲酸二苯甲酯](57 mg，0.09 mmol)、DIC (63 mg，0.5 mmol)、DMAP/p-TsOH鹽(60 mg，0.2 mmol)在DCM (5 mL)中的混合物在室溫下攪拌隔夜。所得混合物使用己烷/乙酸乙酯(0%à30%乙酸乙酯)溶離劑進行快速層析法純化。將所需溶離份收集並濃縮，得到黃色固體(30 mg，產率為27%)。LCMS (APCI)：C₇₇ H₆₉ BF₂ N₄ O₉ (M+)的計算值：1242；實測值：1242。¹ H NMR (400 MHz, ) δ 8.56-8.46 (m, 2H), 8.14 (d,J = 8.8 Hz, 1H), 7.81 (d,J = 8.8 Hz, 2H), 7.62-7.53 (m, 1H), 7.47 (d,J = 8.0 Hz, 1H), 7.39 (t,J = 7.8 Hz, 1H), 7.32-7.21 (m, 14H), 7.16 (d,J = 7.6 Hz, 3H), 6.93 (d,J = 7.9 Hz, 4H), 5.18 (s, 4H), 3.27 (s, 2H), 2.91 (s, 2H), 2.74 (s, 6H), 2.65 (t,J = 6.8 Hz, 2H), 2.03 (s, 6H), 1.62 (s, 6H), 1.07 (d,J = 6.8 Hz, 12H)。 Example 2.5 : PLC-5

Compound 5.1 : A mixture of 4-bromo-1,8-naphthalenedicarboxylic acid anhydride (2.5 g, 9 mmol), 2,5-diisopropylaniline (5 mL, 27 mmol) in 30 mL of propionic acid, and argon Heat to reflux overnight under air atmosphere. The resulting mixture was cooled to room temperature, then filtered, washed with methanol and air-dried to obtain a white solid (3.9 g, yield 99%). LCMS (APCI): _{calculated value of C 24} H ₂₂ BrNO ₂ (M-): 435; actually measured value: 435. ¹ H NMR (400 MHz) δ 8.64-8.54 (m, 2H), 8.36 (d, J = 7.8 Hz, 1H), 8.04 (d, J = 7.8 Hz, 1H), 7.84 (dd, J = 8.5, 7.3 Hz, 1H), 7.39 (t, J = 7.7 Hz, 1H), 7.23 (d, J = 7.7 Hz, 2H), 2.59 (p, J = 6.8 Hz, 2H), 1.04 (d, J = 6.9 Hz, 12H). Compound 5.2 : Combine compound 5.1 (1.0 g, 2.29 mmol), N,N'-diphenylamine (0.62 g, 3.7 mmol), Pd(dppf)Cl ₂ (0.15 g, 0.2 mmol) and sodium tertiary butoxide (0.36 g, 3.8 mmol) in anhydrous toluene (25 mL) was degassed and heated at 110°C overnight. The resulting mixture was loaded on silica gel and purified by flash chromatography using hexane/DCM (0%→20% DCM) eluent. Collect the required fractions and remove the solvent to obtain a solid (0.75 g, 62% yield). LCMS (APCI): _{calculated value for C 36} H ₃₃ N ₂ O ₂ (M+H): 525; actually measured value: 525. Compounds 5.3.1 and 5.3.2 : To a solution of compound 5.2 (0.4 g, 0.76 mmol) in DCE (20 mL) was added methyl 4-chloro-4-oxobutyrate (0.24 g, 1.6 mmol) And 1.0 M ZnCl ₂ in ether (1.0 mL, 1.0 mmol). The resulting mixture was degassed and heated at 50°C, followed by flash chromatography purification using hexane/DCM (50%→100% DCM) and DCM/ethyl acetate (0%→60% ethyl acetate) eluents. Two required fractions were collected, and the less polar fraction was concentrated to obtain a red solid, which was characterized as ester compound 5.3.1 (250 mg, yield 52%). LCMS (APCI): _{calculated value for C 41} H ₃₉ N ₂ O ₅ (M+H): 639; found value: 639. The most polar fraction was concentrated to obtain another red solid, which was characterized as an acid, namely compound 5.3.2 (62 mg, yield 12.6%). LCMS (APCI): _{calculated value for C 40} H ₃₆ N ₂ O ₅ (M-): 624; actually measured value: 624. PLC-5 : Compound 5.3.1 (62 mg, 0.1 mmol), compound 3.5 [5,5-difluoro-10-(4-hydroxy-2,6-dimethylphenyl)-1,3,7 ,9-Tetramethyl-5 H -4λ ⁴ ,5λ ⁴ -Dipyrrolo[1,2- c :2',1'- f ][1,3,2]diazepine-2 ,8-Diphenylmethyl dicarboxylate] (57 mg, 0.09 mmol), DIC (63 mg, 0.5 mmol), DMAP/p-TsOH salt (60 mg, 0.2 mmol) in DCM (5 mL) in a mixture Stir overnight at room temperature. The resulting mixture was purified by flash chromatography using hexane/ethyl acetate (0%→30% ethyl acetate) eluent. The required fractions were collected and concentrated to obtain a yellow solid (30 mg, 27% yield). LCMS (APCI): _{calculated value of C 77} H ₆₉ BF ₂ N ₄ O ₉ (M+): 1242; found value: 1242. ¹ H NMR (400 MHz,) δ 8.56-8.46 (m, 2H), 8.14 (d, J = 8.8 Hz, 1H), 7.81 (d, J = 8.8 Hz, 2H), 7.62-7.53 (m, 1H) , 7.47 (d, J = 8.0 Hz, 1H), 7.39 (t, J = 7.8 Hz, 1H), 7.32-7.21 (m, 14H), 7.16 (d, J = 7.6 Hz, 3H), 6.93 (d, J = 7.9 Hz, 4H), 5.18 (s, 4H), 3.27 (s, 2H), 2.91 (s, 2H), 2.74 (s, 6H), 2.65 (t, J = 6.8 Hz, 2H), 2.03 ( s, 6H), 1.62 (s, 6H), 1.07 (d, J = 6.8 Hz, 12H).

PLC-6((T -4)-[2-[(4,5- 二氫 -3- 甲基 -2H- 苯并 [g ] 吲哚 -2- 亞基 -κN )(3,5- 二甲基 -4-(4-((2-(2,6- 二異丙基苯基 )-1,3- 二側氧基 -2,3- 二氫 -1H - 苯并 [de ] 異喹啉 -6- 基 ) 苯基 ) 甲基 ]-4,5- 二氫 -3- 甲基 -1H - 苯并 [g ] 吲哚 -κN ] 二氟化硼 ) ： 將4-(4-((2-(2,6-二異丙基苯基)-1,3-二側氧基-2,3-二氫-1H-苯并[de]異喹啉-6-基)(苯基)胺基)苯基)-4-側氧基丁酸(0.050 mmol，31 mg)、化合物20.3 (參見下文)(0.055 mmol，30 mg)、DAMP/p-TsOH鹽(60 mg，0.2 mmol)、DIC (63 mg，0.5 mmol)在DCM (5 mL)中的混合物在室溫下攪拌隔夜。所得混合物使用DCM/乙酸乙酯(0%à5%乙酸乙酯)溶離劑進行快速層析法純化。粗產物藉由在矽膠(60%甲苯/己烷(2 CV)à100%甲苯(等度))上進行快速層析法而純化。將含有產物的溶離份蒸發至乾，得到37 mg (產率為64%)。MS (APCI)：針對化學式C₇₅ H₆₅ BF₂ N₄ O₅ (M-)的計算值=1150，實測值：1150。¹ H NMR (400 MHz，四氯乙烷-d₂ ) δ 8.76 (d,J = 8.1 Hz, 2H), 8.60 (dd,J = 7.3, 1.1 Hz, 1H), 8.59 (d,J = 7.9 Hz, 1H), 8.24 (dd,J = 8.6, 1.2 Hz, 1H), 7.92 (d,J = 8.9 Hz, 2H), 7.66 (dd,J = 8.4, 7.4 Hz, 1H), 7.56 (d,J = 7.9 Hz, 1H), 7.48 (t,J = 7.8 Hz, 1H), 7.46-7.37 (m, 4H), 7.37-7.28 (m, 6H), 7.27-7.22 (m, 3H), 7.03 (d,J = 9.1 Hz, 2H), 7.02 (s, 2H), 3.38 (t,J = 6.2 Hz, 2H), 3.03 (t,J = 6.2 Hz, 2H), 2.91 (t,J = 7.0 Hz, 4H), 2.74 (hept,J = 6.8 Hz, 2H), 2.56 (t,J = 7.1 Hz, 2H), 2.23 (s, 6H), 1.40 (s, 6H), 1.17 (d,J = 6.8 Hz, 12H)。 Example 2.6 : PLC-6

PLC-6(( T -4)-[2-[(4,5 -Dihydro- 3 -methyl -2H- benzo [ g ] indole- 2- ylidene- κ N )(3,5- Dimethyl- 4-(4-((2-(2,6 -diisopropylphenyl )-1,3 -dioxy -2,3 -dihydro- 1 H -benzo [ de ] isoquinolin-6-yl) phenyl) methyl] -4,5-dihydro-3-methyl -1 H - benzo [g] indol--κ N] boron difluoride): 4- (4-((2-(2,6-Diisopropylphenyl)-1,3-di-side oxy-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl )(Phenyl)amino)phenyl)-4-oxobutyric acid (0.050 mmol, 31 mg), compound 20.3 (see below) (0.055 mmol, 30 mg), DAMP/p-TsOH salt (60 mg A mixture of 0.2 mmol), DIC (63 mg, 0.5 mmol) in DCM (5 mL) was stirred overnight at room temperature. The resulting mixture was quickly prepared using DCM/ethyl acetate (0%→5% ethyl acetate) eluent Purified by chromatography. The crude product was purified by flash chromatography on silica gel (60% toluene/hexane (2 CV) à 100% toluene (isocratic)). The fraction containing the product was evaporated to dryness to obtain 37 mg (64% yield). MS (APCI): _{calculated value for chemical formula C 75} H ₆₅ BF ₂ N ₄ O ₅ (M-) = 1150, measured value: 1150. ¹ H NMR (400 MHz, four Chloroethane- d ₂ ) δ 8.76 (d, J = 8.1 Hz, 2H), 8.60 (dd, J = 7.3, 1.1 Hz, 1H), 8.59 (d, J = 7.9 Hz, 1H), 8.24 (dd, J = 8.6, 1.2 Hz, 1H), 7.92 (d, J = 8.9 Hz, 2H), 7.66 (dd, J = 8.4, 7.4 Hz, 1H), 7.56 (d, J = 7.9 Hz, 1H), 7.48 ( t, J = 7.8 Hz, 1H), 7.46-7.37 (m, 4H), 7.37-7.28 (m, 6H), 7.27-7.22 (m, 3H), 7.03 (d, J = 9.1 Hz, 2H), 7.02 (s, 2H), 3.38 (t, J = 6.2 Hz, 2H), 3.03 (t, J = 6.2 Hz, 2H), 2.91 (t, J = 7.0 Hz, 4H), 2.74 (hept, J = 6.8 H z, 2H), 2.56 (t, J = 7.1 Hz, 2H), 2.23 (s, 6H), 1.40 (s, 6H), 1.17 (d, J = 6.8 Hz, 12H).

化合物 7.1 ：將4-溴-1,8-萘二甲酸酐(2.78 g，10 mmol)、γ-胺基丁酸三級丁酯鹽酸鹽(2.35 g，12 mmol)、三乙胺(1.21 g，12 mmol)在60 mL乙醇中的混合物在氬氣下回流加熱隔夜。將混合物冷卻至室溫並靜置4小時。過濾並用甲醇洗滌，接著風乾，得到淺黃色固體作為所需產物(3.48 g，產率為83%)。LCMS (APCI)：C₂₀ H₂₀ BrNO₄ (M+)的計算值：418；實測值：418。¹ H NMR (400 MHz，氯仿-d ) δ 8.68 (dd,J = 7.3, 1.2 Hz, 1H), 8.59 (dd,J = 8.5, 1.2 Hz, 1H), 8.43 (d,J = 7.8 Hz, 1H), 8.06 (d,J = 7.9 Hz, 1H), 7.87 (dd,J = 8.5, 7.3 Hz, 1H), 4.25 (dd,J = 7.7, 6.8 Hz, 2H), 2.38 (t,J = 7.5 Hz, 2H), 2.06 (p,J = 7.4 Hz, 2H), 1.44 (s, 9H)。化合物 7.2 ： 將化合物7.1 (1.0 g，2.4 mmol)、N,N'-二苯胺(0.62 g，3.7 mmol)、Pd(dppf)Cl₂ (0.15 g，0.2 mmol)、三級丁醇鈉(0.36 g，3.7 mmol)在無水甲苯(25 mL)中的混合物除氣並在110℃下加熱隔夜。冷卻至室溫後，將反應混合物用100 mL DCM稀釋，濾除固體，將溶液濃縮至25 mL，接著使用DCM/乙酸乙酯(0%à5%乙酸乙酯)溶離劑進行柱層析純化。收集橙色溶離份並減壓移除溶劑，得到橙色固體(0.65 g，產率53%)。LCMS (APCI)：C₃₂ H₃₁ N₂ O₄ (M+H)的計算值：507；實測值：507。¹ H NMR (400 MHz，氯仿-d ) δ 8.58-8.49 (m, 4H), 8.20 (dd,J = 8.6, 1.2 Hz, 2H), 7.51 (dd,J = 8.5, 7.3 Hz, 2H), 7.39 (d,J = 8.0 Hz, 2H), 7.32-7.23 (m, 8H), 7.13-7.07 (m, 3H), 7.07-7.01 (m, 8H), 4.30-4.22 (m, 4H), 4.14 (q,J = 7.2 Hz, 1H), 2.38 (dd,J = 8.0, 7.2 Hz, 4H), 2.13 - 2.01 (m, 5H), 1.28 (t,J = 7.1 Hz, 2H)。化合物 7.3 ： 將化合物7.2 (0.65 g)在DCM/TFA (10 mL/10 mL)中的溶液在室溫下攪拌隔夜，接著減壓移除溶劑。將所得油性固體再溶於20 mL甲醇中，接著在攪拌的同時將溶液滴入水(100 mL)中。將所得沈澱物過濾並風乾，得到橙色固體(0.45 g，產率為78%)。LCMS (APCI)：C₂₈ H₂₃ N₂ O₄ (M+H)的計算值：451；實測值：451。¹ H NMR (400 MHz，氯仿-d ) δ 8.59-8.49 (m, 2H), 8.21 (dd,J = 8.5, 1.1 Hz, 1H), 7.52 (dd,J = 8.5, 7.2 Hz, 1H), 7.40 (d,J = 8.0 Hz, 1H), 7.33-7.24 (m, 4H), 7.14-7.02 (m, 6H), 4.30 (t,J = 6.9 Hz, 2H), 2.51 (t,J = 7.4 Hz, 2H), 2.14 (p,J = 7.2 Hz, 2H)。PLC-7 ： 將化合物7.3 (50 mg，0.11 mmol)、5,5-二氟-10-(4-羥基-2,6-二甲基苯基)-1,3,7,9-四甲基-5H -4λ⁴ ,5λ⁴ -二吡咯并[1,2-c :2',1'-f ][1,3,2]二氮雜環己硼烷-2,8-二甲酸二苯甲酯)(64 mg，0.1 mol)、DMAP/p-TsOH鹽(59 mg，0.2 mmol)、DIC (63 mg，0.5 mmol)在DCM (5 mL)中的混合物在室溫下攪拌隔夜，接著提交進行使用DCM/乙酸乙酯(0%à10%乙酸乙酯)溶離劑的快速層析法純化。收集所需溶離份，並移除溶劑，得到橙色固體(75 mg，產率為70%)。LCMS (APCI)：C₆₅ H₅₅ BF₂ N₄ O₈ (M-)的計算值：1068；實測值：1068。¹ H NMR (400 MHz, TCE) δ 8.57-8.37 (m, 2H), 8.15 (dd,J = 8.6, 1.2 Hz, 1H), 7.48 (dd,J = 8.6, 7.3 Hz, 1H), 7.38-7.28 (m, 11H), 7.23 (dd,J = 8.4, 7.3 Hz, 4H), 7.09-6.93 (m, 8H), 5.23 (s, 4H), 4.27 (t,J = 7.0 Hz, 2H), 2.79 (s, 6H), 2.69 (t,J = 7.3 Hz, 2H), 2.17 (t,J = 7.1 Hz, 2H), 2.07 (s, 6H), 1.66 (s, 6H)。 Example 2.7 : PLC-7

Compound 7.1 : Combine 4-bromo-1,8-naphthalenedicarboxylic acid anhydride (2.78 g, 10 mmol), γ-aminobutyric acid tertiary butyl hydrochloride (2.35 g, 12 mmol), triethylamine (1.21 g, 12 mmol) in 60 mL ethanol was heated at reflux under argon overnight. The mixture was cooled to room temperature and allowed to stand for 4 hours. It was filtered and washed with methanol, followed by air drying to obtain a light yellow solid as the desired product (3.48 g, yield 83%). LCMS (APCI): _{calculated value of C 20} H ₂₀ BrNO ₄ (M+): 418; actually measured value: 418. ¹ H NMR (400 MHz, chloroform- d ) δ 8.68 (dd, J = 7.3, 1.2 Hz, 1H), 8.59 (dd, J = 8.5, 1.2 Hz, 1H), 8.43 (d, J = 7.8 Hz, 1H ), 8.06 (d, J = 7.9 Hz, 1H), 7.87 (dd, J = 8.5, 7.3 Hz, 1H), 4.25 (dd, J = 7.7, 6.8 Hz, 2H), 2.38 (t, J = 7.5 Hz , 2H), 2.06 (p, J = 7.4 Hz, 2H), 1.44 (s, 9H). Compound 7.2 : Combine compound 7.1 (1.0 g, 2.4 mmol), N,N'-diphenylamine (0.62 g, 3.7 mmol), Pd(dppf)Cl ₂ (0.15 g, 0.2 mmol), sodium tertiary butoxide (0.36 g, 3.7 mmol) in anhydrous toluene (25 mL) was degassed and heated at 110°C overnight. After cooling to room temperature, the reaction mixture was diluted with 100 mL DCM, the solid was filtered off, the solution was concentrated to 25 mL, and then purified by column chromatography using DCM/ethyl acetate (0%→5% ethyl acetate) eluent. The orange fractions were collected and the solvent was removed under reduced pressure to obtain an orange solid (0.65 g, yield 53%). LCMS (APCI): _{calculated value for C 32} H ₃₁ N ₂ O ₄ (M+H): 507; actually measured value: 507. ¹ H NMR (400 MHz, chloroform- d ) δ 8.58-8.49 (m, 4H), 8.20 (dd, J = 8.6, 1.2 Hz, 2H), 7.51 (dd, J = 8.5, 7.3 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 7.32-7.23 (m, 8H), 7.13-7.07 (m, 3H), 7.07-7.01 (m, 8H), 4.30-4.22 (m, 4H), 4.14 (q , J = 7.2 Hz, 1H), 2.38 (dd, J = 8.0, 7.2 Hz, 4H), 2.13-2.01 (m, 5H), 1.28 (t, J = 7.1 Hz, 2H). Compound 7.3 : A solution of compound 7.2 (0.65 g) in DCM/TFA (10 mL/10 mL) was stirred at room temperature overnight, and then the solvent was removed under reduced pressure. The obtained oily solid was redissolved in 20 mL of methanol, and then the solution was dropped into water (100 mL) while stirring. The resulting precipitate was filtered and air-dried to obtain an orange solid (0.45 g, yield 78%). LCMS (APCI): _{calculated value for C 28} H ₂₃ N ₂ O ₄ (M+H): 451; found value: 451. ¹ H NMR (400 MHz, chloroform- d ) δ 8.59-8.49 (m, 2H), 8.21 (dd, J = 8.5, 1.1 Hz, 1H), 7.52 (dd, J = 8.5, 7.2 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.33-7.24 (m, 4H), 7.14-7.02 (m, 6H), 4.30 (t, J = 6.9 Hz, 2H), 2.51 (t, J = 7.4 Hz, 2H), 2.14 (p, J = 7.2 Hz, 2H). PLC-7 : Compound 7.3 (50 mg, 0.11 mmol), 5,5-difluoro-10-(4-hydroxy-2,6-dimethylphenyl)-1,3,7,9-tetramethyl Group -5 H ^{-4λ 4} ,5λ ⁴ -dipyrrolo[1,2- c :2',1'- f ][1,3,2]diazepine-2,8-dicarboxylic acid A mixture of diphenylmethyl ester) (64 mg, 0.1 mol), DMAP/p-TsOH salt (59 mg, 0.2 mmol), DIC (63 mg, 0.5 mmol) in DCM (5 mL) was stirred at room temperature overnight , And then submitted for purification by flash chromatography using DCM/ethyl acetate (0%→10% ethyl acetate) eluent. Collect the required fractions and remove the solvent to obtain an orange solid (75 mg, yield 70%). LCMS (APCI): _{calculated value of C 65} H ₅₅ BF ₂ N ₄ O ₈ (M-): 1068; actually measured value: 1068. ¹ H NMR (400 MHz, TCE) δ 8.57-8.37 (m, 2H), 8.15 (dd, J = 8.6, 1.2 Hz, 1H), 7.48 (dd, J = 8.6, 7.3 Hz, 1H), 7.38-7.28 (m, 11H), 7.23 (dd, J = 8.4, 7.3 Hz, 4H), 7.09-6.93 (m, 8H), 5.23 (s, 4H), 4.27 (t, J = 7.0 Hz, 2H), 2.79 ( s, 6H), 2.69 (t, J = 7.3 Hz, 2H), 2.17 (t, J = 7.1 Hz, 2H), 2.07 (s, 6H), 1.66 (s, 6H).

化合物 8.1 ： 將化合物7.1 (1.0 g，2.4 mmol)、(4-(二苯基胺基)苯基)

酸(0.69 g，2.4 mmol)、Pd(PPh₃ )₄ (115 mg，0.1 mmol)、K₂ CO₃ (0.48 g，3.5 mmol)在二㗁烷/水(10 mL/2 mL)中的混合物除氣，接著在氬氣下在80℃加熱隔夜。將所得混合物用50 mL甲苯稀釋，用鹽水洗滌，經Na₂ SO₄ 乾燥，接著減壓移除溶劑。將所得油性固體溶於10 mL DCM中，接著使用己烷/乙酸乙酯(0%à15%乙酸乙酯)溶離劑進行快速層析法純化。收集所需溶離份，並移除溶劑，得到黃橙色固體(1.28 g，產率為91.5%)。LCMS (APCI)：C₃₈ H₃₅ N₂ O₄ (M+H)的計算值：583；實測值：583。¹ H NMR (400 MHz, TCE) δ 8.62-8.54 (m, 2H), 8.40 (dd,J = 8.5, 1.2 Hz, 1H), 7.71 (dt,J = 7.3, 4.1 Hz, 2H), 7.39-7.32 (m, 2H), 7.32-7.25 (m, 4H), 7.22-7.14 (m, 6H), 7.11-7.02 (m, 2H), 4.18 (t,J = 7.2 Hz, 2H), 2.33 (t,J = 7.6 Hz, 2H), 1.99 (p,J = 7.5 Hz, 2H), 1.39 (s, 9H)。化合物 8.2 ： 將化合物8.1 (50 mg)在DCM/TFA (1 mL/1 mL)中的溶液在室溫下攪拌隔夜。在移除溶劑後，將殘餘固體溶於2 mL甲醇中，接著滴加至水(5 mL)中。將沈澱物藉由過濾收集並用水洗滌，並風乾(36 mg，產率為78%)。LCMS (APCI)：C₃₄ H₂₇ N₂ O₄ (M+H)的計算值：527；實測值：527。PLC-8 ：將化合物8.2 (36 mg，0.068 mmol)、化合物3.5 (38 mg，0.06 mmol)、DMAP/p-TsOH鹽(59 mg，0.2 mmol)和DIC (63 mg，0.5 mmol)在DCM (5 mL)中的混合物在室溫下攪拌隔夜。所得混合物提交使用DCM/乙酸乙酯(0%à5%乙酸乙酯)溶離劑進行快速層析法純化。收集所需溶離份，並減壓濃縮。固體藉由在DCM/甲醇中再沈澱進一步純化，得到橙色固體(50 mg，產率為73%)。LCMS (APCI)：C₇₁ H₆₀ BF₂ N₄ O₈ (M+H)的計算值：1145；實測值：1145。¹ H NMR (400 MHz, TCE) δ 8.56 (dd,J = 7.5, 3.2 Hz, 2H), 8.38 (d,J = 8.5 Hz, 1H), 7.67 (dt,J = 8.1, 4.1 Hz, 2H), 7.33-7.21 (m, 16H), 7.18-7.10 (m, 6H), 7.04 (q,J = 8.1, 7.3 Hz, 2H), 6.88 (s, 2H), 5.18 (s, 4H), 4.26 (t,J = 6.9 Hz, 2H), 2.74 (s, 6H), 2.66 (t,J = 7.2 Hz, 2H), 2.22 -2.10 (m, 2H), 2.01 (s, 6H), 1.60 (s, 6H)。 Example 2.8 : PLC-8

Compound 8.1 : Compound 7.1 (1.0 g, 2.4 mmol), (4-(diphenylamino)phenyl)

A mixture of acid (0.69 g, 2.4 mmol), Pd(PPh ₃ ) ₄ (115 mg, 0.1 mmol), K ₂ CO ₃ (0.48 g, 3.5 mmol) in diethane/water (10 mL/2 mL) Degassed, followed by heating at 80°C overnight under argon. The resulting mixture was diluted with 50 mL of toluene, washed with brine, dried over Na ₂ SO _4, then the solvent was removed under reduced pressure. The obtained oily solid was dissolved in 10 mL DCM, and then purified by flash chromatography using hexane/ethyl acetate (0%→15% ethyl acetate) eluent. Collect the required fractions and remove the solvent to obtain a yellow-orange solid (1.28 g, yield 91.5%). LCMS (APCI): _{calculated value for C 38} H ₃₅ N ₂ O ₄ (M+H): 583; found value: 583. ¹ H NMR (400 MHz, TCE) δ 8.62-8.54 (m, 2H), 8.40 (dd, J = 8.5, 1.2 Hz, 1H), 7.71 (dt, J = 7.3, 4.1 Hz, 2H), 7.39-7.32 (m, 2H), 7.32-7.25 (m, 4H), 7.22-7.14 (m, 6H), 7.11-7.02 (m, 2H), 4.18 (t, J = 7.2 Hz, 2H), 2.33 (t, J = 7.6 Hz, 2H), 1.99 (p, J = 7.5 Hz, 2H), 1.39 (s, 9H). Compound 8.2 : A solution of compound 8.1 (50 mg) in DCM/TFA (1 mL/1 mL) was stirred at room temperature overnight. After removing the solvent, the residual solid was dissolved in 2 mL of methanol, and then added dropwise to water (5 mL). The precipitate was collected by filtration, washed with water, and air-dried (36 mg, yield 78%). LCMS (APCI): _{calculated value for C 34} H ₂₇ N ₂ O ₄ (M+H): 527; found value: 527. PLC-8 : Compound 8.2 (36 mg, 0.068 mmol), compound 3.5 (38 mg, 0.06 mmol), DMAP/p-TsOH salt (59 mg, 0.2 mmol) and DIC (63 mg, 0.5 mmol) in DCM ( The mixture in 5 mL) was stirred at room temperature overnight. The resulting mixture was submitted for purification by flash chromatography using DCM/ethyl acetate (0%→5% ethyl acetate) eluent. Collect the required fractions and concentrate under reduced pressure. The solid was further purified by reprecipitation in DCM/methanol to obtain an orange solid (50 mg, 73% yield). LCMS (APCI): _{calculated value of C 71} H ₆₀ BF ₂ N ₄ O ₈ (M+H): 1145; found value: 1145. ¹ H NMR (400 MHz, TCE) δ 8.56 (dd, J = 7.5, 3.2 Hz, 2H), 8.38 (d, J = 8.5 Hz, 1H), 7.67 (dt, J = 8.1, 4.1 Hz, 2H), 7.33-7.21 (m, 16H), 7.18-7.10 (m, 6H), 7.04 (q, J = 8.1, 7.3 Hz, 2H), 6.88 (s, 2H), 5.18 (s, 4H), 4.26 (t, J = 6.9 Hz, 2H), 2.74 (s, 6H), 2.66 (t, J = 7.2 Hz, 2H), 2.22 -2.10 (m, 2H), 2.01 (s, 6H), 1.60 (s, 6H).

化合物 9.1 ： 將4-(4-胺基苯基)丁酸(3.3 g，18 mmol)、4-溴-1,8-萘二甲酸酐(4.43 g，16 mmol)在乙醇(80 mL)中的混合物加熱至回流隔夜。冷卻至室溫後，將混合物過濾並用乙醇洗滌，風乾得到淺黃色固體(6.2 g，產率為88%)。LCMS (APCI)：C₂₂ H₁₇ BrNO₄ (M+H)的計算值：438；實測值：438。¹ H NMR (400 MHz，氯仿-d ) δ 8.70 (dd,J = 7.3, 1.2 Hz, 1H), 8.63 (dd,J = 8.5, 1.2 Hz, 1H), 8.45 (d,J = 7.9 Hz, 1H), 8.08 (d,J = 7.9 Hz, 1H), 7.88 (dd,J = 8.5, 7.3 Hz, 1H), 7.42-7.34 (m, 2H), 7.27-7.19 (m, 2H), 2.78 (t,J = 7.6 Hz, 2H), 2.44 (t,J = 7.3 Hz, 2H), 2.11-1.99 (m, 2H)。化合物 9.2 ：將化合物9.1 (1.0 g，2.3 mmol)、(4-(二苯基胺基)苯基)

酸(0.69 g，2.4 mmol)、Pd(PPh₃ )₄ (115 mg，0.1 mmol)、K₂ CO₃ (0.48 g，3.5 mmol)在乙醇/水(20 mL/1 mL)中的混合物除氣，並在80℃加熱隔夜。將所得混合物過濾並用乙醇洗滌，並風乾，得到固體(1.80 g，定量產率)。LCMS (APCI)：C₄₀ H₂₉ N₂ O₄ (M-K)的計算值：602；實測值：602。¹ H NMR (400 MHz, TCE) δ 8.24 (d,J = 22.7 Hz, 2H), 8.10 (d,J = 8.2 Hz, 1H), 7.33 (s, 3H), 7.25 (d,J = 7.8 Hz, 3H), 7.20-7.07 (m, 7H), 7.06-6.91 (m, 17H), 2.61 (bs, 2H), 2.19 (bs, 2H), 1.89 (bs, 2H)。PLC-9 ： 將化合物9.2 (72 mg，0.11 mmol)、化合物3.5 (50 mg，0.079 mmol)、DMAP/p-TsOH鹽(60 mg，0.2 mmol)、DIC(63 mg，0.5 mmol)在DCM(5 mL)中的混合物在室溫下攪拌隔夜。所得混合物使用DCM/乙酸乙酯(0%à5%乙酸乙酯)溶離劑進行快速層析法純化。收集主溶離份，並移除溶劑，得到橙色固體(88 mg，產率為91%)。LCMS (APCI)：C₇₇ H₆₃ BF₂ N₄ O₈ (M-)的計算值：1220；實測值：1220。¹ H NMR (400 MHz, TCE) δ 8.60-8.53 (m, 2H), 8.43 (dd,J = 8.5, 1.2 Hz, 1H), 7.76-7.67 (m, 2H), 7.38 (d,J = 8.1 Hz, 2H), 7.36-7.25 (m, 14H), 7.25-7.19 (m, 4H), 7.19-7.12 (m, 6H), 7.04 (t,J = 7.4 Hz, 2H), 6.92 (s, 2H), 5.19 (s, 4H), 2.81 (t,J = 7.5 Hz, 2H), 2.75 (s, 6H), 2.61 (t,J = 7.4 Hz, 2H), 2.10 (t,J = 7.5 Hz, 2H), 2.05 (s, 6H), 1.64 (s, 6H)。 Example 2.9 : PLC-9

Compound 9.1 : Combine 4-(4-aminophenyl)butyric acid (3.3 g, 18 mmol), 4-bromo-1,8-naphthalenedicarboxylic acid anhydride (4.43 g, 16 mmol) in ethanol (80 mL) The mixture was heated to reflux overnight. After cooling to room temperature, the mixture was filtered and washed with ethanol, and air-dried to obtain a pale yellow solid (6.2 g, yield 88%). LCMS (APCI): _{calculated value of C 22} H ₁₇ BrNO ₄ (M+H): 438; actually measured value: 438. ¹ H NMR (400 MHz, chloroform- d ) δ 8.70 (dd, J = 7.3, 1.2 Hz, 1H), 8.63 (dd, J = 8.5, 1.2 Hz, 1H), 8.45 (d, J = 7.9 Hz, 1H ), 8.08 (d, J = 7.9 Hz, 1H), 7.88 (dd, J = 8.5, 7.3 Hz, 1H), 7.42-7.34 (m, 2H), 7.27-7.19 (m, 2H), 2.78 (t, J = 7.6 Hz, 2H), 2.44 (t, J = 7.3 Hz, 2H), 2.11-1.99 (m, 2H). Compound 9.2 : Compound 9.1 (1.0 g, 2.3 mmol), (4-(diphenylamino)phenyl)

Degas a mixture of acid (0.69 g, 2.4 mmol), Pd(PPh ₃ ) ₄ (115 mg, 0.1 mmol), K ₂ CO ₃ (0.48 g, 3.5 mmol) in ethanol/water (20 mL/1 mL) , And heated at 80°C overnight. The resulting mixture was filtered and washed with ethanol, and air-dried to obtain a solid (1.80 g, quantitative yield). LCMS (APCI): _{calculated value for C 40} H ₂₉ N ₂ O ₄ (MK): 602; actually measured value: 602. ¹ H NMR (400 MHz, TCE) δ 8.24 (d, J = 22.7 Hz, 2H), 8.10 (d, J = 8.2 Hz, 1H), 7.33 (s, 3H), 7.25 (d, J = 7.8 Hz, 3H), 7.20-7.07 (m, 7H), 7.06-6.91 (m, 17H), 2.61 (bs, 2H), 2.19 (bs, 2H), 1.89 (bs, 2H). PLC-9 : Compound 9.2 (72 mg, 0.11 mmol), compound 3.5 (50 mg, 0.079 mmol), DMAP/p-TsOH salt (60 mg, 0.2 mmol), DIC (63 mg, 0.5 mmol) in DCM ( The mixture in 5 mL) was stirred at room temperature overnight. The resulting mixture was purified by flash chromatography using DCM/ethyl acetate (0%→5% ethyl acetate) eluent. The main fractions were collected and the solvent was removed to obtain an orange solid (88 mg, yield 91%). LCMS (APCI): _{Calculated value for C 77} H ₆₃ BF ₂ N ₄ O ₈ (M-): 1220; found value: 1220. ¹ H NMR (400 MHz, TCE) δ 8.60-8.53 (m, 2H), 8.43 (dd, J = 8.5, 1.2 Hz, 1H), 7.76-7.67 (m, 2H), 7.38 (d, J = 8.1 Hz , 2H), 7.36-7.25 (m, 14H), 7.25-7.19 (m, 4H), 7.19-7.12 (m, 6H), 7.04 (t, J = 7.4 Hz, 2H), 6.92 (s, 2H), 5.19 (s, 4H), 2.81 (t, J = 7.5 Hz, 2H), 2.75 (s, 6H), 2.61 (t, J = 7.4 Hz, 2H), 2.10 (t, J = 7.5 Hz, 2H), 2.05 (s, 6H), 1.64 (s, 6H).

化合物 10.1 ： 將化合物9.2 (0.64 g，1 mmol)、γ-胺基丁酸三級丁酯鹽酸鹽(0.196 g，1 mmol)、DIC (0.252 g，2 mmol)、DMAP/p-TsOH鹽(0.44 g，1.5 mmol)在DCM (20 mL)中的混合物在室溫下攪拌隔夜。將所得混合物提交以進行使用DCM/乙酸乙酯(0%à50%乙酸乙酯)溶離劑的快速層析法純化。在移除溶劑後獲得了所需化合物，為橙黃色固體(0.74 g，產率為100%)。LCMS (APCI)：C₄₈ H₄₆ N₃ O₅ (M+H)的計算值：744；實測值：744。化合物 10.2 ： 向化合物10.1 (0.74 g，1mmol)在DCM (10 mL)中的溶液中添加TFA(10 mL)。將溶液在室溫下攪拌隔夜，接著減壓移除溶劑。向殘餘固體中添加50 mL甲醇，並攪拌10分鐘以形成懸浮液。將混合物過濾並用甲醇洗滌，得到黃色固體(0.67 g，產率為97%)。LCMS (APCI)：C₄₄ H₃₈ N₃ O₅ (M+H)的計算值：688；實測值：688。¹ H NMR (400 MHz, TCE ) δ 8.60-8.52 (m, 2H), 8.43 (dd,J = 8.6, 1.2 Hz, 1H), 7.75-7.67 (m, 2H), 7.32 (dt,J = 7.6, 2.9 Hz, 4H), 7.26 (dd,J = 8.5, 7.2 Hz, 4H), 7.21-7.10 (m, 8H), 7.10-6.99 (m, 2H), 3.25 (q,J = 6.2 Hz, 2H), 2.71 (t,J = 7.2 Hz, 2H), 2.34-2.26 (m, 2H), 2.19 (t,J = 7.5 Hz, 2H), 1.99 (q,J = 7.2 Hz, 2H), 1.76 (p,J = 6.5 Hz, 2H)。PLC-10 ： 將化合物10.2 (50 mg，0.073 mmol)、化合物3.5 (40 mg，0.063 mmol)、DIC (63 mg，0.5 mmol)、DMAP/p-TsOH鹽(60 mg，0.2 mmol)在DCM (5 mL)中的混合物在室溫下攪拌隔夜。所得混合物使用DCM/乙酸乙酯(0%à30%乙酸乙酯)溶離劑進行快速層析法進行純化。收集所需溶離份，並移除溶劑，得到紅色固體(60 mg，產率為73%)。LCMS (APCI)：C₈₁ H₇₀ BF₂ N₅ O₉ (M-)的計算值：1305；實測值：1305。¹ H NMR (400 MHz, TCE) δ 8.59-8.51 (m, 2H), 8.46-8.39 (m, 1H), 7.71 (t,J = 7.2 Hz, 2H), 7.37-7.22 (m, 18H), 7.21-7.12 (m, 8H), 7.08-6.99 (m, 2H), 6.90 (s, 2H), 5.54 (t,J = 5.9 Hz, 1H), 5.18 (s, 4H), 3.30 (q,J = 6.6 Hz, 2H), 2.74 (s, 6H), 2.70 (d,J = 7.4 Hz, 2H), 2.55 (t,J = 7.3 Hz, 2H), 2.18 (t,J = 7.4 Hz, 2H), 2.03 (s, 6H), 1.98 (t,J = 7.5 Hz, 2H), 1.88 (p,J = 6.9 Hz, 2H), 1.63 (s, 6H)。 Example 2.10 : PLC-10

Compound 10.1 : Compound 9.2 (0.64 g, 1 mmol), γ-aminobutyric acid tertiary butyl hydrochloride (0.196 g, 1 mmol), DIC (0.252 g, 2 mmol), DMAP/p-TsOH salt A mixture of (0.44 g, 1.5 mmol) in DCM (20 mL) was stirred at room temperature overnight. The resulting mixture was submitted for flash chromatography purification using DCM/ethyl acetate (0%→50% ethyl acetate) eluent. After removing the solvent, the desired compound was obtained as an orange-yellow solid (0.74 g, 100% yield). LCMS (APCI): _{calculated value for C 48} H ₄₆ N ₃ O ₅ (M+H): 744; actually measured value: 744. Compound 10.2 : To a solution of compound 10.1 (0.74 g, 1 mmol) in DCM (10 mL) was added TFA (10 mL). The solution was stirred at room temperature overnight, and then the solvent was removed under reduced pressure. 50 mL of methanol was added to the residual solid and stirred for 10 minutes to form a suspension. The mixture was filtered and washed with methanol to obtain a yellow solid (0.67 g, yield 97%). LCMS (APCI): _{calculated value for C 44} H ₃₈ N ₃ O ₅ (M+H): 688; found value: 688. ¹ H NMR (400 MHz, TCE) δ 8.60-8.52 (m, 2H), 8.43 (dd, J = 8.6, 1.2 Hz, 1H), 7.75-7.67 (m, 2H), 7.32 (dt, J = 7.6, 2.9 Hz, 4H), 7.26 (dd, J = 8.5, 7.2 Hz, 4H), 7.21-7.10 (m, 8H), 7.10-6.99 (m, 2H), 3.25 (q, J = 6.2 Hz, 2H), 2.71 (t, J = 7.2 Hz, 2H), 2.34-2.26 (m, 2H), 2.19 (t, J = 7.5 Hz, 2H), 1.99 (q, J = 7.2 Hz, 2H), 1.76 (p, J = 6.5 Hz, 2H). PLC-10 : Compound 10.2 (50 mg, 0.073 mmol), compound 3.5 (40 mg, 0.063 mmol), DIC (63 mg, 0.5 mmol), DMAP/p-TsOH salt (60 mg, 0.2 mmol) in DCM ( The mixture in 5 mL) was stirred at room temperature overnight. The resulting mixture was purified by flash chromatography using DCM/ethyl acetate (0%→30% ethyl acetate) eluent. Collect the required fractions and remove the solvent to obtain a red solid (60 mg, 73% yield). LCMS (APCI): _{calculated value of C 81} H ₇₀ BF ₂ N ₅ O ₉ (M-): 1305; actually measured value: 1305. ¹ H NMR (400 MHz, TCE) δ 8.59-8.51 (m, 2H), 8.46-8.39 (m, 1H), 7.71 (t, J = 7.2 Hz, 2H), 7.37-7.22 (m, 18H), 7.21 -7.12 (m, 8H), 7.08-6.99 (m, 2H), 6.90 (s, 2H), 5.54 (t, J = 5.9 Hz, 1H), 5.18 (s, 4H), 3.30 (q, J = 6.6 Hz, 2H), 2.74 (s, 6H), 2.70 (d, J = 7.4 Hz, 2H), 2.55 (t, J = 7.3 Hz, 2H), 2.18 (t, J = 7.4 Hz, 2H), 2.03 ( s, 6H), 1.98 (t, J = 7.5 Hz, 2H), 1.88 (p, J = 6.9 Hz, 2H), 1.63 (s, 6H).

化合物 11.1 [4-(4-(1,3-二側氧基-6-(9-苯基-9H -咔唑-3-基)-1H -苯并[de ]異喹啉-2(3H )-基)苯基)丁酸鉀]：將化合物9.1 (1.0 g，2.5 mmol)、(9-苯基-9H-咔唑-3-基)

酸(0.69 g，2.4 mmol)、Pd(PPh₃ )₄ (0.15 g，0.1 mmol)和碳酸鉀(0.48 g，3.5 mmol)在乙醇/水(20 mL/1 mL)中的混合物除氣，接著在90℃加熱隔夜。將所得混合物過濾，將固體用甲醇洗滌，接著風乾，得到黃色固體(1.5 g，以定量產率計)。LCMS (APCI)：C₄₀ H₂₈ N₂ O₄ (M-K+H)的計算值：600；實測值：600。PLC-11 ： 將化合物11.1 [4-(4-(1,3-二側氧基-6-(9-苯基-9H -咔唑-3-基)-1H -苯并[de ]異喹啉-2(3H )-基)苯基)丁酸鉀](70 mg，0.11 mmol)、化合物3.5 [5,5-二氟-10-(4-羥基-2,6-二甲基苯基)-1,3,7,9-四甲基-5H -4λ⁴ ,5λ⁴ -二吡咯并[1,2-c :2',1'-f ][1,3,2]二氮雜環己硼烷-2,8-二甲酸二苯甲酯](50 mg，0.079 mmol)、DMAP/p-TsOH鹽(60 mg，0.2 mmol)、DIC (63 mg，0.5 mmol)在DCM (5 mL)中的混合物在室溫下攪拌隔夜。所得混合物使用DCM/乙酸乙酯(0%à10%乙酸乙酯)溶離劑進行快速層析法純化。收集主溶離份，並移除溶劑，得到橙色固體(80 mg，產率為83%)。LCMS (APCI)：C₇₇ H₆₁ BF₂ N₄ O₈ (M-)的計算值：1218；實測值：1218。¹ H NMR (400 MHz, d₂ -TCE) δ 8.66-8.56 (m, 2H), 8.48-8.39 (m, 1H), 8.24 (d,J = 1.4 Hz, 1H), 8.12 (d,J = 7.7 Hz, 1H), 7.83 (d,J = 7.5 Hz, 1H), 7.75-7.66 (m, 1H), 7.65-7.57 (m, 4H), 7.57-7.52 (m, 2H), 7.52-7.36 (m, 5H), 7.34-7.21 (m, 13H), 6.93 (s, 2H), 5.19 (s, 4H), 2.82 (t,J = 7.6 Hz, 2H), 2.75 (s, 6H), 2.62 (t,J = 7.5 Hz, 2H), 2.15-2.07 (m, 2H), 2.05 (s, 6H), 1.65 (s, 6H)。 Example 2.11 : PLC-11

Compound 11.1 [4-(4-(1,3-Di-side oxy-6-(9-phenyl-9 H -carbazol-3-yl)-1 H -benzo[ de ]isoquinoline-2 (3 H )-Phenyl) potassium butyrate]: Compound 9.1 (1.0 g, 2.5 mmol), (9-phenyl-9H-carbazol-3-yl)

The mixture of acid (0.69 g, 2.4 mmol), Pd(PPh ₃ ) ₄ (0.15 g, 0.1 mmol) and potassium carbonate (0.48 g, 3.5 mmol) in ethanol/water (20 mL/1 mL) is degassed, and then Heat at 90°C overnight. The resulting mixture was filtered, the solid was washed with methanol, and then air-dried to obtain a yellow solid (1.5 g, in a quantitative yield). LCMS (APCI): _{calculated value for C 40} H ₂₈ N ₂ O ₄ (M-K+H): 600; actually measured value: 600. PLC-11: Compound 11.1 [4- (4- (1,3-oxo-6- (9-phenyl -9 H - carbazol-3-yl) -1 H - benzo [de] Isoquinoline-2(3 H )-yl)phenyl)potassium butyrate] (70 mg, 0.11 mmol), compound 3.5 [5,5-difluoro-10-(4-hydroxy-2,6-dimethyl Phenyl)-1,3,7,9-tetramethyl-5 H -4λ ⁴ ,5λ ⁴ -dipyrrolo[1,2- c :2',1'- f ][1,3,2 ]Diazacyclohexaborane-2,8-diphenylmethyl dicarboxylate] (50 mg, 0.079 mmol), DMAP/p-TsOH salt (60 mg, 0.2 mmol), DIC (63 mg, 0.5 mmol) The mixture in DCM (5 mL) was stirred at room temperature overnight. The resulting mixture was purified by flash chromatography using DCM/ethyl acetate (0%→10% ethyl acetate) eluent. Collect the main fractions and remove the solvent to obtain an orange solid (80 mg, yield 83%). LCMS (APCI): _{Calculated value for C 77} H ₆₁ BF ₂ N ₄ O ₈ (M-): 1218; found value: 1218. ¹ H NMR (400 MHz, d ₂ -TCE) δ 8.66-8.56 (m, 2H), 8.48-8.39 (m, 1H), 8.24 (d, J = 1.4 Hz, 1H), 8.12 (d, J = 7.7 Hz, 1H), 7.83 (d, J = 7.5 Hz, 1H), 7.75-7.66 (m, 1H), 7.65-7.57 (m, 4H), 7.57-7.52 (m, 2H), 7.52-7.36 (m, 5H), 7.34-7.21 (m, 13H), 6.93 (s, 2H), 5.19 (s, 4H), 2.82 (t, J = 7.6 Hz, 2H), 2.75 (s, 6H), 2.62 (t, J = 7.5 Hz, 2H), 2.15-2.07 (m, 2H), 2.05 (s, 6H), 1.65 (s, 6H).

化合物 12.1 [4-(4-(6-溴-1,3-二側氧基-1H -苯并[de ]異喹啉-2(3H )-基)苯基)丁酸甲酯]： 將化合物9.1 (0.50 g，1.1 mmol)在10 mL無水甲醇和0.25 mL 96%硫酸中的溶液在80℃下加熱6小時。在冷卻至室溫後，將混合物過濾，並將固體用甲醇洗滌並風乾，得到白色固體(0.54 g，以定量產率計)。¹ H NMR (400 MHz，氯仿-d ) δ 8.71 (dd,J = 7.3, 1.1 Hz, 1H), 8.64 (dd,J = 8.5, 1.2 Hz, 1H), 8.46 (d,J = 7.9 Hz, 1H), 8.09 (d,J = 7.8 Hz, 1H), 7.89 (dd,J = 8.5, 7.3 Hz, 1H), 7.40-7.33 (m, 2H), 7.26-7.19 (m, 2H), 3.69 (s, 3H), 2.79-2.71 (m, 2H), 2.41 (t,J = 7.4 Hz, 2H), 2.04 (p,J = 7.4 Hz, 2H)。化合物 12.2 [4-(4-(6-(二苯基胺基)-1,3-二側氧基-1H -苯并[de ]異喹啉-2(3H )-基)苯基)丁酸甲酯]： 將化合物12.1 [4-(4-(6-溴-1,3-二側氧基-1H -苯并[de ]異喹啉-2(3H )-基)苯基)丁酸甲酯](0.45 g，1 mmol)、二苯胺(0.27 g，1.6 mmol)、Pd(dppf)Cl₂ (0.073 g，0.1 mmol)和三級丁醇鈉(0.31 g，3.1 mmol)在無水甲苯(10 ML)中的混合物除氣，接著在110℃加熱隔夜。冷卻至室溫後，將混合物倒入100 mL DCM中，並攪拌5分鐘，接著將沈澱物濾除，並將濾液濃縮至5 mL，接著裝載到矽膠柱上以使用DCM/乙酸乙酯(0%à5%乙酸乙酯)溶離劑進行純化。收集所需溶離份，並移除溶劑，得到固體(100 mg，產率為18.5%)。LCMS (APCI)：C₃₅ H₂₈ N₂ O₄ (M+)的計算值：540；實測值：540。化合物 12.3 [4-(4-(6-(二苯基胺基)-1,3-二側氧基-1H -苯并[de ]異喹啉-2(3H )-基)苯基)丁酸]：向化合物12.2 [4-(4-(6-(二苯基胺基)-1,3-二側氧基-1H -苯并[de ]異喹啉-2(3H )-基)苯基)丁酸甲酯](100 mg，0.18 mmol)在10 mL THF中的溶液中添加5 mL 10N HCl水溶液。將混合物在90℃加熱一個小時，接著減壓移除溶劑。將殘餘物在甲醇/水中再沈澱，得到紅色固體(35 mg，產率為40%)。LCMS (APCI)：C₃₄ H₂₇ N₂ O₄ (M+H)的計算值：527；實測值：527。PLC-12 ： 將化合物12.3 [4-(4-(6-(二苯基胺基)-1,3-二側氧基-1H -苯并[de ]異喹啉-2(3H )-基)苯基)丁酸](35 mg，0.066 mmol)、化合物3.5 [5,5-二氟-10-(4-羥基-2,6-二甲基苯基)-1,3,7,9-四甲基-5H -4λ⁴ ,5λ⁴ -二吡咯并[1,2-c :2',1'-f ][1,3,2]二氮雜環己硼烷-2,8-二甲酸二苯甲酯](35 mg，0.055mmol)、DMAP/p-TsOH鹽(40 mg，0.14 mmol)、DIC (50 mg，0.4 mmol)在DCM(5 mL)中的混合物在室溫下攪拌隔夜。將所得混合物藉由使用DCM/乙酸乙酯(0%à10%乙酸乙酯)溶離劑進行快速層析法(矽膠)來純化。將所需溶離份收集，濃縮並用甲醇沈澱，得到橙色固體(44 mg，產率70%)。LCMS (APCI)：C₇₁ H₅₉ BF₂ N₄ O₈ (M-)的計算值：1144；實測值：1144。 Example 2.12 : PLC-12

Compound 12.1 [4-(4-(6-Bromo-1,3-dioxo-1 H -benzo[ de ]isoquinoline-2(3 H )-yl)phenyl)methyl butyrate] : A solution of compound 9.1 (0.50 g, 1.1 mmol) in 10 mL anhydrous methanol and 0.25 mL 96% sulfuric acid was heated at 80° C. for 6 hours. After cooling to room temperature, the mixture was filtered, and the solid was washed with methanol and air-dried to obtain a white solid (0.54 g, in quantitative yield). ¹ H NMR (400 MHz, chloroform- d ) δ 8.71 (dd, J = 7.3, 1.1 Hz, 1H), 8.64 (dd, J = 8.5, 1.2 Hz, 1H), 8.46 (d, J = 7.9 Hz, 1H ), 8.09 (d, J = 7.8 Hz, 1H), 7.89 (dd, J = 8.5, 7.3 Hz, 1H), 7.40-7.33 (m, 2H), 7.26-7.19 (m, 2H), 3.69 (s, 3H), 2.79-2.71 (m, 2H), 2.41 (t, J = 7.4 Hz, 2H), 2.04 (p, J = 7.4 Hz, 2H). Compound 12.2 [4-(4-(6-(Diphenylamino)-1,3-di-side oxy-1 H -benzo[ de ]isoquinoline-2(3 H )-yl)phenyl ) Methyl butyrate] : Compound 12.1 [4-(4-(6-Bromo-1,3-dioxo-1 H -benzo[ de ]isoquinoline-2(3 H )-yl) (Phenyl) methyl butyrate] (0.45 g, 1 mmol), diphenylamine (0.27 g, 1.6 mmol), Pd(dppf)Cl ₂ (0.073 g, 0.1 mmol) and sodium tertiary butoxide (0.31 g, 3.1 The mixture in anhydrous toluene (10 ML) was degassed, followed by heating at 110°C overnight. After cooling to room temperature, the mixture was poured into 100 mL DCM and stirred for 5 minutes, then the precipitate was filtered off, and the filtrate was concentrated to 5 mL, and then loaded on a silica gel column to use DCM/ethyl acetate (0 %à5% ethyl acetate) eluent for purification. Collect the required fractions and remove the solvent to obtain a solid (100 mg, 18.5% yield). LCMS (APCI): _{calculated value for C 35} H ₂₈ N ₂ O ₄ (M+): 540; found value: 540. Compound 12.3 [4-(4-(6-(Diphenylamino)-1,3-di-side oxy-1 H -benzo[ de ]isoquinoline-2(3 H )-yl)phenyl )Butyric acid]: To compound 12.2 [4-(4-(6-(diphenylamino)-1,3-di-side oxy-1 H -benzo[ de ]isoquinoline-2(3 H )-Yl)phenyl)butyric acid methyl ester] (100 mg, 0.18 mmol) in 10 mL THF was added 5 mL 10N HCl aqueous solution. The mixture was heated at 90°C for one hour, and then the solvent was removed under reduced pressure. The residue was reprecipitated in methanol/water to obtain a red solid (35 mg, yield 40%). LCMS (APCI): _{calculated value for C 34} H ₂₇ N ₂ O ₄ (M+H): 527; found value: 527. PLC-12 : The compound 12.3 [4-(4-(6-(diphenylamino)-1,3-di-side oxy- 1H -benzo[ de ]isoquinoline-2( 3H ) -Yl)phenyl)butyric acid] (35 mg, 0.066 mmol), compound 3.5 [5,5-difluoro-10-(4-hydroxy-2,6-dimethylphenyl)-1,3,7 ,9-Tetramethyl-5 H -4λ ⁴ ,5λ ⁴ -Dipyrrolo[1,2- c :2',1'- f ][1,3,2]diazepine-2 ,8-Diphenylmethyl dicarboxylate] (35 mg, 0.055 mmol), DMAP/p-TsOH salt (40 mg, 0.14 mmol), DIC (50 mg, 0.4 mmol) in DCM (5 mL) in a mixture Stir overnight at room temperature. The resulting mixture was purified by flash chromatography (silica gel) using DCM/ethyl acetate (0%→10% ethyl acetate) eluent. The required fractions were collected, concentrated and precipitated with methanol to obtain an orange solid (44 mg, yield 70%). LCMS (APCI): _{Calculated value for C 71} H ₅₉ BF ₂ N ₄ O ₈ (M-): 1144; actually measured value: 1144.

化合物 13.1 [3- 甲基 -1,4- 二氫茚并 [1,2-b ] 吡咯 -2- 甲酸乙酯 ] ： 在180℃下經由注射器泵向1-茚酮(30.0 mmol，3.96 g)、Zn顆粒-20目(50.0 mmol，3.27 g)和丙酸鈉(5.00 mmol，480 mg)在戊酸(20.0 mL)中的混合物中添加2-(羥基亞胺基)-3-側氧基丁酸乙酯(10.0 mmol，1.59 g)在戊酸(10.0 mL)中的溶液持續1小時。添加完成後，將反應混合物攪拌另外15分鐘，接著冷卻至室溫，並分溶於6 M鹽酸(100 mL)與EtOAc(100 mL)之間。水層用EtOAc (3×100 mL)萃取，合併的有機物用1 M NaOH水溶液(3×200 mL)洗滌，乾燥(MgSO₄ )，並減壓濃縮。從EtOH中再沈澱得到505 mg化合物13.1 (產率為21%)，為無色固體。¹ H NMR (400 MHz, 氯仿-d ) δ 9.05 (br s, 1H), 7.48 (dt,J = 7.5, 1.1 Hz, 1H), 7.44 (dt,J = 7.5, 1.0 Hz, 1H), 7.30 (td,J = 7.5, 1.0 Hz, 1H), 7.19 (td,J = 7.5, 1.1 Hz, 1H), 4.37 (q,J = 7.1 Hz, 2H), 3.49 (s, 2H), 2.42 (s, 3H), 1.40 (t,J = 7.1 Hz, 3H)。化合物 13.2 [3- 甲基 -1,4- 二氫茚并 [1,2-b ] 吡咯 ] ： 向化合物 13.1 (0.1.61 mmol，388 mg)和氫氧化鈉(4.82 mmol，193 mg)在乙二醇(16 mL)中的懸浮液中添加水(500 µL)，並將反應混合物在150℃下攪拌1小時。接著將其冷卻至室溫，並添加1.0 M的NH₄ Cl水溶液(50.0 mL)。藉由真空過濾分離出沈澱物並風乾，得到264 mg化合物13.2 (產率為97%)，為紫色固體。¹ H NMR (400 MHz, 乙腈-d ₃ ) δ 9.17 (br s, 1H), 7.42 (d,J = 7.4 Hz, 1H), 7.35 (d,J = 7.5 Hz, 1H), 7.22 (dd,J = 7.4, 7.5 Hz, 1H), 7.03 (ddd,J = 7.5, 7.5, 1.2 Hz, 1H), 6.61 (dd,J = 2.3, 1.1 Hz, 1H), 3.38 (s, 2H), 2.11 (s, 3H)。化合物 13.3 [4-(4-(6-(4-( 二苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁酸 4- 甲醯基 -3,5- 二甲基苯酯 ] 合成：

化合物 13.3.1 [4-(4-(6- 溴 -1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁酸 ] ： 向6-溴-1H ,3H -苯并[de ]異色烯-1,3-二酮(18.4 mmol，3.30 g)在EtOH (200標準酒精度，80.0 mL)中的溶液中添加4-(4-胺基苯基)丁酸(16.0 mmol，4.43 g)，並將反應混合物加熱至回流達16小時。接著將其冷卻至室溫，用EtOH (200標準酒精度，50.0 mL)稀釋，過濾並用更多EtOH (200標準酒精度，100 mL)和己烷(100 mL)洗滌，得到5.02 g化合物13.3.1 (產率為72%)，為灰白色固體。¹ H NMR (400 MHz, DMSO-d ₆ ) δ 12.15 (s, 1H), 8.63-8.55 (m, 2H), 8.34 (d,J = 7.8 Hz, 1H), 8.25 (d,J = 7.9 Hz, 1H), 8.03 (dd,J = 8.5, 7.3 Hz, 1H), 7.34 (d,J = 8.3 Hz, 2H), 7.29 (d,J = 8.2 Hz, 2H), 2.68 (t,J = 7.3 Hz, 2H), 2.29 (t,J = 7.3 Hz, 2H), 1.87 (p,J = 7.5 Hz, 2H);¹³ C NMR (101 MHz, DMSO-d ₆ ) δ 174.3, 163.3, 163.2, 141.8, 133.5, 132.7, 131.6, 131.4, 131.0, 130.0, 129.2, 128.9, 128.8, 128.8, 128.7, 123.4, 122.7, 34.1, 33.2, 26.3。化合物 13.3.2 [4-(4-(6-(4-( 二苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁酸 ] ： 在Ar氛圍下向化合物13.3.1 (11.2 mmol，4.93 g)和K₂ CO₃ (16.8 mmol，2.32 g)在20:1 EtOH/H₂ O (115 mL)中的懸浮液中添加Pd(PPh₃ )₄ (0.562 mmol，649 mg)和(4-(二苯基胺基)苯基)

酸(11.8 mmol，3.41 g)，並將反應混合物在80℃攪拌16小時。接著將其過濾並用EtOH (200標準酒精度，200 mL)洗滌。將濾餅分溶於1 M HCl (300 mL)與CH₂ Cl₂ (300 mL)之間，並用CH₂ Cl₂ (3×300 mL)萃取混合物。將合併的有機物乾燥(MgSO₄ )並減壓濃縮，得到6.50 g化合物13.3.2 (產率為96%)，為橙色/紅色固體。¹ H NMR (400 MHz, 氯仿-d ) δ 8.67 (dd,J = 7.5, 2.5 Hz, 2H), 8.47 (d,J = 8.5 Hz, 1H), 7.79-7.71 (m, 2H), 7.42-7.36 (m, 4H), 7.33 (表觀t,J = 7.8 Hz, 4H), 7.28-7.19 (m, 8H), 7.10 (表觀t,J = 7.3 Hz, 2H), 2.79 (t,J = 7.6 Hz, 2H), 2.46 (t,J = 7.3 Hz, 2H), 2.06 (表觀p,J = 7.6 Hz, 2H)；¹³ C NMR (101 MHz, 氯仿-d ) δ 177.9, 164.6, 148.4, 147.3, 147.1, 141.8, 133.3, 133.2, 131.8, 131.6, 131.3, 130.8, 130.2, 129.5, 129.5, 128.5, 127.7, 126.7, 125.0, 123.6, 123.0, 122.5, 34.8, 33.1, 26.0。化合物 13.3 [4-(4-(6-(4-( 二苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁酸 4- 甲醯基 -3,5- 二甲基苯酯 ] ： 向4-羥基-2,6-二甲基苯甲醛(5.97 mmol，897 mg)、化合物13.3.2 (4.98 mmol，3.00 g)和DMAP·p TsOH鹽(9.96 mmol，2.93 g)在無水CH₂ Cl₂ (25.0 mL)中的溶液中添加DIC (29.9 mmol，4.68 mL)，並在室溫下攪拌反應物80分鐘。接著經由矽藻土過濾反應混合物並減壓濃縮。快速層析法(甲苯→9:1，甲苯/EtOAc)得到3.05 g化合物13.3 (產率為83%)，為黃色固體。¹ H NMR (400 MHz, 氯仿-d ) δ 10.57 (s, 1H), 8.70-8.64 (m, 2H), 8.48 (dd,J = 8.5, 1.2 Hz, 1H), 7.76 (dd,J = 9.1, 7.4 Hz, 2H), 7.44-7.37 (m, 4H), 7.37-7.26 (m, 6H), 7.25-7.19 (m, 6H), 7.14-7.08 (m, 2H), 6.87 (s, 2H), 2.85 (t,J = 7.6 Hz, 2H), 2.69-2.59 (m, 8H), 2.16 (p,J = 7.5 Hz, 2H)；¹³ C NMR (101 MHz, 氯仿-d ) δ 192.3, 171.4, 164.6, 164.4, 148.4, 147.3, 147.2, 143.6, 141.5, 133.5, 133.2, 131.8, 131.6, 131.3, 130.8, 130.2, 130.1, 129.5, 129.5, 129.2, 128.6, 127.7, 126.7, 125.0, 123.7, 123.0, 122.6, 122.4, 121.3, 34.7, 33.6, 26.1, 20.7。PLC-13 [4-(4-(6-(4-( 二苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁酸 4-(6,6- 二氟 -13,15- 二甲基 -12,16- 二氫 -6H -5λ⁴ ,6λ⁴ - 茚并 [2',1':4,5] 吡咯并 [1,2-c ] 茚并 [2',1':4,5] 吡咯并 [2,1-f ][1,3,2] 二氮雜環己硼烷 -14- 基 )-3,5- 二甲基苯酯 ] ： 在氬氛圍圍下，在室溫下向化合物13.2 (0.473 mmol，80.0 mg)和p TsOH·H₂ O (0.005 mmol，1.00 mg)在無水DCE(5.00 mL)中的溶液中添加化合物13.3 (0.215 mmol，158 mg)。將反應混合物在室溫下攪拌2.5小時，接著將其冷卻至0℃，一次性添加四氯對苯醌(0.215 mmol，53.0 mg)，並繼續攪拌15分鐘。添加三乙胺(1.29 mmol，180 µL)，並將該混合物在0℃下攪拌5分鐘，接著添加BF₃ ·OEt₂ (1.94 mmol，239 µL)，並在室溫下繼續攪拌另外15分鐘。將反應混合物用EtOAc (30.0 mL)稀釋，用1M HCl (3×30.0 mL)和飽和NaCl水溶液(30.0 mL)洗滌，乾燥(MgSO₄ )並減壓濃縮。快速層析法(7:3，己烷/EtOAc)得到125 mg的PLC-13(產率為53%)，為暗紫色粉末。¹ H NMR (400 MHz, 氯仿-d ) δ 8.71-8.65 (m, 2H), 8.48 (dd,J = 8.6, 1.2 Hz, 1H), 8.39 (d,J = 7.8 Hz, 2H), 7.77 (dd,J = 9.3, 7.5 Hz, 2H), 7.50-7.27 (m, 16H), 7.25-7.19 (m, 6H), 7.14-7.08 (m, 2H), 6.99 (s, 2H), 3.53 (s, 4H), 2.89 (t,J = 7.5 Hz, 2H), 2.69 (t,J = 7.4 Hz, 2H), 2.27 (s, 6H), 2.20 (tt,J = 7.5, 7.4 Hz, 2H), 1.52 (s, 6H)。 Example 2.13 : PLC-13

Compound 13.1 [3- Methyl -1,4- dihydroindeno [1,2- b ] pyrrole -2 -ethyl carboxylate ] : Add 1-indanone (30.0 mmol, 3.96 g) via a syringe pump at 180°C ), Zn particles-20 mesh (50.0 mmol, 3.27 g) and sodium propionate (5.00 mmol, 480 mg) in the mixture of valeric acid (20.0 mL), add 2-(hydroxyimino)-3-oxo A solution of ethyl butyrate (10.0 mmol, 1.59 g) in valeric acid (10.0 mL) for 1 hour. After the addition was complete, the reaction mixture was stirred for another 15 minutes, then cooled to room temperature, and partitioned between 6 M hydrochloric acid (100 mL) and EtOAc (100 mL). The aqueous layer was extracted with EtOAc (3×100 mL), and the combined organics were washed with 1 M aqueous NaOH (3×200 mL), dried (MgSO ₄ ), and concentrated under reduced pressure. Reprecipitation from EtOH gave 505 mg of compound 13.1 (21% yield) as a colorless solid. ¹ H NMR (400 MHz, chloroform- d ) δ 9.05 (br s, 1H), 7.48 (dt, J = 7.5, 1.1 Hz, 1H), 7.44 (dt, J = 7.5, 1.0 Hz, 1H), 7.30 ( td, J = 7.5, 1.0 Hz, 1H), 7.19 (td, J = 7.5, 1.1 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 3.49 (s, 2H), 2.42 (s, 3H ), 1.40 (t, J = 7.1 Hz, 3H). Compound 13.2 [3- Methyl -1,4- dihydroindeno [1,2- b ] pyrrole ] : To compound 13.1 (0.1.61 mmol, 388 mg) and sodium hydroxide (4.82 mmol, 193 mg) in Water (500 µL) was added to the suspension in ethylene glycol (16 mL), and the reaction mixture was stirred at 150°C for 1 hour. Then it was cooled to room temperature, and 1.0 M NH ₄ Cl aqueous solution (50.0 mL) was added. The precipitate was separated by vacuum filtration and air-dried to obtain 264 mg of compound 13.2 (yield 97%) as a purple solid. ¹ H NMR (400 MHz, acetonitrile- d ₃ ) δ 9.17 (br s, 1H), 7.42 (d, J = 7.4 Hz, 1H), 7.35 (d, J = 7.5 Hz, 1H), 7.22 (dd, J = 7.4, 7.5 Hz, 1H), 7.03 (ddd, J = 7.5, 7.5, 1.2 Hz, 1H), 6.61 (dd, J = 2.3, 1.1 Hz, 1H), 3.38 (s, 2H), 2.11 (s, 3H). Compound 13.3 [4-(4-(6-(4-( Diphenylamino ) phenyl )-1,3 -di-side oxy -1 H -benzo [ de ] isoquinoline- 2(3 H ) - yl) phenyl) butanoic acid 4-acyl-3,5-dimethylphenyl] synthesis:

Compound 13.3.1 [4-(4-(6- Bromo- 1,3 -dioxo -1 H -benzo [ de ] isoquinoline- 2(3 H ) -yl ) phenyl ) butyric acid ] : Add 4 to 6-bromo-1 H ,3 H -benzo[ de ]isochrome-1,3-dione (18.4 mmol, 3.30 g) in EtOH (200 standard alcohol, 80.0 mL) -(4-Aminophenyl)butyric acid (16.0 mmol, 4.43 g), and heat the reaction mixture to reflux for 16 hours. Then it was cooled to room temperature, diluted with EtOH (200 standard alcohol, 50.0 mL), filtered and washed with more EtOH (200 standard alcohol, 100 mL) and hexane (100 mL) to obtain 5.02 g of compound 13.3.1 (The yield is 72%), it is an off-white solid. ¹ H NMR (400 MHz, DMSO- d ₆ ) δ 12.15 (s, 1H), 8.63-8.55 (m, 2H), 8.34 (d, J = 7.8 Hz, 1H), 8.25 (d, J = 7.9 Hz, 1H), 8.03 (dd, J = 8.5, 7.3 Hz, 1H), 7.34 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 2.68 (t, J = 7.3 Hz, 2H), 2.29 (t, J = 7.3 Hz, 2H), 1.87 (p, J = 7.5 Hz, 2H); ¹³ C NMR (101 MHz, DMSO- d ₆ ) δ 174.3, 163.3, 163.2, 141.8, 133.5, 132.7, 131.6, 131.4, 131.0, 130.0, 129.2, 128.9, 128.8, 128.8, 128.7, 123.4, 122.7, 34.1, 33.2, 26.3. Compound 13.3.2 [ 4-(4-(6-(4-( Diphenylamino ) phenyl )-1,3 -di-side oxy -1 H -benzo [ de ] isoquinoline- 2( 3 H ) -yl ) phenyl ) butyric acid ] : Compound 13.3.1 (11.2 mmol, 4.93 g) and K ₂ CO ₃ (16.8 mmol, 2.32 g) in 20:1 EtOH/H ₂ O under Ar atmosphere (115 mL) add Pd(PPh ₃ ) ₄ (0.562 mmol, 649 mg) and (4-(diphenylamino)phenyl) to the suspension

Acid (11.8 mmol, 3.41 g), and the reaction mixture was stirred at 80°C for 16 hours. Then it was filtered and washed with EtOH (200 standard alcohol, 200 mL). The filter cake was partitioned between 1 M HCl (300 mL) and CH ₂ Cl ₂ (300 mL), and the mixture was extracted with CH ₂ Cl ₂ (3×300 mL). The combined organics were dried (MgSO ₄ ) and concentrated under reduced pressure to obtain 6.50 g of compound 13.3.2 (96% yield) as an orange/red solid. ¹ H NMR (400 MHz, chloroform- d ) δ 8.67 (dd, J = 7.5, 2.5 Hz, 2H), 8.47 (d, J = 8.5 Hz, 1H), 7.79-7.71 (m, 2H), 7.42-7.36 (m, 4H), 7.33 (apparent t, J = 7.8 Hz, 4H), 7.28-7.19 (m, 8H), 7.10 (apparent t, J = 7.3 Hz, 2H), 2.79 (t, J = 7.6 Hz, 2H), 2.46 (t, J = 7.3 Hz, 2H), 2.06 (apparent p, J = 7.6 Hz, 2H); ¹³ C NMR (101 MHz, chloroform- d ) δ 177.9, 164.6, 148.4, 147.3 , 147.1, 141.8, 133.3, 133.2, 131.8, 131.6, 131.3, 130.8, 130.2, 129.5, 129.5, 128.5, 127.7, 126.7, 125.0, 123.6, 123.0, 122.5, 34.8, 33.1, 26.0. Compound 13.3 [4-(4-(6-(4-( Diphenylamino ) phenyl )-1,3 -di-side oxy -1 H -benzo [ de ] isoquinoline- 2(3 H ) - yl) phenyl) butanoic acid 4-acyl-3,5-dimethylphenyl]: 4-hydroxy-2,6-dimethylbenzaldehyde (5.97 mmol, 897 mg), compound 13.3 .2 (4.98 mmol, 3.00 g) and DMAP· p TsOH salt (9.96 mmol, 2.93 g) in anhydrous CH ₂ Cl ₂ (25.0 mL) in a solution, add DIC (29.9 mmol, 4.68 mL), and at room temperature The reaction was stirred for 80 minutes. The reaction mixture was then filtered through Celite and concentrated under reduced pressure. Flash chromatography (toluene→9:1, toluene/EtOAc) gave 3.05 g of compound 13.3 (83% yield) as a yellow solid. ¹ H NMR (400 MHz, chloroform- d ) δ 10.57 (s, 1H), 8.70-8.64 (m, 2H), 8.48 (dd, J = 8.5, 1.2 Hz, 1H), 7.76 (dd, J = 9.1, 7.4 Hz, 2H), 7.44-7.37 (m, 4H), 7.37-7.26 (m, 6H), 7.25-7.19 (m, 6H), 7.14-7.08 (m, 2H), 6.87 (s, 2H), 2.85 (t, J = 7.6 Hz, 2H), 2.69-2.59 (m, 8H), 2.16 (p, J = 7.5 Hz, 2H); ¹³ C NMR (101 MHz, chloroform- d ) δ 192.3, 171.4, 164.6, 164.4, 148.4, 147.3, 147.2, 143.6, 141.5, 133.5, 133.2, 131.8, 131.6, 131.3, 130.8, 130.2, 130.1, 129.5, 129.5, 129.2, 128.6, 127.7, 126.7, 125.0, 123.7, 123.0, 122.6, 122.4, 121.3, 34.7, 33.6, 26.1, 20.7. PLC-13 [4-(4-(6-(4-( Diphenylamino ) phenyl )-1,3 -dioxy -1 H -benzo [ de ] isoquinoline- 2(3 H) - yl) phenyl) butanoic acid 4- (6,6-difluoro--13,15- dimethyl -12,16- dihydro -6 H -5λ ^4, 6λ ⁴ - indeno [2 ', 1':4,5] pyrrolo [1,2- c ] indeno [2',1':4,5] pyrrolo [2,1- f ][1,3,2] diazepine Borane- 14 -yl )-3,5- dimethylphenyl ester ] : under an argon atmosphere, compound 13.2 (0.473 mmol, 80.0 mg) and p TsOH·H ₂ O (0.005 mmol, 1.00 mg) Compound 13.3 (0.215 mmol, 158 mg) was added to a solution in anhydrous DCE (5.00 mL). The reaction mixture was stirred at room temperature for 2.5 hours, then it was cooled to 0°C, tetrachloro-p-benzoquinone (0.215 mmol, 53.0 mg) was added in one portion, and stirring was continued for 15 minutes. Triethylamine (1.29 mmol, 180 µL) was added, and the mixture was stirred at 0°C for 5 minutes, then BF ₃ ·OEt ₂ (1.94 mmol, 239 µL) was added, and stirring was continued for another 15 minutes at room temperature. The reaction mixture was diluted with EtOAc (30.0 mL), washed with 1M HCl (3×30.0 mL) and saturated aqueous NaCl (30.0 mL), dried (MgSO ₄ ) and concentrated under reduced pressure. Flash chromatography (7:3, hexane/EtOAc) gave 125 mg of PLC-13 (53% yield) as a dark purple powder. ¹ H NMR (400 MHz, chloroform- d ) δ 8.71-8.65 (m, 2H), 8.48 (dd, J = 8.6, 1.2 Hz, 1H), 8.39 (d, J = 7.8 Hz, 2H), 7.77 (dd , J = 9.3, 7.5 Hz, 2H), 7.50-7.27 (m, 16H), 7.25-7.19 (m, 6H), 7.14-7.08 (m, 2H), 6.99 (s, 2H), 3.53 (s, 4H) ), 2.89 (t, J = 7.5 Hz, 2H), 2.69 (t, J = 7.4 Hz, 2H), 2.27 (s, 6H), 2.20 (tt, J = 7.5, 7.4 Hz, 2H), 1.52 (s , 6H).

化合物 14.1 [6-溴-2-(4-羥基-2,6-二甲基苯基)-1H -苯并[de ]異喹啉-1,3(2H )-二酮]：將4-溴-1,8-萘二甲酸酐(1.0 g，3.6 mmol)、4-胺基-3,5-二甲基苯酚(1.37 g，10 mmol)在10 mL 1-丁醇中的混合物除氣，接著在150℃加熱隔夜。在冷卻至室溫後，將混合物過濾，用甲醇洗滌並風乾，得到灰白色固體(1.4 g，產率為98%)。LCMS (APCI)：C₂₀ H₁₅ BrNO₃ (M+H)的計算值：396；實測值：396。¹ H NMR (400 MHz, 氯仿-d ) δ 8.71 (d,J = 8.0 Hz, 1H), 8.47 (d,J = 9.1 Hz, 1H), 8.23-8.06 (m, 1H), 7.93 (d,J = 7.6 Hz, 1H), 7.42-7.32 (m, 1H), 6.74-6.67 (m, 2H), 2.18-2.13 (m, 1H), 2.12-2.02 (s, 6H)。化合物 14.2 [6-(4-(二苯基胺基)苯基)-2-(4-羥基-2,6-二甲基苯基)-1H -苯并[de ]異喹啉-1,3(2H )-二酮]： 將化合物14.1 [6-溴-2-(4-羥基-2,6-二甲基苯基)-1H -苯并[de ]異喹啉-1,3(2H )-二酮](0.98 g，2.47 mmol)、(4-(二苯基胺基)苯基)

酸(0.722 g，2.5 mmol)、Pd(PPh₃ )₄ (115 mg，0.1 mmol)、K₂ CO₃ (0.48 g，2.5 mmol)在乙醇/水(20 mL/2 mL)中的混合物除氣，並在80℃加熱隔夜。冷卻至室溫後，將混合物過濾，用乙醇洗滌，風乾，得到橙色固體(1.4 g,，以定量產率計)。LCMS (APCI)：C₃₈ H₂₉ N₂ O₃ (M+H)的計算值：561；實測值：561。¹ H NMR (400 MHz, ) δ 8.59-8.52 (m, 2H), 8.40 (dd,J = 8.4, 1.2 Hz, 1H), 7.69 (t,J = 7.8 Hz, 2H), 7.34-7.19 (m, 6H), 7.16-7.09 (m, 6H), 7.00 (t,J = 7.3 Hz, 2H), 6.60 (s, 2H), 2.43 (s, 1H), 1.95 (s, 6H)。化合物 14.3 [4-(4-(6-(4-(二苯基胺基)苯基)-1,3-二側氧基-1H -苯并[de ]異喹啉-2(3H )-基)-3,5-二甲基苯氧基)丁酸乙酯]： 將化合物14.2 [6-(4-(二苯基胺基)苯基)-2-(4-羥基-2,6-二甲基苯基)-1H-苯并[de]異喹啉-1,3(2H)-二酮](3.9 g，0.7 mmol)、4-溴丁酸乙酯(0.156 g，0.8 mmol)和碳酸鉀(0.207 g，1.5 mmol)在DMF (3 mL)中的混合物除氣，接著在60℃加熱隔夜。將所得混合物用乙酸乙酯/鹽水處理。將有機相收集，經MgSO₄ 乾燥，裝載到矽膠上，並藉由使用己烷/乙酸乙酯(0%à40%乙酸乙酯)溶離劑進行快速層析法而純化。收集黃色溶離份，並移除溶劑，得到黃色固體(0.22 g，產率為47%)。LCMS (APCI)：C₄₄ H₃₉ N₂ O₅ 的計算值：675；實測值：675。化合物 14.4 [4-(4-(6-(4-(二苯基胺基)苯基)-1,3-二側氧基-1H -苯并[de ]異喹啉-2(3H )-基)-3,5-二甲基苯氧基)丁酸]：向化合物14.3 [4-(4-(6-(4-(二苯基胺基)苯基)-1,3-二側氧基-1H -苯并[de ]異喹啉-2(3H )-基)-3,5-二甲基苯氧基)丁酸乙酯](0.22 g，0.326 mmol)在1-丁醇/1,4-二㗁烷(10 mL/5 mL)中的溶液中添加0.2 mL 5M KOH水溶液。將混合物在60℃加熱1小時，接著濃縮至1 mL，並添加10 mL水中。向混合物中添加1 mL 6N HCl溶液，將沈澱物過濾並風乾，得到固體(200 mg，產率為95%)。LCMS (APCI)：C₄₂ H₃₅ N₂ O₅ (M+H)的計算值：647；實測值：647。PLC-14 ： 將化合物14.4 [4-(4-(6-(4-(二苯基胺基)苯基)-1,3-二側氧基-1H -苯并[de]異喹啉-2(3H )-基)-3,5-二甲基苯氧基)丁酸](30 mg，0.046 mmol)、化合物3.5 [5,5-二氟-10-(4-羥基-2,6-二甲基苯基)-1,3,7,9-四甲基-5H -4λ⁴ ,5λ⁴ -二吡咯并[1,2-c :2',1'-f ][1,3,2]二氮雜環己硼烷-2,8-二甲酸二苯甲酯](25 mg，0.04 mmol)、DMAP/p-TsOH鹽(40 mg，0.14 mmol)、DIC (50 mg，0.4 mmol)在DCM (4 mL)中的混合物在室溫下攪拌隔夜。將所得混合物藉由使用DCM/乙酸乙酯(0%à10%乙酸乙酯)溶離劑進行快速層析法(矽膠)來純化。將所需溶離份收集，濃縮並用甲醇沈澱，得到橙色固體(41 mg，產率81%)。LCMS (APCI)：C₇₉ H₆₇ BF₂ N₄ O₉ (M-)的計算值：1264；實測值：1264。¹ H NMR (400 MHz, d₂ -TCE) δ 8.59 (dd,J = 7.4, 4.5 Hz, 2H), 8.43 (d,J = 8.5 Hz, 1H), 7.71 (t,J = 7.8 Hz, 2H), 7.36-7.22 (m, 16H), 7.19-7.12 (m, 6H), 7.04 (t,J = 7.3 Hz, 2H), 6.94 (s, 2H), 6.75 (s, 2H), 5.19 (s, 4H), 4.09 (t,J = 5.8 Hz, 2H), 2.79 (d,J = 7.2 Hz, 2H), 2.74 (s, 6H), 2.29-2.13 (m, 2H), 2.05 (s, 6H), 2.03 (s, 6H), 1.64 (s, 6H)。 Example 2.14 : PLC-14

Compound 14.1 [6-Bromo-2-(4-hydroxy-2,6-dimethylphenyl)-1 H -benzo[ de ]isoquinoline-1,3(2 H )-dione]: will A mixture of 4-bromo-1,8-naphthalenedicarboxylic acid anhydride (1.0 g, 3.6 mmol) and 4-amino-3,5-dimethylphenol (1.37 g, 10 mmol) in 10 mL 1-butanol Degassed, followed by heating at 150°C overnight. After cooling to room temperature, the mixture was filtered, washed with methanol and air-dried to obtain an off-white solid (1.4 g, 98% yield). LCMS (APCI): _{calculated value of C 20} H ₁₅ BrNO ₃ (M+H): 396; found value: 396. ¹ H NMR (400 MHz, chloroform- d ) δ 8.71 (d, J = 8.0 Hz, 1H), 8.47 (d, J = 9.1 Hz, 1H), 8.23-8.06 (m, 1H), 7.93 (d, J = 7.6 Hz, 1H), 7.42-7.32 (m, 1H), 6.74-6.67 (m, 2H), 2.18-2.13 (m, 1H), 2.12-2.02 (s, 6H). Compound 14.2 [6-(4-(Diphenylamino)phenyl)-2-(4-hydroxy-2,6-dimethylphenyl)-1 H -benzo[ de ]isoquinoline-1 ,3(2 H )-Diketone] : The compound 14.1 [6-bromo-2-(4-hydroxy-2,6-dimethylphenyl)-1 H -benzo[ de ]isoquinoline-1 ,3(2 H )-dione] (0.98 g, 2.47 mmol), (4-(diphenylamino)phenyl)

Degas a mixture of acid (0.722 g, 2.5 mmol), Pd(PPh ₃ ) ₄ (115 mg, 0.1 mmol), K ₂ CO ₃ (0.48 g, 2.5 mmol) in ethanol/water (20 mL/2 mL) , And heated at 80°C overnight. After cooling to room temperature, the mixture was filtered, washed with ethanol, and air-dried to obtain an orange solid (1.4 g, in quantitative yield). LCMS (APCI): _{calculated value for C 38} H ₂₉ N ₂ O ₃ (M+H): 561; found value: 561. ¹ H NMR (400 MHz,) δ 8.59-8.52 (m, 2H), 8.40 (dd, J = 8.4, 1.2 Hz, 1H), 7.69 (t, J = 7.8 Hz, 2H), 7.34-7.19 (m, 6H), 7.16-7.09 (m, 6H), 7.00 (t, J = 7.3 Hz, 2H), 6.60 (s, 2H), 2.43 (s, 1H), 1.95 (s, 6H). Compound 14.3 [4-(4-(6-(4-(Diphenylamino)phenyl)-1,3-di-side oxy-1 H -benzo[ de ]isoquinoline-2(3 H )-Yl)-3,5-dimethylphenoxy)butyric acid ethyl ester] : Compound 14.2 [6-(4-(diphenylamino)phenyl)-2-(4-hydroxy-2 ,6-Dimethylphenyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione] (3.9 g, 0.7 mmol), ethyl 4-bromobutyrate (0.156 g, A mixture of 0.8 mmol) and potassium carbonate (0.207 g, 1.5 mmol) in DMF (3 mL) was degassed, followed by heating at 60°C overnight. The resulting mixture was treated with ethyl acetate/brine. The organic phase was collected, dried over MgSO ₄ , loaded onto silica gel, and purified by flash chromatography using hexane/ethyl acetate (0%→40% ethyl acetate) eluent. The yellow fractions were collected, and the solvent was removed to obtain a yellow solid (0.22 g, yield 47%). LCMS (APCI): _{calculated value of C 44} H ₃₉ N ₂ O ₅ : 675; found value: 675. Compound 14.4 [4-(4-(6-(4-(Diphenylamino)phenyl)-1,3-di-side oxy-1 H -benzo[ de ]isoquinoline-2(3 H )-Yl)-3,5-dimethylphenoxy)butyric acid]: To compound 14.3 [4-(4-(6-(4-(diphenylamino)phenyl)-1,3- Di-side oxy-1 H -benzo[ de ]isoquinoline-2(3 H )-yl)-3,5-dimethylphenoxy)butyric acid ethyl ester] (0.22 g, 0.326 mmol) in Add 0.2 mL of 5M KOH aqueous solution to the solution in 1-butanol/1,4-dioxane (10 mL/5 mL). The mixture was heated at 60°C for 1 hour, then concentrated to 1 mL, and 10 mL of water was added. 1 mL of 6N HCl solution was added to the mixture, and the precipitate was filtered and air-dried to obtain a solid (200 mg, 95% yield). LCMS (APCI): _{calculated value for C 42} H ₃₅ N ₂ O ₅ (M+H): 647; found value: 647. PLC-14 : The compound 14.4 [4-(4-(6-(4-(diphenylamino)phenyl)-1,3-di-side oxy-1 H -benzo[de]isoquinoline -2(3 H )-yl)-3,5-dimethylphenoxy)butyric acid] (30 mg, 0.046 mmol), compound 3.5 [5,5-difluoro-10-(4-hydroxy-2 ,6-Dimethylphenyl)-1,3,7,9-tetramethyl-5 H -4λ ⁴ ,5λ ⁴ -dipyrrolo[1,2- c :2',1'- f ][ 1,3,2] Diazacyclohexaborane-2,8-diphenylmethyl dicarboxylate] (25 mg, 0.04 mmol), DMAP/p-TsOH salt (40 mg, 0.14 mmol), DIC (50 mg, 0.4 mmol) in DCM (4 mL) was stirred at room temperature overnight. The resulting mixture was purified by flash chromatography (silica gel) using DCM/ethyl acetate (0%→10% ethyl acetate) eluent. The required fractions were collected, concentrated and precipitated with methanol to obtain an orange solid (41 mg, yield 81%). LCMS (APCI): _{Calculated value of C 79} H ₆₇ BF ₂ N ₄ O ₉ (M-): 1264; actually measured value: 1264. ¹ H NMR (400 MHz, d ₂ -TCE) δ 8.59 (dd, J = 7.4, 4.5 Hz, 2H), 8.43 (d, J = 8.5 Hz, 1H), 7.71 (t, J = 7.8 Hz, 2H) , 7.36-7.22 (m, 16H), 7.19-7.12 (m, 6H), 7.04 (t, J = 7.3 Hz, 2H), 6.94 (s, 2H), 6.75 (s, 2H), 5.19 (s, 4H) ), 4.09 (t, J = 5.8 Hz, 2H), 2.79 (d, J = 7.2 Hz, 2H), 2.74 (s, 6H), 2.29-2.13 (m, 2H), 2.05 (s, 6H), 2.03 (s, 6H), 1.64 (s, 6H).

PLC-15 ： 向2-甲基-1H-吡咯-3-甲酸乙酯(61 mg，0.4 mmol)、化合物13.3 [4-(4-(6-(4-(二苯基胺基)苯基)-1,3-二側氧基-1H -苯并[de ]異喹啉-2(3H )-基)苯基)丁酸4-甲醯基-3,5-二甲基苯酯](100 mg，0.136 mmol)、MgSO₄ (120 mg，1.0 mmol)在二氯乙烷(5 mL)中的混合物中添加3滴TFA，接著在65℃加熱3天。向所得混合物中添加三乙胺(0.13 mL，0.9 mmol)、BF₃ -醚合物(0.09 mL，0.5 mmol)，接著在60℃加熱30分鐘。冷卻至室溫後，將混合物裝載到矽膠上，並藉由使用DCM/乙酸乙酯(0%à10%乙酸乙酯)溶離劑進行快速層析法來純化。收集主溶離份，並移除溶劑，得到橙紅色固體(40 mg，總體產率為27%)。LCMS (APCI)：C₆₅ H₅₅ BF₂ N₄ O₈ (M-)的計算值：1068；實測值：1068。¹ H NMR (400 MHz, d₂ -TCE) δ 8.60-8.53 (m, 2H), 8.43 (dd,J = 8.6, 1.2 Hz, 1H), 7.75-7.67 (m, 2H), 7.39 (d,J = 8.3 Hz, 2H), 7.36-7.30 (m, 2H), 7.24 (dt,J = 13.8, 8.1 Hz, 6H), 7.15 (d,J = 8.6 Hz, 6H), 7.08-6.99 (m, 4H), 6.91 (s, 2H), 4.17 (q,J = 7.1 Hz, 4H), 2.84 (s, 6H), 2.80 (m, 2H), 2.65 (t,J = 7.4 Hz, 2H), 2.13 (m, 2H), 2.08 (s, 6H), 1.24 (t,J = 7.1 Hz, 6H)。 Example 2.15 : PLC-15

PLC-15 : To ethyl 2-methyl-1H-pyrrole-3-carboxylate (61 mg, 0.4 mmol), compound 13.3 [4-(4-(6-(4-(diphenylamino)phenyl )-1,3-Di-side oxy-1 H -benzo[ de ]isoquinoline-2(3 H )-yl)phenyl)butyric acid 4-methanyl-3,5-dimethylbenzene Ester] (100 mg, 0.136 mmol), MgSO ₄ (120 mg, 1.0 mmol) in dichloroethane (5 mL) was added with 3 drops of TFA, followed by heating at 65° C. for 3 days. To the resulting mixture were added triethylamine (0.13 mL, 0.9 mmol) and BF ₃ -etherate (0.09 mL, 0.5 mmol), followed by heating at 60° C. for 30 minutes. After cooling to room temperature, the mixture was loaded on silica gel and purified by flash chromatography using DCM/ethyl acetate (0%→10% ethyl acetate) eluent. Collect the main fractions and remove the solvent to obtain an orange-red solid (40 mg, overall yield 27%). LCMS (APCI): _{calculated value of C 65} H ₅₅ BF ₂ N ₄ O ₈ (M-): 1068; actually measured value: 1068. ¹ H NMR (400 MHz, d ₂ -TCE) δ 8.60-8.53 (m, 2H), 8.43 (dd, J = 8.6, 1.2 Hz, 1H), 7.75-7.67 (m, 2H), 7.39 (d, J = 8.3 Hz, 2H), 7.36-7.30 (m, 2H), 7.24 (dt, J = 13.8, 8.1 Hz, 6H), 7.15 (d, J = 8.6 Hz, 6H), 7.08-6.99 (m, 4H) , 6.91 (s, 2H), 4.17 (q, J = 7.1 Hz, 4H), 2.84 (s, 6H), 2.80 (m, 2H), 2.65 (t, J = 7.4 Hz, 2H), 2.13 (m, 2H), 2.08 (s, 6H), 1.24 (t, J = 7.1 Hz, 6H).

PLC-16((T-4)-[2-[(4,5- 二氫 -3- 甲基 -2H - 苯并 [g ] 吲哚 -2- 亞基 -κN )( 3,5- 二甲基 -4-((4-(6-(4-( 二苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁酸酯 ) 苯基 ) 甲基 ]-4,5- 二氫 -3- 甲基 -1H- 苯并 [g ] 吲哚 -κN ] 二氟化硼 ) ： 將化合物9.2 (0.120 mmol，77 mg)、化合物20.3 (參見下文)(0.100 mmol，54 mg)、DAMP/p-TsOH鹽(60 mg，0.2 mmol)、DIC (63 mg，0.5 mmol)在DCM (5 mL)中的混合物在室溫下攪拌隔夜。所得混合物使用DCM/乙酸乙酯(0%à5%乙酸乙酯)溶離劑進行快速層析法純化。粗產物藉由在矽膠上進行快速層析法(100%甲苯(2 CV)à10% EtOAc/甲苯(15 CV))而純化。將含有產物的溶離份蒸發至乾，得到100 mg (產率為89%)。MS (APCI)：化學式C₇₅ H₅₉ BF₂ N₄ O₄ (M-)的計算值=1128；實測值：1128。¹ H NMR (400 MHz, 四氯乙烷-d₂ ) δ 8.77 (d,J = 8.1 Hz, 2H), 8.66 (dd,J = 7.3, 1.2 Hz, 1H), 8.65 (d,J = 7.6 Hz, 1H), 8.52 (dd,J = 8.6, 1.2 Hz, 1H), 7.81 (t,J = 7.2 Hz, 1H), 7.79 (d,J = 7.3 Hz, 1H), 7.52 - 7.46 (m, 2H), 7.46-7.40 (m, 4H), 7.34 (tdd,J = 8.5, 6.7, 4.7 Hz, 10H), 7.27-7.22 (m, 6H), 7.13 (tt,J = 7.3, 1.2 Hz, 2H), 7.01 (s, 2H), 2.92 (t,J = 7.2 Hz, 6H), 2.73 (t,J = 7.5 Hz, 2H), 2.57 (t,J = 7.0 Hz, 4H), 2.29-2.15 (m, 8H), 1.42 (s, 6H)。 Example 2.16 : PLC-16

PLC-16((T-4)-[2-[(4,5 -Dihydro- 3 -methyl- 2 H -benzo [ g ] indole- 2- ylidene- κ N )( 3,5 - dimethyl-4 - ((4- (6- (4- (diphenylphosphino) phenyl) -1,3-oxo -1 H - benzo [de] isoquinolin-2 (3 H ) -yl ) phenyl ) butyrate ) phenyl ) methyl )-4,5 -dihydro- 3 -methyl -1H- benzo [ g ] indole- κ N ] boron difluoride ) : Compound 9.2 (0.120 mmol, 77 mg), compound 20.3 (see below) (0.100 mmol, 54 mg), DAMP/p-TsOH salt (60 mg, 0.2 mmol), DIC (63 mg, 0.5 mmol) in The mixture in DCM (5 mL) was stirred at room temperature overnight. The resulting mixture was purified by flash chromatography using DCM/ethyl acetate (0%→5% ethyl acetate) eluent. The crude product was purified by flash chromatography (100% toluene (2 CV) à 10% EtOAc/toluene (15 CV)) on silica gel. The fraction containing the product was evaporated to dryness, yielding 100 mg (89% yield). MS (APCI): _{the calculated value of the chemical formula C 75} H ₅₉ BF ₂ N ₄ O ₄ (M-)=1128; the measured value: 1128. ¹ H NMR (400 MHz, Tetrachloroethane- d ₂ ) δ 8.77 (d, J = 8.1 Hz, 2H), 8.66 (dd, J = 7.3, 1.2 Hz, 1H), 8.65 (d, J = 7.6 Hz , 1H), 8.52 (dd, J = 8.6, 1.2 Hz, 1H), 7.81 (t, J = 7.2 Hz, 1H), 7.79 (d, J = 7.3 Hz, 1H), 7.52-7.46 (m, 2H) , 7.46-7.40 (m, 4H), 7.34 (tdd, J = 8.5, 6.7, 4.7 Hz, 10H), 7.27-7.22 (m, 6H), 7.13 (tt, J = 7.3, 1.2 Hz, 2H), 7.01 (s, 2H), 2.92 (t, J = 7.2 Hz, 6H), 2.73 (t, J = 7.5 Hz, 2H), 2.57 (t, J = 7.0 Hz, 4H), 2.29-2.15 (m, 8H) , 1.42 (s, 6H).

化合物 17.1 [3- 甲基 -4,5- 二氫 -1H - 苯并 [g ] 吲哚 -2- 甲酸乙酯 ] ： 在180℃下經由注射器泵向1-四氫萘酮(3.00 mmol，403 µL)、Zn顆粒-20目(5.00 mmol，327 mg)和丙酸鈉(0.50 mmol，48 mg)在戊酸(2.00 mL)中的混合物中添加2-(羥基亞胺基)-3-側氧基丁酸乙酯(1.00 mmol，159 mg)的戊酸(1.00 mL)溶液持續1小時。添加完成後，將反應混合物攪拌另外15分鐘，接著冷卻至室溫，並且分溶於6 M鹽酸(10.0 mL)與EtOAc (10.0 mL)之間。水層用EtOAc (3×10.0 mL)萃取，合併的有機物用1 m NaOH水溶液(3×20.0 mL)洗滌，乾燥(MgSO₄ )，並減壓濃縮。快速層析法(19:1，己烷/EtOAc→9:1，己烷/EtOAc)得到134 mg的化合物17.1(產率為52%)，為無色固體。¹ H NMR (400 MHz, 氯仿-d ) δ 8.99 (br s, 1H), 7.34-7.30 (m, 1H), 7.25-7.20 (m, 2H), 7.17-7.13 (m, 1H), 4.35 (q,J = 7.1 Hz, 2H), 2.94 (t,J = 7.5 Hz, 2H), 2.69-2.62 (m, 2H), 2.30 (s, 3H), 1.39 (t,J = 7.1 Hz, 3H)。化合物 17.2 [3- 甲基 -4,5- 二氫 -1H - 苯并 [g ] 吲哚 ] ： 在氬氣氛圍下，在配備有帶翅片之冷凝器和氣體適配器的250 mL兩頸燒瓶中，向化合物17.1 [3-甲基-4,5-二氫-1H-苯并[g]吲哚-2-甲酸乙酯](2.48 g，9.71 mmol)在乙二醇(100 mL)中的溶液中添加KOH (9.71 mL，48.6 mmol的5.0 M水溶液)。將反應混合物加熱至100℃達70分鐘，接著加熱至160℃達40分鐘，接著冷卻至室溫，並倒入水(500 mL)中。沈澱物藉由真空過濾收集並用水(100 mL)洗滌，得到化合物17.2(352 mg，20%)，為淺藍色粉末。 將濾液用TFA酸化至pH=3，藉由真空過濾收集沈澱物，將其用水(100 mL)洗滌，並在氬氣氛圍下溶於CH₂ Cl₂ (100 mL)中。添加TFA (1.00 mL)，並將反應混合物在室溫下攪拌15分鐘。減壓移除揮發物，並將殘餘物用MeOH(2.00 mL)稀釋。藉由添加水(100 mL)誘導沈澱，並將沈澱物藉由真空過濾收集並用水(50.0 mL)洗滌，得到化合物17.2 (306 mg，17%)，為藍色粉末。¹ H NMR (400 MHz, 乙腈-d ₃ ) δ 9.16 (br s, 1H), 7.24 (dd,J = 7.5, 1.3 Hz, 1H), 7.16 (ddd,J = 8.7, 7.4, 1.8 Hz, 2H), 7.00 (ddd,J = 7.5, 7.4, 1.3 Hz, 1H), 6.52 (dd,J = 2.5, 1.1 Hz, 1H), 2.87 (t,J = 7.6 Hz, 2H), 2.59 (dd,J = 8.5, 6.7 Hz, 2H), 2.00 (d,J = 0.9 Hz, 3H)。化合物 17.3 [(T -4)-[2-[(4,5- 二氫 -3- 甲基 -2H - 苯并 [g ] 吲哚 -2- 亞基 -κN )-(4'- 羥基苯基 ) 甲基 ]-4,5- 二氫 -3- 甲基 -1H - 苯并 [g ] 吲哚 -κN ] 二氟化硼 ] ： 在氬氣氛圍下在室溫下向化合物17.2 [3-甲基-4,5-二氫-1H -苯并[g]吲哚](652 mg，3.55 mmol)和4-羥基苯甲醛(216 mg，1.77 mmol)在無水1,2-二氯乙烷(35.0 mL)中的溶液中添加TFA (35.0 µL)。將反應混合物在室溫下攪拌70分鐘，冷卻至0℃，一次性添加四氯對苯醌(435 mg，1.77 mmol)，並繼續攪拌15分鐘。添加三乙胺(1.48 mL，10.6 mmol)，並在10分鐘內將該混合物溫熱至室溫，接著添加BF₃ ·OEt₂ (1.96 mL，15.9 mmol)，並繼續攪拌75分鐘。添加更多的三乙胺(1.48 mL，10.6 mmol)和BF₃ ·OEt₂ (1.96 mL，15.9 mmol)，將混合物攪拌另外75分鐘，並減壓移除所有揮發物。將殘餘物用EtOAc (100 mL)稀釋，用1M HCl (2×100 mL)和6M HCl (100 mL)洗滌，乾燥(MgSO₄ )，並減壓濃縮。快速層析法(CH₂ Cl₂ )得到化合物17.3 (130 mg，17%)，為深藍色/綠色粉末。¹ H NMR (400 MHz,) δ 8.65 (d,J = 8.0 Hz, 2H), 7.34 (表觀td,J = 7.6, 1.7 Hz, 2H), 7.28-7.16 (m, 6H), 6.95-6.90 (m, 2H), 4.96 (d,J = 1.2 Hz, 1H), 2.80 (dd,J = 8.3, 5.9 Hz, 4H), 2.47 (dd,J = 8.3, 5.9 Hz, 4H), 1.35 (s, 6H)。PLC-17 [(T -4)-[2-[(4,5- 二氫 -3- 甲基 -2H - 苯并 [g ] 吲哚 -2- 亞基 -κN )-(4 ' -(4-(4-(6-(4-( 二苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁醯基 ) 苯基 ) 甲基 ]-4,5- 二氫 -3- 甲基 -1H - 苯并 [g ] 吲哚 -κN ] 二氟化硼 ] ： 在氬氣氛圍下在室溫下向化合物17.3 [(T -4)-[2-[(4,5-二氫-3-甲基-2H -苯并[g ]吲哚-2-亞基-κN )-(4'-羥基苯基)甲基]-4,5-二氫-3-甲基-1H -苯并[g ]吲哚-κN ]二氟化硼](52 mg，0.100 mmol)、化合物9.2 [4-(4-(6-(4-(二苯基胺基)苯基)-1,3-二側氧基-1H -苯并[de ]異喹啉-2(3H )-基)苯基)丁酸鉀](77 mg，0.120 mmol)和DMAP·p TsOH鹽(59 mg，0.200 mmol)在無水1,2-二氯乙烷(10.0 mL)中的溶液中添加DIC (94.0 µL，0.600 mmol)，並將反應混合物在室溫下攪拌2小時，接著在50℃攪拌1小時，冷卻至室溫並用1:1己烷/甲苯(10.0 mL)稀釋。將所得混合物藉由快速層析法(甲苯→9:1甲苯/EtOAc)純化，得到PLC-17(103 mg，94%)，為暗紫色粉末。¹ H NMR (400 MHz,) δ 8.67 (d,J = 8.1 Hz, 2H), 8.58 (dd,J = 7.4, 4.9 Hz, 2H), 8.44 (d,J = 8.5 Hz, 1H), 7.72 (表觀t,J = 7.3 Hz, 2H), 7.43-7.14 (m, 27H), 7.04 (表觀t,J = 7.3 Hz, 2H), 2.91-2.76 (m, 6H), 2.68 (t,J = 7.4 Hz, 2H), 2.48 (t,J = 6.9 Hz, 4H), 2.15 (表觀p,J = 7.5 Hz, 2H), 1.36 (s, 6H)。 Example 2.17 : PLC-17

Compound 17.1 [3- Methyl -4,5 -dihydro - 1H - benzo [ g ] indole- 2 -ethyl carboxylate ] : Add 1-tetralone (3.00 mmol , 403 µL), Zn particles-20 mesh (5.00 mmol, 327 mg) and sodium propionate (0.50 mmol, 48 mg) in the mixture of valeric acid (2.00 mL), add 2-(hydroxyimino)-3 -A solution of ethyl pendant oxybutyrate (1.00 mmol, 159 mg) in valeric acid (1.00 mL) for 1 hour. After the addition was complete, the reaction mixture was stirred for another 15 minutes, then cooled to room temperature, and partitioned between 6 M hydrochloric acid (10.0 mL) and EtOAc (10.0 mL). The aqueous layer was extracted with EtOAc (3×10.0 mL), and the combined organics were washed with 1 m aqueous NaOH (3×20.0 mL), dried (MgSO ₄ ), and concentrated under reduced pressure. Flash chromatography (19:1, hexane/EtOAc→9:1, hexane/EtOAc) gave 134 mg of compound 17.1 (yield 52%) as a colorless solid. ¹ H NMR (400 MHz, chloroform- d ) δ 8.99 (br s, 1H), 7.34-7.30 (m, 1H), 7.25-7.20 (m, 2H), 7.17-7.13 (m, 1H), 4.35 (q , J = 7.1 Hz, 2H), 2.94 (t, J = 7.5 Hz, 2H), 2.69-2.62 (m, 2H), 2.30 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H). Compound 17.2 [3- Methyl -4,5 -dihydro- 1 H - benzo [ g ] indole ] : In an argon atmosphere, in a 250 mL two-neck equipped with a finned condenser and a gas adapter In the flask, add compound 17.1 [3-methyl-4,5-dihydro-1H-benzo[g]indole-2-ethyl carboxylate] (2.48 g, 9.71 mmol) in ethylene glycol (100 mL) KOH (9.71 mL, 48.6 mmol of 5.0 M aqueous solution) was added to the solution in. The reaction mixture was heated to 100°C for 70 minutes, then to 160°C for 40 minutes, then cooled to room temperature and poured into water (500 mL). The precipitate was collected by vacuum filtration and washed with water (100 mL) to obtain compound 17.2 (352 mg, 20%) as a light blue powder. The filtrate was acidified with TFA to pH=3, and the precipitate was collected by vacuum filtration, washed with water (100 mL), and dissolved in CH ₂ Cl ₂ (100 mL) under an argon atmosphere. TFA (1.00 mL) was added, and the reaction mixture was stirred at room temperature for 15 minutes. The volatiles were removed under reduced pressure, and the residue was diluted with MeOH (2.00 mL). The precipitation was induced by adding water (100 mL), and the precipitate was collected by vacuum filtration and washed with water (50.0 mL) to obtain compound 17.2 (306 mg, 17%) as a blue powder. ¹ H NMR (400 MHz, acetonitrile- d ₃ ) δ 9.16 (br s, 1H), 7.24 (dd, J = 7.5, 1.3 Hz, 1H), 7.16 (ddd, J = 8.7, 7.4, 1.8 Hz, 2H) , 7.00 (ddd, J = 7.5, 7.4, 1.3 Hz, 1H), 6.52 (dd, J = 2.5, 1.1 Hz, 1H), 2.87 (t, J = 7.6 Hz, 2H), 2.59 (dd, J = 8.5 , 6.7 Hz, 2H), 2.00 (d, J = 0.9 Hz, 3H). Compound 17.3 [( T -4)-[2-[(4,5 -Dihydro- 3 -methyl- 2 H -benzo [ g ] indol- 2- ylidene- κ N )-(4'- Hydroxyphenyl ) methyl ]-4,5 -dihydro- 3 -methyl- 1 H -benzo [ g ] indole- κ N ] boron difluoride ] : under argon atmosphere at room temperature Compound 17.2 [3-methyl-4,5-dihydro-1 H -benzo[g]indole] (652 mg, 3.55 mmol) and 4-hydroxybenzaldehyde (216 mg, 1.77 mmol) in anhydrous 1, Add TFA (35.0 µL) to the solution in 2-dichloroethane (35.0 mL). The reaction mixture was stirred at room temperature for 70 minutes, cooled to 0°C, tetrachloro-p-benzoquinone (435 mg, 1.77 mmol) was added in one portion, and stirring was continued for 15 minutes. Triethylamine (1.48 mL, 10.6 mmol) was added, and the mixture was warmed to room temperature in 10 minutes, then BF ₃ ·OEt ₂ (1.96 mL, 15.9 mmol) was added, and stirring was continued for 75 minutes. More triethylamine (1.48 mL, 10.6 mmol) and BF ₃ ·OEt ₂ (1.96 mL, 15.9 mmol) were added, the mixture was stirred for another 75 minutes, and all volatiles were removed under reduced pressure. The residue was diluted with EtOAc (100 mL), washed with 1M HCl (2×100 mL) and 6M HCl (100 mL), dried (MgSO ₄ ), and concentrated under reduced pressure. Flash chromatography (CH ₂ Cl ₂ ) gave compound 17.3 (130 mg, 17%) as a dark blue/green powder. ¹ H NMR (400 MHz,) δ 8.65 (d, J = 8.0 Hz, 2H), 7.34 (apparent td, J = 7.6, 1.7 Hz, 2H), 7.28-7.16 (m, 6H), 6.95-6.90 ( m, 2H), 4.96 (d, J = 1.2 Hz, 1H), 2.80 (dd, J = 8.3, 5.9 Hz, 4H), 2.47 (dd, J = 8.3, 5.9 Hz, 4H), 1.35 (s, 6H ). PLC-17 [( T -4)-[2-[(4,5 -Dihydro- 3 -methyl- 2 H -benzo [ g ] indole- 2- ylidene- κ N )-(4 ' -(4-(4-(6-(4-( Diphenylamino ) phenyl )-1,3 -dioxy -1 H -benzo [ de ] isoquinoline- 2(3 H ) - yl) phenyl) butan-acyl) phenyl) methyl] -4,5-dihydro-3-methyl -1 H - benzo [g] indol--κ N] boron difluoride]: in an argon atmosphere To compound 17.3 [( T -4)-[2-[(4,5-dihydro-3-methyl-2 H -benzo[ g ]indol-2-ylidene-κ N )-(4'-hydroxyphenyl)methyl]-4,5-dihydro-3-methyl-1 H -benzo[ g ]indole-κ N ]boron difluoride](52 mg, 0.100 mmol), compound 9.2 [4-(4-(6-(4-(diphenylamino)phenyl)-1,3-di-side oxy- 1H -benzo[ de ]isoquinoline- 2(3 H )-Phenyl)potassium butyrate] (77 mg, 0.120 mmol) and DMAP· p TsOH salt (59 mg, 0.200 mmol) in anhydrous 1,2-dichloroethane (10.0 mL) DIC (94.0 µL, 0.600 mmol) was added to the solution, and the reaction mixture was stirred at room temperature for 2 hours, then at 50°C for 1 hour, cooled to room temperature and diluted with 1:1 hexane/toluene (10.0 mL) . The resulting mixture was purified by flash chromatography (toluene→9:1 toluene/EtOAc) to obtain PLC-17 (103 mg, 94%) as a dark purple powder. ¹ H NMR (400 MHz,) δ 8.67 (d, J = 8.1 Hz, 2H), 8.58 (dd, J = 7.4, 4.9 Hz, 2H), 8.44 (d, J = 8.5 Hz, 1H), 7.72 (table View t, J = 7.3 Hz, 2H), 7.43-7.14 (m, 27H), 7.04 (apparent t, J = 7.3 Hz, 2H), 2.91-2.76 (m, 6H), 2.68 (t, J = 7.4 Hz, 2H), 2.48 (t, J = 6.9 Hz, 4H), 2.15 (apparent p, J = 7.5 Hz, 2H), 1.36 (s, 6H).

化合物 18.1 [3,3- 二甲基 -2,3- 二氫 -1H - 茚 -1- 酮 ] ： 將3-甲基巴豆酸(19.0 mmol，1.90 g)在苯(10.0 mL)中的溶液緩慢添加至100 mL圓底燒瓶中的AlCl₃ (57.0 mmol，7.60 g)中。將所得混合物加熱至回流達5小時，冷卻至0℃，用1M HCl (50.0 mL)淬滅並用EtOAc (3×50.0 mL)萃取。合併的有機物用飽和NaHCO₃ 水溶液(3×100 mL)和飽和NaCl水溶液(100 mL)洗滌，乾燥(MgSO₄ )並減壓濃縮。快速層析法(9:1，己烷/EtOAc)得到2.62 g化合物18.1 (產率為86%)，為橙色油狀物。¹ H NMR (400 MHz, 氯仿-d ) δ 7.72-7.67 (m, 1H), 7.65-7.57 (m, 1H), 7.53-7.47 (m, 1H), 7.39-7.32 (m, 1H), 2.60-2.58 (m, 2H), 1.47-1.36 (m, 6H)；¹³ C NMR (101 MHz, 氯仿-d ) δ 205.7, 163.7, 135.1, 134.8, 127.2, 123.4, 123.2, 52.8, 38.4, 29.8。化合物 18.2 [3,4,4- 三甲基 -1,4- 二氫茚并 [1,2-b ] 吡咯 -2- 甲酸乙酯 ] ： 在180℃下經由注射器泵向化合物18.1(3.00 mmol，481 mg)、Zn顆粒-20目(5.00 mmol，327 mg)和丙酸鈉(0.50 mmol，48 mg)在戊酸(2.00 mL)中的混合物中添加2-(羥基亞胺基)-3-側氧基丁酸乙酯(1.00 mmol，159 mg)的戊酸(1.00 mL)溶液持續1小時。添加完成後，將反應混合物攪拌另外15分鐘，接著冷卻至室溫，並分溶於6 M鹽酸(10.0 mL)與EtOAc (10.0 mL)之間。水層用EtOAc(3×10.0 mL)萃取，合併的有機物用1 m NaOH水溶液(3×20.0 mL)洗滌，乾燥(MgSO₄ )，並減壓濃縮。快速層析法(19:1，己烷/EtOAc→9:1，己烷/EtOAc)得到81 mg化合物18.2 (產率為31%)，為無色固體。¹ H NMR (400 MHz, 氯仿-d ) δ 9.19 (s, 1H), 7.40-7.34 (m, 2H), 7.27-7.18 (m, 2H), 4.38 (q,J = 7.1 Hz, 2H), 2.47 (s, 3H), 1.51 (s, 6H), 1.40 (t,J = 7.1 Hz, 3H)。化合物 18.3 [3,4,4- 三甲基 -1,4- 二氫茚并 [1,2-b ] 吡咯 ] ： 向化合物18.2 (0.149 mmol，42 mg)和氫氧化鈉(0.446 mmol，18.0 mg)在乙二醇(1.50 mL)中的懸浮液中添加水(50.0 µL)，並將反應混合物在150℃下攪拌1小時。接著將其冷卻至室溫，並添加1.0 M的NH₄ Cl水溶液(5.00 mL)。將混合物用CH₂ Cl₂ (3×10.0 mL)萃取，得到29 mg化合物18.3(產率為99%)，為紫色固體。¹ H NMR (400 MHz, 氯仿-d ) δ 7.97 (br s, 1H), 7.30 (dt,J = 7.3, 0.9 Hz, 1H), 7.21-7.14 (m, 2H), 7.07 (ddd,J = 7.4, 5.4, 3.3 Hz, 1H), 6.57 (dd,J = 2.2, 1.1 Hz, 1H), 2.20 (d,J = 1.0 Hz, 3H), 1.50 (s, 6H)。PLC-18 [4-(4-(6-(4-( 二苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁酸 4-(6,6- 二氟 -12,12,13,15,16,16- 六甲基 -12,16- 二氫 -6H -5λ⁴ ,6λ⁴ - 茚并 [2',1':4,5] 吡咯并 [1,2-c ] 茚并 [2',1':4,5] 吡咯并 [2,1-f ][1,3,2] 二氮雜環己硼烷 -14- 基 )-3,5- 二甲基苯酯 ] ： 在氬氣氛圍下在室溫下向化合物18.3 (0.061 mmol，12.0 mg)和p TsOH·H₂ O (1個晶體)在無水CH₂ Cl₂ (0.60 mL)中的溶液中添加化合物13.3 (0.033 mmol，25.0 mg)。將反應混合物在室溫下攪拌1小時，接著將其冷卻至0℃，一次性添加四氯對苯醌(0.031 mmol，8.00 mg)，並繼續攪拌15分鐘。添加三乙胺(0.186 mmol，26.0 µL)，並在10分鐘內將該混合物溫熱至室溫，接著添加BF₃ ·OEt₂ (0.279 mmol，34.0 µL)，並繼續攪拌另外30分鐘。將反應混合物用EtOAc (5.00 mL)稀釋，用1M HCl (3×5.00 mL)和飽和NaCl水溶液(5.00 mL)洗滌，乾燥(MgSO₄ )並減壓濃縮。快速層析法(甲苯→19:1，甲苯/EtOAc)得到14.0 mg的PLC-18 (產率為39%)，為暗紫色固體。δ¹ H NMR (400 MHz, 氯仿-d ) δ 8.68 (dd,J = 7.4, 2.5 Hz, 2H), 8.48 (d,J = 8.5 Hz, 1H), 8.31 (d,J = 7.4 Hz, 2H), 7.80-7.72 (m, 2H), 7.47-7.28 (m, 16H), 7.25-7.20 (m, 6H), 7.11 (表觀t,J = 7.3 Hz, 2H), 6.97 (s, 2H), 2.88 (t,J = 7.5 Hz, 2H), 2.69 (t,J = 7.4 Hz, 2H), 2.28 (s, 6H), 2.19 (表觀p,J = 7.5 Hz, 2H), 1.54 (s, 6H), 1.50 (s, 12H)。 Example 2.18 : PLC-18

Compound 18.1 [3,3 -Dimethyl -2,3 -dihydro - 1H - inden- 1 -one ] : Combine 3-methylcrotonic acid (19.0 mmol, 1.90 g) in benzene (10.0 mL) The solution was slowly added to AlCl ₃ (57.0 mmol, 7.60 g) in a 100 mL round bottom flask. The resulting mixture was heated to reflux for 5 hours, cooled to 0°C, quenched with 1M HCl (50.0 mL) and extracted with EtOAc (3×50.0 mL). The combined organics were washed with saturated aqueous NaHCO ₃ (3×100 mL) and saturated aqueous NaCl (100 mL), dried (MgSO ₄ ) and concentrated under reduced pressure. Flash chromatography (9:1, hexane/EtOAc) gave 2.62 g of compound 18.1 (86% yield) as an orange oil. ¹ H NMR (400 MHz, chloroform- d ) δ 7.72-7.67 (m, 1H), 7.65-7.57 (m, 1H), 7.53-7.47 (m, 1H), 7.39-7.32 (m, 1H), 2.60- 2.58 (m, 2H), 1.47-1.36 (m, 6H); ¹³ C NMR (101 MHz, chloroform- d ) δ 205.7, 163.7, 135.1, 134.8, 127.2, 123.4, 123.2, 52.8, 38.4, 29.8. Compound 18.2 [3,4,4 -Trimethyl -1,4- dihydroindeno [1,2- b ] pyrrole -2 -ethyl carboxylate ] : Compound 18.1 (3.00 mmol , 481 mg), Zn particles-20 mesh (5.00 mmol, 327 mg) and sodium propionate (0.50 mmol, 48 mg) in the mixture of valeric acid (2.00 mL), add 2-(hydroxyimino)-3 -A solution of ethyl pendant oxybutyrate (1.00 mmol, 159 mg) in valeric acid (1.00 mL) for 1 hour. After the addition was complete, the reaction mixture was stirred for another 15 minutes, then cooled to room temperature, and partitioned between 6 M hydrochloric acid (10.0 mL) and EtOAc (10.0 mL). The aqueous layer was extracted with EtOAc (3×10.0 mL), and the combined organics were washed with 1 m aqueous NaOH (3×20.0 mL), dried (MgSO ₄ ), and concentrated under reduced pressure. Flash chromatography (19:1, hexane/EtOAc→9:1, hexane/EtOAc) gave 81 mg of compound 18.2 (yield 31%) as a colorless solid. ¹ H NMR (400 MHz, chloroform- d ) δ 9.19 (s, 1H), 7.40-7.34 (m, 2H), 7.27-7.18 (m, 2H), 4.38 (q, J = 7.1 Hz, 2H), 2.47 (s, 3H), 1.51 (s, 6H), 1.40 (t, J = 7.1 Hz, 3H). Compound 18.3 [3,4,4 -Trimethyl -1,4- dihydroindeno [1,2- b ] pyrrole ] : To compound 18.2 (0.149 mmol, 42 mg) and sodium hydroxide (0.446 mmol, 18.0 mg) Water (50.0 µL) was added to the suspension in ethylene glycol (1.50 mL), and the reaction mixture was stirred at 150°C for 1 hour. Then it was cooled to room temperature, and 1.0 M _{aqueous NH 4} Cl solution (5.00 mL) was added. The mixture was extracted with CH ₂ Cl ₂ (3×10.0 mL) to obtain 29 mg of compound 18.3 (99% yield) as a purple solid. ¹ H NMR (400 MHz, chloroform- d ) δ 7.97 (br s, 1H), 7.30 (dt, J = 7.3, 0.9 Hz, 1H), 7.21-7.14 (m, 2H), 7.07 (ddd, J = 7.4 , 5.4, 3.3 Hz, 1H), 6.57 (dd, J = 2.2, 1.1 Hz, 1H), 2.20 (d, J = 1.0 Hz, 3H), 1.50 (s, 6H). PLC-18 [4-(4-(6-(4-( Diphenylamino ) phenyl )-1,3 -dioxy -1 H -benzo [ de ] isoquinoline- 2(3 H ) -yl ) phenyl ) butyric acid 4-(6,6 -difluoro- 12,12,13,15,16,16- hexamethyl- 12,16 -dihydro- 6 H ^{-5λ 4} ,6λ ⁴ -Indeno [2',1':4,5] pyrrolo [1,2- c ] indeno [2',1':4,5] pyrrolo [2,1- f ][1,3 , 2] diazepin-14-yl-cyclohexyl borane) -3,5-dimethylphenyl]: under argon atmosphere a solution of compound 18.3 (0.061 mmol, 12.0 mg) and at room temperature p TsOH · To a solution of H ₂ O (1 crystal) in anhydrous CH ₂ Cl ₂ (0.60 mL) was added compound 13.3 (0.033 mmol, 25.0 mg). The reaction mixture was stirred at room temperature for 1 hour, then it was cooled to 0°C, tetrachloro-p-benzoquinone (0.031 mmol, 8.00 mg) was added in one portion, and stirring was continued for 15 minutes. Triethylamine (0.186 mmol, 26.0 µL) was added, and the mixture was warmed to room temperature within 10 minutes, then BF ₃ ·OEt ₂ (0.279 mmol, 34.0 µL) was added, and stirring was continued for another 30 minutes. The reaction mixture was diluted with EtOAc (5.00 mL), washed with 1M HCl (3×5.00 mL) and saturated aqueous NaCl (5.00 mL), dried (MgSO ₄ ) and concentrated under reduced pressure. Flash chromatography (toluene→19:1, toluene/EtOAc) gave 14.0 mg of PLC-18 (39% yield) as a dark purple solid. δ ¹ H NMR (400 MHz, chloroform- d ) δ 8.68 (dd, J = 7.4, 2.5 Hz, 2H), 8.48 (d, J = 8.5 Hz, 1H), 8.31 (d, J = 7.4 Hz, 2H) , 7.80-7.72 (m, 2H), 7.47-7.28 (m, 16H), 7.25-7.20 (m, 6H), 7.11 (apparent t, J = 7.3 Hz, 2H), 6.97 (s, 2H), 2.88 (t, J = 7.5 Hz, 2H), 2.69 (t, J = 7.4 Hz, 2H), 2.28 (s, 6H), 2.19 (apparent p, J = 7.5 Hz, 2H), 1.54 (s, 6H) , 1.50 (s, 12H).

化合物 19.1 [4-(4-(6-(4-( 二苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁酸 4- 甲醯基 -3,5- 二甲氧基苯酯 ] ： 向2,6-二甲氧基-4-羥基苯甲醛(1.00 mmol，182 mg)、化合物13.3.2 (1.10 mmol，662 mg)和DMAP·p TsOH鹽(1.00 mmol，294 mg)在CH₂ Cl₂ (5.00 mL)中的溶液中添加DIC (6.00 mmol，939 µL)，並將反應混合物在室溫下攪拌20小時。接著將反應混合物濾過矽藻土並減壓濃縮。快速層析法(4:1，甲苯/EtOAc)得到643 mg的化合物19.1(84%產率)，為亮橙色固體。¹ H NMR (400 MHz, 氯仿-d ) δ 10.44 (s, 1H), 8.71-8.64 (m, 2H), 8.48 (dd,J = 8.5, 1.2 Hz, 1H), 7.81-7.72 (m, 2H), 7.44-7.37 (m, 4H), 7.36-7.27 (m, 6H), 7.25-7.20 (m, 6H), 7.13-7.08 (m, 2H), 6.39 (s, 2H), 3.90 (s, 6H), 2.85 (t,J = 7.5 Hz, 2H), 2.67 (t,J = 7.6 Hz, 2H), 2.17 (表觀p,J = 7.6 Hz, 2H)。PLC-19 [(T -4)-[2-[(4,5- 二氫 -3- 甲基 -2H - 苯并 [g ] 吲哚 -2- 亞基 -κN )-(2',6'- 二甲氧基 -4'-(4-(4-(6-(4-( 二苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁醯基 ) 苯基 ) 甲基 ]-4,5- 二氫 -3- 甲基 -1H - 苯并 [g ] 吲哚 -κN ] 二氟化硼 ] ： 向3-甲基-4,5-二氫-1H -苯并[g ]吲哚(0.210 mmol，39 mg)和化合物19.1 (0.100 mmol，77 mg)在CH₂ Cl₂ (2.10 mL)中的溶液中添加p TsOH·H₂ O (0.010 mmol，1.20 mg)，並將反應混合物在室溫下攪拌1小時。接著將其冷卻至0℃，添加四氯對苯醌(0.100 mmol，25 mg)，並將混合物在0℃下攪拌15分鐘。添加三乙胺(0.600 mmol，83 µL)，將混合物在0℃下攪拌15分鐘，接著添加BF₃ ·OEt₂ (0.900 mmol，111 µL)，並將混合物在室溫下攪拌45分鐘。添加更多三乙胺(0.600 mmol，83 µL)，並且在室溫下攪拌5分鐘後，添加BF₃ ·OEt₂ (0.900 mmol，111 µL)，並將混合物在室溫下再攪拌1小時。接著將該混合物用EtOAc(10.0 mL)稀釋，用3M HCl (3×10.0 mL)洗滌，乾燥(MgSO₄ )並減壓濃縮。快速層析法(甲苯→19:1，甲苯/EtOAc)得到97 mg的PLC-19 (產率為84%)，為深藍色/紫色固體。¹ H NMR (400 MHz, 氯仿-d ) δ 8.83 (d,J = 8.1 Hz, 2H), 8.71-8.66 (m, 2H), 8.49 (dd,J = 8.5, 1.2 Hz, 1H), 7.80-7.74 (m, 2H), 7.47-7.27 (m, 13H), 7.25-7.19 (m, 9H), 7.11 (表觀td,J = 7.3, 1.2 Hz, 2H), 6.52 (s, 2H), 3.77 (s, 6H), 2.94-2.84 (m, 6H), 2.71 (t,J = 7.5 Hz, 2H), 2.59-2.50 (m, 4H), 2.21 (表觀p,J = 7.6 Hz, 2H), 1.55 (s, 6H)。 Example 2.19 : PLC-19

Compound 19.1 [4-(4-(6-(4-( Diphenylamino ) phenyl )-1,3 -dioxo -1 H -benzo [ de ] isoquinoline- 2(3 H ) - yl) phenyl) butanoic acid 4-acyl ester of 3,5-dimethoxybenzene]: 2,6-dimethoxy-4-hydroxybenzaldehyde (1.00 mmol, 182 mg), Compound 13.3.2 (1.10 mmol, 662 mg) and DMAP· p TsOH salt (1.00 mmol, 294 mg) in CH ₂ Cl ₂ (5.00 mL) were added DIC (6.00 mmol, 939 µL), and the reaction The mixture was stirred at room temperature for 20 hours. Then the reaction mixture was filtered through Celite and concentrated under reduced pressure. Flash chromatography (4:1, toluene/EtOAc) gave 643 mg of compound 19.1 (84% yield) as a bright orange solid. ¹ H NMR (400 MHz, chloroform- d ) δ 10.44 (s, 1H), 8.71-8.64 (m, 2H), 8.48 (dd, J = 8.5, 1.2 Hz, 1H), 7.81-7.72 (m, 2H) , 7.44-7.37 (m, 4H), 7.36-7.27 (m, 6H), 7.25-7.20 (m, 6H), 7.13-7.08 (m, 2H), 6.39 (s, 2H), 3.90 (s, 6H) , 2.85 (t, J = 7.5 Hz, 2H), 2.67 (t, J = 7.6 Hz, 2H), 2.17 (apparent p, J = 7.6 Hz, 2H). PLC-19 [( T -4)-[2-[(4,5 -Dihydro- 3 -methyl- 2 H -benzo [ g ] indole- 2- ylidene- κ N )-(2',6' -Dimethoxy -4'-(4-(4-(6-(4-( diphenylamino ) phenyl )-1,3 -di-side oxy -1 H -benzo [ de ] isoquinoline- 2(3 H ) -yl ) phenyl ) butyryl ) phenyl ) methyl ]-4,5 -dihydro- 3 -methyl- 1 H -benzo [ g ] indole- κ N ] boron difluoride ] : To 3-methyl-4,5-dihydro- 1H -benzo[ g ]indole (0.210 mmol, 39 mg) and compound 19.1 (0.100 mmol, 77 mg) in CH _To a solution in 2 Cl ₂ (2.10 mL) was added p TsOH·H ₂ O (0.010 mmol, 1.20 mg), and the reaction mixture was stirred at room temperature for 1 hour. Then it was cooled to 0°C, tetrachloro-p-benzoquinone (0.100 mmol, 25 mg) was added, and the mixture was stirred at 0°C for 15 minutes. Triethylamine (0.600 mmol, 83 µL) was added, the mixture was stirred at 0°C for 15 minutes, then BF ₃ ·OEt ₂ (0.900 mmol, 111 µL) was added, and the mixture was stirred at room temperature for 45 minutes. More triethylamine (0.600 mmol, 83 µL) was added, and after stirring at room temperature for 5 minutes, BF ₃ ·OEt ₂ (0.900 mmol, 111 µL) was added, and the mixture was stirred at room temperature for another 1 hour. The mixture was then diluted with EtOAc (10.0 mL), washed with 3M HCl (3×10.0 mL), dried (MgSO ₄ ) and concentrated under reduced pressure. Flash chromatography (toluene→19:1, toluene/EtOAc) yielded 97 mg of PLC-19 (84% yield) as a dark blue/purple solid. ¹ H NMR (400 MHz, chloroform- d ) δ 8.83 (d, J = 8.1 Hz, 2H), 8.71-8.66 (m, 2H), 8.49 (dd, J = 8.5, 1.2 Hz, 1H), 7.80-7.74 (m, 2H), 7.47-7.27 (m, 13H), 7.25-7.19 (m, 9H), 7.11 (apparent td, J = 7.3, 1.2 Hz, 2H), 6.52 (s, 2H), 3.77 (s , 6H), 2.94-2.84 (m, 6H), 2.71 (t, J = 7.5 Hz, 2H), 2.59-2.50 (m, 4H), 2.21 (apparent p, J = 7.6 Hz, 2H), 1.55 ( s, 6H).

化合物 20.1(3- 甲基 -4,5- 二氫 -1H - 苯并 [g ] 吲哚 -2- 甲酸乙酯 ) ： 在250 mL的2頸圓底燒瓶中添加攪拌棒，並放到加熱塊中。向該燒瓶中添加1-四氫萘酮(100.0 mmol，14.620 g)和丙酸鈉(100.0 mmol，9.610 g)，之後添加乙酸(50 mL)。在敞開至空氣進行攪拌下將反應加熱至145℃。向40 mL螺旋蓋小瓶中添加2-(羥基亞胺基)-3-側氧基丁酸乙酯(2.50 mmol，398 mg)和Zn (粉，＜10 um)(12.5 mmol，818 mg)。使此等物質在乙酸中成漿(12.5 mL)，並在約5分鐘的時段內分批添加含有酮的經攪拌反應中。重複該過程三次，至於總體10.0 mmol的2-(羥基亞胺基)-3-氧化丁酸酯和50.0 mmol鋅粉。在145℃下攪拌反應物2.5小時，接著冷卻至室溫。藉由在攪拌下倒入水(600 mL)中淬滅反應物。用水使體積達到900 mL，接著用二氯甲烷(4×160 mL)萃取。將合併的有機層用水(100 mL)、鹽水(100 mL)洗滌，經MgSO₄ 乾燥，過濾，並蒸發至乾燥。在加熱下高真空移除大部分過量的1-四氫萘酮。將粗產物藉由在矽膠(5% EtOAc/己烷(1 CV)à20% EtOAc/己烷(10 CV))上進行快速層析法來純化。將含有產物的溶離份蒸發至乾，得到1.417 g(55%產率)。MS (APCI)：化學式C₁₆ H₁₇ NO₂ (M+H)的計算值=256，實測值：256。¹ H NMR (400 MHz) δ 8.98 (s, 1H), 7.35-7.31 (m, 1H), 7.27-7.21 (m, 2H), 7.20-7.15 (m, 1H), 4.34 (q,J = 7.1 Hz, 2H), 2.99-2.92 (m, 2H), 2.70-2.64 (m, 2H), 2.31 (s, 3H), 1.39 (t,J = 7.1 Hz, 3H)。化合物 20.2 (3- 甲基 -4,5- 二氫 -1H - 苯并 [g ] 吲哚 ) ： 向250 mL的2頸圓底燒瓶中裝入攪拌棒，並裝配帶翅片的冷凝器和氣體適配器。用氬氣沖洗燒瓶，並向該燒瓶中添加化合物20.1 (5.01 mmol，1.278 g)，之後添加乙二醇(50 mL)。向該反應混合物中添加KOH (在H₂ O中5.0 M，25.03 mmol，5.01 mL)。將反應物塞住，並在氬氣下在100℃加熱塊中加熱90分鐘。使用加熱使溶液變得均勻。將溫度升至160℃持續30分鐘，接著冷卻至100℃。藉由倒入經攪拌的水(300 mL)中淬滅反應物。用水使反應物達到500 mL的總體積，接著將其用2.5 M乙酸/2.5 M NaOAc(20 mL)溶液酸化。使用TFA將pH降至約3.5。將所得紫色固體濾出，乾燥，並藉由在矽膠(5% EtOAc/己烷(1 CV)à20% EtOAc/己烷(10 CV))上進行快速層析法來純化。將含有產物的溶離份蒸發至乾，得到767 mg (84%產率)。MS (APCI)：化學式C₁₃ H₁₃ N (M+H)的計算值=184，實測值：184。¹ H NMR (400 MHz, 乙腈-d ₃ ) δ 9.15 (s, 1H), 7.24 (d,J = 7.5 Hz, 1H), 7.20-7.13 (m, 2H), 7.00 (td,J = 7.4, 1.4 Hz, 1H), 6.52 (dd,J = 2.3, 0.9 Hz, 1H), 2.90-2.83 (m, 2H), 2.62-2.55 (m, 2H), 2.00 (s, 3H)。化合物 20.3 ((T -4)-[2-[(4,5- 二氫 -3- 甲基 -2H - 苯并 [g ] 吲哚 -2- 亞基 -κN )(3,5- 二甲基 -4- 羥基苯基 ) 甲基 ]-4,5- 二氫 -3- 甲基 -1H - 苯并 [g ] 吲哚 -κN ] 二氟化硼 ) ： 以與化合物3.2相似的方式從化合物20.2 (3.97 mmol，728 mg)和4-羥基-2,6-二甲基苯甲醛(2.02 mmol，304 mg)合成化合物9.3。粗產物藉由在矽膠(100%的甲苯(2 CV)à10%的EtOAc/甲苯(10 CV))上進行快速層析法而純化。將含有產物的溶離份蒸發，得到563 mg (對於從吡咯開始的3個步驟，產率為52%)。MS (APCI)：化學式C₃₅ H₃₁ BF₂ N₂ O (M+H)的計算值=544，實測值：544。¹ H NMR (400 MHz, DMSO-d ₆ ) δ 9.61 (s, 1H), 8.62 (d,J = 7.9 Hz, 2H), 7.45-7.38 (m, 2H), 7.38-7.34 (m, 4H), 6.68 (s, 2H), 2.91-2.83 (m, 4H), 2.58-2.52 (m, 4H), 2.04 (s, 6H), 1.41 (s, 6H)。PLC-20 [(T -4)-[2-[(4,5- 二氫 -3- 甲基 -2H - 苯并 [g ] 吲哚 -2- 亞基 -κN )-(2',6'- 二甲基 -4'-(4-(4-(6-(4-( 二對甲苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁醯基 ) 苯基 ) 甲基 ]-4,5- 二氫 -3- 甲基 -1H - 苯并 [g ] 吲哚 -κN ] 二氟化硼 ] ： 向化合物20.3 (0.032 mmol，17 mg)、化合物24.3 (參見下文，0.033 mmol，21 mg)和DMAP·p TsOH鹽(0.032 mmol，9 mg)在CH₂ Cl₂ (0.30 mL)中的溶液中添加DIC (0.192 mmol，30 µL)，並將反應混合物在室溫下攪拌2小時。接著將反應混合物濾過矽藻土並減壓濃縮。快速層析法(甲苯→19:1，甲苯/EtOAc))之後，在甲苯/己烷中進行再沈澱，得到13 mg的PLC-20 (產率為35%)，為藍色固體。¹ H NMR (400 MHz, 二氯甲烷-d₂ ) δ 8.80-8.71 (m, 2H), 8.65-8.60 (m, 2H), 8.50 (d,J = 8.7 Hz, 1H), 7.80-7.73 (m, 2H), 7.48-7.25 (m, 13H), 7.19-7.05 (m, 9H), 7.01 (s, 2H), 2.98-2.86 (m, 6H), 2.71 (t,J = 7.4 Hz, 2H), 2.57 (s, 4H), 2.34 (br s, 6H), 2.24 (s, 6H), 2.23-2.17 (m, 2H), 1.42 (s, 6H)。 Example 2.20 : PLC-20

Compound 20.1 (3- methyl -4,5 -dihydro - 1H - benzo [ g ] indole- 2 -ethyl carboxylate ) : Add a stir bar to a 250 mL 2-neck round bottom flask and place it in In the heating block. To the flask were added 1-tetralone (100.0 mmol, 14.620 g) and sodium propionate (100.0 mmol, 9.610 g), followed by acetic acid (50 mL). The reaction was heated to 145°C while opening to air and stirring. Add ethyl 2-(hydroxyimino)-3-oxobutyrate (2.50 mmol, 398 mg) and Zn (powder, <10 um) (12.5 mmol, 818 mg) to a 40 mL screw cap vial. These materials were slurried in acetic acid (12.5 mL) and added in batches to the stirred reaction containing ketones over a period of about 5 minutes. Repeat this process three times, as for the total of 10.0 mmol of 2-(hydroxyimino)-3-oxybutyrate and 50.0 mmol of zinc powder. The reaction was stirred at 145°C for 2.5 hours and then cooled to room temperature. The reaction was quenched by pouring into water (600 mL) with stirring. The volume was brought to 900 mL with water, followed by extraction with dichloromethane (4×160 mL). The combined organic layer was washed with water (100 mL), brine (100 mL), dried over MgSO ₄ , filtered, and evaporated to dryness. Most of the excess 1-tetralone is removed under high vacuum under heating. The crude product was purified by flash chromatography on silica gel (5% EtOAc/hexane (1 CV)→20% EtOAc/hexane (10 CV)). The fraction containing the product was evaporated to dryness, yielding 1.417 g (55% yield). MS (APCI): _{The calculated value of the chemical formula C 16} H ₁₇ NO ₂ (M+H)=256, the measured value: 256. ¹ H NMR (400 MHz) δ 8.98 (s, 1H), 7.35-7.31 (m, 1H), 7.27-7.21 (m, 2H), 7.20-7.15 (m, 1H), 4.34 (q, J = 7.1 Hz , 2H), 2.99-2.92 (m, 2H), 2.70-2.64 (m, 2H), 2.31 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H). Compound 20.2 (3- methyl -4,5 -dihydro- 1 H - benzo [ g ] indole ) : A 250 mL 2-neck round-bottomed flask was charged with a stir bar and equipped with a finned condenser And gas adapter. The flask was flushed with argon, and compound 20.1 (5.01 mmol, 1.278 g) was added to the flask, followed by ethylene glycol (50 mL). Was added KOH (in H ₂ O in 5.0 M, 25.03 mmol, 5.01 mL ) to the reaction mixture. The reaction was stoppered and heated in a heating block at 100°C for 90 minutes under argon. Use heat to make the solution uniform. The temperature was increased to 160°C for 30 minutes, and then cooled to 100°C. The reaction was quenched by pouring into stirred water (300 mL). The reactants were brought to a total volume of 500 mL with water, and then they were acidified with a 2.5 M acetic acid/2.5 M NaOAc (20 mL) solution. Use TFA to lower the pH to about 3.5. The resulting purple solid was filtered off, dried, and purified by flash chromatography on silica gel (5% EtOAc/hexane (1 CV)→20% EtOAc/hexane (10 CV)). The fraction containing the product was evaporated to dryness, yielding 767 mg (84% yield). MS (APCI): _{The calculated value of the chemical formula C 13} H ₁₃ N (M+H)=184, the measured value: 184. ¹ H NMR (400 MHz, acetonitrile- d ₃ ) δ 9.15 (s, 1H), 7.24 (d, J = 7.5 Hz, 1H), 7.20-7.13 (m, 2H), 7.00 (td, J = 7.4, 1.4 Hz, 1H), 6.52 (dd, J = 2.3, 0.9 Hz, 1H), 2.90-2.83 (m, 2H), 2.62-2.55 (m, 2H), 2.00 (s, 3H). Compound 20.3 (( T -4)-[2-[(4,5 -Dihydro- 3 -methyl- 2 H -benzo [ g ] indol- 2- ylidene- κ N )(3,5- Dimethyl- 4 -hydroxyphenyl ) methyl ]-4,5 -dihydro- 3 -methyl- 1 H - benzo [ g ] indole- κ N ] boron difluoride ) : with compound 3.2 In a similar manner, compound 9.3 was synthesized from compound 20.2 (3.97 mmol, 728 mg) and 4-hydroxy-2,6-dimethylbenzaldehyde (2.02 mmol, 304 mg). The crude product was purified by flash chromatography on silica gel (100% toluene (2 CV) à 10% EtOAc/toluene (10 CV)). The fraction containing the product was evaporated to give 563 mg (52% yield for 3 steps starting from pyrrole). MS (APCI): _{The calculated value of the chemical formula C 35} H ₃₁ BF ₂ N ₂ O (M+H)=544, the measured value: 544. ¹ H NMR (400 MHz, DMSO- d ₆ ) δ 9.61 (s, 1H), 8.62 (d, J = 7.9 Hz, 2H), 7.45-7.38 (m, 2H), 7.38-7.34 (m, 4H), 6.68 (s, 2H), 2.91-2.83 (m, 4H), 2.58-2.52 (m, 4H), 2.04 (s, 6H), 1.41 (s, 6H). PLC-20 [( T -4)-[2-[(4,5 -Dihydro- 3 -methyl- 2 H -benzo [ g ] indol- 2- ylidene- κ N )-(2',6' -Dimethyl- 4'-(4-(4-(6-(4-( Di-p-tolylamino ) phenyl )-1,3 -dioxo -1 H -benzo [ de ] isoquinoline- 2(3 H ) -yl ) phenyl ) butyryl ) phenyl ) methyl ]-4,5 -dihydro- 3 -methyl- 1 H -benzo [ g ] indole- κ N ] boron difluoride ] : To compound 20.3 (0.032 mmol, 17 mg), compound 24.3 (see below, 0.033 mmol, 21 mg) and DMAP· p TsOH salt (0.032 mmol, 9 mg) in CH ₂ Cl ₂ ( DIC (0.192 mmol, 30 µL) was added to the solution in 0.30 mL), and the reaction mixture was stirred at room temperature for 2 hours. Then the reaction mixture was filtered through Celite and concentrated under reduced pressure. After flash chromatography (toluene→19:1, toluene/EtOAc)), reprecipitation was performed in toluene/hexane to obtain 13 mg of PLC-20 (yield 35%) as a blue solid. ¹ H NMR (400 MHz, dichloromethane- d ₂ ) δ 8.80-8.71 (m, 2H), 8.65-8.60 (m, 2H), 8.50 (d, J = 8.7 Hz, 1H), 7.80-7.73 (m , 2H), 7.48-7.25 (m, 13H), 7.19-7.05 (m, 9H), 7.01 (s, 2H), 2.98-2.86 (m, 6H), 2.71 (t, J = 7.4 Hz, 2H), 2.57 (s, 4H), 2.34 (br s, 6H), 2.24 (s, 6H), 2.23-2.17 (m, 2H), 1.42 (s, 6H).

PLC-21 10-(4-((4-(4-(6-(4-( 二苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁醯基 ) 氧 )-2,6- 二甲基苯基 )-5,5- 二氟 -1,3,7,9- 四甲基 -5H -4λ⁴ ,5λ⁴ - 二吡咯并 [1,2-c:2',1'-f][1,3,2] 二氮雜環己硼烷 -2,8- 二甲酸二苯甲酯 (1575-46) ： 向化合物3.5 [5,5-二氟-10-(4-羥基-2,6-二甲基苯基)-1,3,7,9-四甲基-5H-4l4,5l4-二吡咯并[1,2-c:2',1'-f][1,3,2]二氮雜環己硼烷-2,8-二甲酸二苯甲酯](1.18 mmol，750 mg)、化合物13.3.2 (1.30 mmol，780 mg)和DMAP·p TsOH鹽(2.36 mmol，694 mg)在無水CH₂ Cl₂ (6.00 mL)中的溶液中添加DIC (7.08 mmol，1.11 mL)，並將反應混合物在室溫下攪拌16小時。接著經由矽藻土過濾反應混合物並減壓濃縮。快速層析法(7:3，己烷/EtOAc→3:2，己烷/EtOAc)得到1.10 g的PLC-21 (產率為76%)，為橙色固體。¹ H NMR (400 MHz, 氯仿-d ) δ 8.68 (dd,J = 7.2, 2.4 Hz, 2H), 8.48 (d,J = 8.5 Hz, 1H), 7.77 (dd,J = 9.3, 7.4 Hz, 2H), 7.44-7.27 (m, 20H), 7.24-7.20 (m, 6H), 7.11 (t,J = 7.3 Hz, 2H), 6.97 (s, 2H), 5.27 (s, 4H), 2.85 (d,J = 13.9 Hz, 8H), 2.67 (t,J = 7.4 Hz, 2H), 2.22-2.06 (m, 8H), 1.72 (s, 6H);¹⁹ F NMR (376 MHz, 氯仿-d ) δ -142.72 - -143.09 (m)；¹³ C NMR (101 MHz, 氯仿-d ) δ 171.5, 164.0, 159.9, 148.4, 147.3, 147.2, 146.9, 136.7, 135.8, 131.6, 131.3, 130.8, 129.5, 128.6, 128.4, 128.3, 127.8, 126.7, 125.1, 123.7, 122.5, 121.8, 121.3, 66.2, 34.8, 33.6, 26.1, 19.7, 15.1, 12.6。 Example 2.21 : PLC-21

PLC-21 10-(4-((4-(4-(6-(4-( diphenylamino ) phenyl )-1,3 -di-side oxy -1 H -benzo [ de ] iso Quinoline- 2( 3H ) -yl ) phenyl ) butyryl ) oxy )-2,6 -dimethylphenyl )-5,5 -difluoro- 1,3,7,9 -tetramethyl- 5 H -4λ ^4, 5λ ⁴ - two-pyrrolo [1,2-c: 2 ', 1'-f] [1,3,2] diazepin-cyclohexyl-2,8-dimethyl benzoic borane Ester (1575-46) : To compound 3.5 [5,5-difluoro-10-(4-hydroxy-2,6-dimethylphenyl)-1,3,7,9-tetramethyl-5H- 4l4,5l4-Dipyrrolo[1,2-c:2',1'-f][1,3,2]diazepine-2,8-diphenylmethyl dicarboxylate](1.18 mmol, 750 mg), compound 13.3.2 (1.30 mmol, 780 mg) and DMAP· p TsOH salt (2.36 mmol, 694 mg) in anhydrous CH ₂ Cl ₂ (6.00 mL) was added DIC (7.08 mmol, 1.11 mL), and the reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was then filtered through Celite and concentrated under reduced pressure. Flash chromatography (7:3, hexane/EtOAc→3:2, hexane/EtOAc) gave 1.10 g of PLC-21 (yield 76%) as an orange solid. ¹ H NMR (400 MHz, chloroform- d ) δ 8.68 (dd, J = 7.2, 2.4 Hz, 2H), 8.48 (d, J = 8.5 Hz, 1H), 7.77 (dd, J = 9.3, 7.4 Hz, 2H ), 7.44-7.27 (m, 20H), 7.24-7.20 (m, 6H), 7.11 (t, J = 7.3 Hz, 2H), 6.97 (s, 2H), 5.27 (s, 4H), 2.85 (d, J = 13.9 Hz, 8H), 2.67 (t, J = 7.4 Hz, 2H), 2.22-2.06 (m, 8H), 1.72 (s, 6H); ¹⁹ F NMR (376 MHz, chloroform- d ) δ -142.72 --143.09 (m); ¹³ C NMR (101 MHz, chloroform- d ) δ 171.5, 164.0, 159.9, 148.4, 147.3, 147.2, 146.9, 136.7, 135.8, 131.6, 131.3, 130.8, 129.5, 128.6, 128.4, 128.3 , 127.8, 126.7, 125.1, 123.7, 122.5, 121.8, 121.3, 66.2, 34.8, 33.6, 26.1, 19.7, 15.1, 12.6.

化合物 22.1 [10-(2,6- 二氟 -4- 羥基苯基 )-5,5- 二氟 -1,3,7,9- 四甲基 -5H -4λ⁴ ,5λ⁴ - 二吡咯并 [1,2-c :2',1'-f ][1,3,2] 二氮雜環己硼烷 -2,8- 二甲酸二苯甲酯 ] ： 向2,4-二甲基-1H- 吡咯-3-甲酸苯甲酯(1.05 mmol，241 mg)和2,6-二氟-4-羥基苯甲醛(0.500 mmol，79 mg)在CH₂ Cl₂ (10.0 mL)中的溶液中添加p TsOH·H₂ O (0.050 mmol，6 mg)，並將反應混合物在室溫下攪拌45 min。接著將該反應混合物冷卻至0℃，添加DDQ(0.600 mmol，136 mg)，並將混合物在室溫下攪拌1 h。添加三乙胺(3.00 mmol，417 μL)，將混合物在0℃下攪拌10 min，接著添加BF₃ ·OEt₂ (4.50 mmol，555 μL)，並將混合物在室溫下攪拌2 h。添加更多三乙胺(3.00 mmol，417 μL)，並且在室溫下攪拌5 min後，添加BF₃ ·OEt₂ (4.50 mmol，555 μL)，並將混合物在室溫下再攪拌1 h。接著將該混合物用EtOAc (30.0mL)稀釋，用3M HCl (3×30.0 mL)洗滌，乾燥(MgSO₄ )並減壓濃縮。快速層析法(9:1，甲苯/EtOAc)得到175 mg化合物22.1 (54%產率)，為橙色固體。¹ H NMR (400 MHz，氯仿-d ) δ 7.41-7.30 (m, 10H), 6.59-6.53 (m, 2H), 5.30 (s, 4H), 2.82 (s, 6H), 1.92 (s, 6H)。PLC-22 [10-(4-((4-(4-(6-(4-( 二苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁醯基 ) 氧 )-2,6- 二氟苯基 )-5,5- 二氟 -1,3,7,9- 四甲基 -5H -4λ⁴ ,5λ⁴ - 二吡咯并 [1,2-c :2',1'-f ][1,3,2] 二氮雜環己硼烷 -2,8- 二甲酸二苯甲酯 ] ： 向化合物22.1 (0.078 mmol，50 mg)、化合物13.3.2 (0.085 mmol，51 mg)和DMAP·p TsOH鹽(0.078 mmol，23 mg)在CH₂ Cl₂ (0.50 mL)中的溶液中添加DIC (0.468 mmol，73 µL)，並將反應混合物在室溫下攪拌1小時。接著將反應混合物濾過矽藻土並減壓濃縮。快速層析法(19:1，甲苯/EtOAc)得到78 mg的PLC-22 (產率為82%)，為褐紅色固體。¹ H NMR (400 MHz, 氯仿-d ) δ 8.68 (dd,J = 7.4, 2.5 Hz, 2H), 8.48 (dd,J = 8.5, 1.2 Hz, 1H), 7.76 (dd,J = 9.1, 7.6 Hz, 2H), 7.44-7.27 (m, 20H), 7.25-7.19 (m, 6H), 7.11 (表觀t,J = 7.4 Hz, 2H), 6.98 (d,J = 7.6 Hz, 2H), 5.28 (s, 4H), 2.89-2.81 (m, 8H), 2.68 (t,J = 7.4 Hz, 2H), 2.18 (表觀p,J = 7.5 Hz, 2H), 1.92 (s, 6H)。 Example 2.22 : PLC-22

Compound 22.1 [10- (2,6-difluoro-4-hydroxyphenyl) -5,5-difluoro--1,3,7,9- tetramethyl -5 H -4λ ^4, 5λ ⁴ - dipyrrole and [1,2- c: 2 ', 1'- f] [1,3,2] diazepin-cyclohexyl-2,8-borane acid diphenylmethyl ester]: to a solution of 2,4-dimethyl Benzyl- 1H- pyrrole-3-carboxylate (1.05 mmol, 241 mg) and 2,6-difluoro-4-hydroxybenzaldehyde (0.500 mmol, 79 mg) in CH ₂ Cl ₂ (10.0 mL) To the solution was added p TsOH·H ₂ O (0.050 mmol, 6 mg), and the reaction mixture was stirred at room temperature for 45 min. Then the reaction mixture was cooled to 0°C, DDQ (0.600 mmol, 136 mg) was added, and the mixture was stirred at room temperature for 1 h. Triethylamine (3.00 mmol, 417 μL) was added, the mixture was stirred at 0° C. for 10 min, then BF ₃ ·OEt ₂ (4.50 mmol, 555 μL) was added, and the mixture was stirred at room temperature for 2 h. More triethylamine (3.00 mmol, 417 μL) was added, and after stirring at room temperature for 5 min, BF ₃ ·OEt ₂ (4.50 mmol, 555 μL) was added, and the mixture was stirred at room temperature for another 1 h. The mixture was then diluted with EtOAc (30.0 mL), washed with 3M HCl (3×30.0 mL), dried (MgSO ₄ ) and concentrated under reduced pressure. Flash chromatography (9:1, toluene/EtOAc) gave 175 mg of compound 22.1 (54% yield) as an orange solid. ¹ H NMR (400 MHz, chloroform- d ) δ 7.41-7.30 (m, 10H), 6.59-6.53 (m, 2H), 5.30 (s, 4H), 2.82 (s, 6H), 1.92 (s, 6H) . PLC-22 [10-(4-((4-(4-(6-(4-( diphenylamino ) phenyl )-1,3 -di-side oxy -1 H -benzo [ de ] Isoquinoline -2( 3H ) -yl ) phenyl ) butyryl ) oxy )-2,6 -difluorophenyl )-5,5 -difluoro- 1,3,7,9 -tetramethyl- 5 H -4λ ^4, 5λ ⁴ - two-pyrrolo [1,2- c: 2 ', 1'- f] [1,3,2] diazepin-cyclohexyl-2,8-dimethyl benzoic borane Ester ] : To a solution of compound 22.1 (0.078 mmol, 50 mg), compound 13.3.2 (0.085 mmol, 51 mg) and DMAP· p TsOH salt (0.078 mmol, 23 mg) in CH ₂ Cl ₂ (0.50 mL) DIC (0.468 mmol, 73 µL) was added to it, and the reaction mixture was stirred at room temperature for 1 hour. Then the reaction mixture was filtered through Celite and concentrated under reduced pressure. Flash chromatography (19:1, toluene/EtOAc) yielded 78 mg of PLC-22 (82% yield) as a brown-red solid. ¹ H NMR (400 MHz, chloroform- d ) δ 8.68 (dd, J = 7.4, 2.5 Hz, 2H), 8.48 (dd, J = 8.5, 1.2 Hz, 1H), 7.76 (dd, J = 9.1, 7.6 Hz , 2H), 7.44-7.27 (m, 20H), 7.25-7.19 (m, 6H), 7.11 (apparent t, J = 7.4 Hz, 2H), 6.98 (d, J = 7.6 Hz, 2H), 5.28 ( s, 4H), 2.89-2.81 (m, 8H), 2.68 (t, J = 7.4 Hz, 2H), 2.18 (apparent p, J = 7.5 Hz, 2H), 1.92 (s, 6H).

化合物 23.1 [10-(2,6- 二氯 -4- 羥基苯基 )-5,5- 二氟 -1,3,7,9- 四甲基 -5H -4λ⁴ ,5λ⁴ - 二吡咯并 [1,2-c :2',1'-f ][1,3,2] 二氮雜環己硼烷 -2,8- 二甲酸二苯甲酯 ] ： 向2,4-二甲基-1H- 吡咯-3-甲酸苯甲酯(1.05 mmol，241 mg)和2,6-二氟-4-羥基苯甲醛(0.500 mmol，96 mg)在CH₂ Cl₂ (10.0 mL)中的溶液中添加p TsOH·H₂ O (0.050 mmol，6 mg)，並將反應混合物在室溫下攪拌1.5 h。添加DDQ (0.600 mmol，136 mg)，並將混合物在室溫下攪拌2 h。接著添加三乙胺(3.00 mmol，417 μL)，將混合物在室溫下攪拌30 min，接著添加BF₃ ·OEt₂ (4.50 mmol，555 μL)，並將混合物在室溫下攪拌1 h。接著將該混合物用EtOAc (30.0mL)稀釋，用3M HCl (3×30.0 mL)洗滌，乾燥(MgSO₄ )並減壓濃縮。快速層析法(甲苯→19:1，甲苯/EtOAc)得到211 mg的化合物23.1 (62%產率)，為橙色固體。¹ H NMR (400 MHz，氯仿-d ) δ 7.42-7.30 (m, 10H), 6.98 (s, 2H), 5.29 (s, 4H), 2.83 (s, 6H), 1.84 (s, 6H)。PLC-23 [10-(4-((4-(4-(6-(4-( 二苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁醯基 ) 氧 )-2,6- 二氟苯基 )-5,5- 二氟 -1,3,7,9- 四甲基 -5H -4λ⁴ ,5λ⁴ - 二吡咯并 [1,2-c :2',1'-f ][1,3,2] 二氮雜環己硼烷 -2,8- 二甲酸二苯甲酯 ] ： 向化合物23.1(0.074 mmol，50 mg)、化合物13.3.2 (0.081 mmol，49 mg)和DMAP·p TsOH鹽(0.074 mmol，22 mg)在CH₂ Cl₂ (0.40 mL)中的溶液中添加DIC (0.296 mmol，46 µL)，並將反應混合物在室溫下攪拌1小時。接著將反應混合物濾過矽藻土並減壓濃縮。快速層析法(甲苯→19:1，甲苯/EtOAc)得到70 mg的PLC-23(產率為75%)，為橙色/紅色固體。¹ H NMR (400 MHz, 氯仿-d ) δ 8.71-8.65 (m, 2H), 8.48 (dd,J = 8.6, 1.2 Hz, 1H), 7.76 (dd,J = 9.1, 7.4 Hz, 2H), 7.44-7.27 (m, 21H), 7.25-7.18 (m, 6H), 7.15-7.08 (m, 2H), 5.28 (s, 4H), 2.89-2.78 (m, 8H), 2.68 (t,J = 7.4 Hz, 2H), 2.17 (表觀p,J = 7.5 Hz, 2H), 1.84 (s, 6H)；¹⁹ F NMR (376 MHz, 氯仿-d ) δ -142.60 - -142.96 (m)。 Example 2.23 : PLC-23

Compound 23.1 [10- (2,6-dichloro-4-hydroxyphenyl) -5,5-difluoro--1,3,7,9- tetramethyl -5 H -4λ ^4, 5λ ⁴ - dipyrrole and [1,2- c: 2 ', 1'- f] [1,3,2] diazepin-cyclohexyl-2,8-borane acid diphenylmethyl ester]: to a solution of 2,4-dimethyl Benzyl- 1H- pyrrole-3-carboxylate (1.05 mmol, 241 mg) and 2,6-difluoro-4-hydroxybenzaldehyde (0.500 mmol, 96 mg) in CH ₂ Cl ₂ (10.0 mL) To the solution was added p TsOH·H ₂ O (0.050 mmol, 6 mg), and the reaction mixture was stirred at room temperature for 1.5 h. DDQ (0.600 mmol, 136 mg) was added, and the mixture was stirred at room temperature for 2 h. Then triethylamine (3.00 mmol, 417 μL) was added, the mixture was stirred at room temperature for 30 min, then BF ₃ ·OEt ₂ (4.50 mmol, 555 μL) was added, and the mixture was stirred at room temperature for 1 h. The mixture was then diluted with EtOAc (30.0 mL), washed with 3M HCl (3×30.0 mL), dried (MgSO ₄ ) and concentrated under reduced pressure. Flash chromatography (toluene→19:1, toluene/EtOAc) gave 211 mg of compound 23.1 (62% yield) as an orange solid. ¹ H NMR (400 MHz, chloroform- d ) δ 7.42-7.30 (m, 10H), 6.98 (s, 2H), 5.29 (s, 4H), 2.83 (s, 6H), 1.84 (s, 6H). PLC-23 [10-(4-((4-(4-(6-(4-( diphenylamino ) phenyl )-1,3 -di-side oxy -1 H -benzo [ de ] Isoquinoline -2( 3H ) -yl ) phenyl ) butyryl ) oxy )-2,6 -difluorophenyl )-5,5 -difluoro- 1,3,7,9 -tetramethyl- 5 H -4λ ^4, 5λ ⁴ - two-pyrrolo [1,2- c: 2 ', 1'- f] [1,3,2] diazepin-cyclohexyl-2,8-dimethyl benzoic borane Ester ] : To a solution of compound 23.1 (0.074 mmol, 50 mg), compound 13.3.2 (0.081 mmol, 49 mg) and DMAP· p TsOH salt (0.074 mmol, 22 mg) in CH ₂ Cl ₂ (0.40 mL) DIC (0.296 mmol, 46 µL) was added to it, and the reaction mixture was stirred at room temperature for 1 hour. Then the reaction mixture was filtered through Celite and concentrated under reduced pressure. Flash chromatography (toluene→19:1, toluene/EtOAc) gave 70 mg of PLC-23 (75% yield) as an orange/red solid. ¹ H NMR (400 MHz, chloroform- d ) δ 8.71-8.65 (m, 2H), 8.48 (dd, J = 8.6, 1.2 Hz, 1H), 7.76 (dd, J = 9.1, 7.4 Hz, 2H), 7.44 -7.27 (m, 21H), 7.25-7.18 (m, 6H), 7.15-7.08 (m, 2H), 5.28 (s, 4H), 2.89-2.78 (m, 8H), 2.68 (t, J = 7.4 Hz , 2H), 2.17 (apparent p, J = 7.5 Hz, 2H), 1.84 (s, 6H); ¹⁹ F NMR (376 MHz, chloroform- d ) δ -142.60--142.96 (m).

化合物 24.1 [4- 溴 -N ,N - 二對甲苯基苯胺 ] ： 向二對甲苯基胺(1.00 mmol，197 mg)、1-溴-4-碘苯(1.10 mmol，311 mg)、Pd(OAc)₂ (0.010 mmol，2.24 mg)和呫噸(xantphos)(0.010 mmol，5.78 mg)在甲苯(1.50 mL)中的溶液中添加三級丁醇鈉(1.20 mmol，115 mg)，並將反應混合物加熱至回流達24小時。反應物用水(10.0 mL)淬滅，並將混合物用CH₂ Cl₂ (3×10.0 mL)萃取。將合併的有機物乾燥(MgSO₄ )，並減壓濃縮。快速層析法(19:1，己烷/EtOAc)得到114 mg的化合物24. 1 (產率為32%)，為無色固體。¹ H NMR (400 MHz, 氯仿-d ) δ 7.27 (dd,J = 7.6, 1.5 Hz, 1H), 7.06 (d,J = 8.3 Hz, 2H), 6.99-6.94 (m, 2H), 6.91-6.86 (m, 1H), 2.31 (s, 3H)；¹³ C NMR (101 MHz, 氯仿-d ) δ 147.4, 144.9, 132.9, 131.9, 130.0, 124.7, 123.9, 113.6, 20.8。化合物 24.2 [4- 甲基 -N -(4-(4,4,5,5- 四甲基 -1,3,2- 二氧雜硼烷 -2- 基 ) 苯基 )-N -( 對甲苯基 ) 苯胺 ] ： 向化合物24.1 (0.207 mmol，73 mg)、雙(頻哪醇合)二硼(0.228 mmol，58 mg)和乙酸鉀(0.621 mmol，61 mg)在二㗁烷(2.00 mL)中的溶液中添加PdCl₂ (dppf) (0.006 mmol，5.00 mg)，並將反應混合物在80℃攪拌3小時，接著在室溫下攪拌14小時。反應物用1.0 M含水NH₄ Cl(10.0 mL)淬滅，並將混合物用CH₂ Cl₂ (3×10.0 mL)萃取。將合併的有機物乾燥(MgSO₄ )，並減壓濃縮。快速層析法(19:1，己烷/EtOAc)得到57 mg化合物24.2(產率為69%)，為無色油狀物。¹ H NMR (400 MHz, 氯仿-d ) δ 7.68-7.61 (m, 2H), 7.08 (dd,J = 8.4, 2.3 Hz, 4H), 7.00 (ddd,J = 14.1, 8.4, 2.8 Hz, 6H), 2.33 (s, 6H), 1.34 (s, 12H)。化合物 24.3 [4-(4-(6-(4-( 二對甲苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁酸 ] ： 向化合物24.2 (0.143 mmol，57 mg)、化合物13.3.1 (0.136 mmol，60 mg)和K₂ CO₃ (0.204 mmol，28 mg)在20:1 v/v EtOH/H₂ O (1.50 mL)中的溶液中添加Pd(PPh₃ )₄ (0.007 mmol，8 mg)，並將反應混合物在80℃攪拌16小時。接著將反應混合物分溶於1 M HCl (20.0 mL)與CH₂ Cl₂ (20.0 mL)之間，並用CH₂ Cl₂ (3×20.0 mL)萃取。將合併的有機物乾燥(MgSO₄ )，並減壓濃縮。快速層析法(1:1，己烷/EtOAc→EtOAc)得到62 mg化合物24.3 (產率為72%)，為橙色粉末。¹ H NMR (400 MHz, 氯仿-d ) δ 8.66 (dd,J = 7.4, 3.7 Hz, 2H), 8.47 (d,J = 8.5 Hz, 1H), 7.78-7.71 (m, 2H), 7.37 (dd,J = 10.4, 8.3 Hz, 4H), 7.26 (d,J = 8.1 Hz, 5H), 7.19-7.06 (m, 10H), 2.79 (t,J = 7.6 Hz, 2H), 2.46 (t,J = 7.3 Hz, 2H), 2.35 (s, 6H), 2.12-2.01 (m, 4H)。PLC-24 10-(4-((4-(4-(6-(4-( 二對甲苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁醯基 ) 氧 )-2,6- 二甲基苯基 )-5,5- 二氟 -1,3,7,9- 四甲基 -5H -4λ⁴ ,5λ⁴ - 二吡咯并 [1,2-c :2',1'-f ][1,3,2] 二氮雜環己硼烷 -2,8- 二甲酸二苯甲酯： 向化合物3.5 [5,5-二氟-10-(4-羥基-2,6-二甲基苯基)-1,3,7,9-四甲基-5H-4l4,5l4-二吡咯并[1,2-c:2',1'-f][1,3,2]二氮雜環己硼烷-2,8-二甲酸二苯甲酯](0.052 mmol，33 mg)、化合物24.3 (0.048 mmol，30 mg)和DMAP·p TsOH鹽(0.096 mmol，28 mg)在CH₂ Cl₂ (0.52 mL)中的溶液中添加DIC (0.288 mmol，45 µL)，並將反應混合物在室溫下攪拌1小時。接著經由矽藻土過濾反應混合物並減壓濃縮。快速層析法(甲苯→19:1，甲苯/EtOAc))之後進行從甲苯/己烷中的重沈澱，得到24 mg的PLC-24 (產率為40%)，為橙色固體。¹ H NMR (400 MHz, 氯仿-d ) δ 8.70-8.63 (m, 2H), 8.49 (dd,J = 8.6, 1.2 Hz, 1H), 7.79-7.72 (m, 2H), 7.46-7.26 (m, 16H), 7.19-7.09 (m, 10H), 6.97 (s, 2H), 5.27 (s, 4H), 2.92-2.78 (m, 8H), 2.67 (t,J = 7.4 Hz, 2H), 2.35 (s, 6H), 2.22-2.08 (m, 8H), 1.72 (s, 6H)。 Example 2.24 : PLC-24

Compound 24.1 [4- bromo - N , N - di-p-tolyl aniline ] : to di-p-tolylamine (1.00 mmol, 197 mg), 1-bromo-4-iodobenzene (1.10 mmol, 311 mg), Pd( OAc) ₂ (0.010 mmol, 2.24 mg) and xantphos (0.010 mmol, 5.78 mg) in toluene (1.50 mL) were added to the solution of tertiary butoxide sodium (1.20 mmol, 115 mg), and the reaction The mixture was heated to reflux for 24 hours. The reaction was quenched with water (10.0 mL), and the mixture was extracted with CH ₂ Cl ₂ (3×10.0 mL). The combined organics were dried (MgSO ₄ ) and concentrated under reduced pressure. Flash chromatography. (19: 1, hexanes / EtOAc) to give 114 mg of compound 241 (yield 32%) as a colorless solid. ¹ H NMR (400 MHz, chloroform- d ) δ 7.27 (dd, J = 7.6, 1.5 Hz, 1H), 7.06 (d, J = 8.3 Hz, 2H), 6.99-6.94 (m, 2H), 6.91-6.86 (m, 1H), 2.31 (s, 3H); ¹³ C NMR (101 MHz, chloroform- d ) δ 147.4, 144.9, 132.9, 131.9, 130.0, 124.7, 123.9, 113.6, 20.8. Compound 24.2 [4- methyl - N -(4-(4,4,5,5 -tetramethyl -1,3,2- dioxaborolan- 2- yl ) phenyl ) -N -( p Tolyl ) aniline ] : Add compound 24.1 (0.207 mmol, 73 mg), bis(pinacolato) diboron (0.228 mmol, 58 mg) and potassium acetate (0.621 mmol, 61 mg) in dioxane (2.00 mL _{PdCl 2} (dppf) (0.006 mmol, 5.00 mg) was added to the solution in ), and the reaction mixture was stirred at 80°C for 3 hours, and then at room temperature for 14 hours. The reaction was quenched with 1.0 M aqueous NH ₄ Cl (10.0 mL), and the mixture was extracted with CH ₂ Cl ₂ (3×10.0 mL). The combined organics were dried (MgSO ₄ ) and concentrated under reduced pressure. Flash chromatography (19:1, hexane/EtOAc) gave 57 mg of compound 24.2 (69% yield) as a colorless oil. ¹ H NMR (400 MHz, chloroform- d ) δ 7.68-7.61 (m, 2H), 7.08 (dd, J = 8.4, 2.3 Hz, 4H), 7.00 (ddd, J = 14.1, 8.4, 2.8 Hz, 6H) , 2.33 (s, 6H), 1.34 (s, 12H). Compound 24.3 [4-(4-(6-(4-( Di-p-tolylamino ) phenyl )-1,3 -diposide oxy -1 H -benzo [ de ] isoquinoline- 2(3 H ) -yl ) phenyl ) butyric acid ] : To compound 24.2 (0.143 mmol, 57 mg), compound 13.3.1 (0.136 mmol, 60 mg) and K ₂ CO ₃ (0.204 mmol, 28 mg) at 20:1 _{Pd(PPh 3} ) ₄ (0.007 mmol, 8 mg) was added to the solution in v/v EtOH/H ₂ O (1.50 mL), and the reaction mixture was stirred at 80° C. for 16 hours. Then the reaction mixture was partitioned between 1 M HCl (20.0 mL) and CH ₂ Cl ₂ (20.0 mL), and extracted with CH ₂ Cl ₂ (3×20.0 mL). The combined organics were dried (MgSO ₄ ) and concentrated under reduced pressure. Flash chromatography (1:1, hexane/EtOAc→EtOAc) gave 62 mg of compound 24.3 (72% yield) as an orange powder. ¹ H NMR (400 MHz, chloroform- d ) δ 8.66 (dd, J = 7.4, 3.7 Hz, 2H), 8.47 (d, J = 8.5 Hz, 1H), 7.78-7.71 (m, 2H), 7.37 (dd , J = 10.4, 8.3 Hz, 4H), 7.26 (d, J = 8.1 Hz, 5H), 7.19-7.06 (m, 10H), 2.79 (t, J = 7.6 Hz, 2H), 2.46 (t, J = 7.3 Hz, 2H), 2.35 (s, 6H), 2.12-2.01 (m, 4H). PLC-24 10-(4-((4-(4-(6-(4-( Di-p-tolylamino ) phenyl )-1,3 -diside oxy -1 H -benzo [ de ] isoquinoline -2 (3 H) - yl) phenyl) butan-acyl) oxy) -2,6-dimethylphenyl) -1,3,7,9- tetramethyl-5,5-difluoro - 5 H -4λ ^4, 5λ ⁴ - two-pyrrolo [1,2- c: 2 ', 1'- f] [1,3,2] diazepin-cyclohexyl-2,8-dicarboxylic acid diphenyl borane Methyl ester: To compound 3.5 [5,5-difluoro-10-(4-hydroxy-2,6-dimethylphenyl)-1,3,7,9-tetramethyl-5H-4l4,5l4- Dipyrrolo[1,2-c:2',1'-f][1,3,2]diazepine-2,8-diphenylmethyl dicarboxylate] (0.052 mmol, 33 mg ), compound 24.3 (0.048 mmol, 30 mg) and DMAP· p TsOH salt (0.096 mmol, 28 mg) in CH ₂ Cl ₂ (0.52 mL), add DIC (0.288 mmol, 45 µL), and react The mixture was stirred at room temperature for 1 hour. The reaction mixture was then filtered through Celite and concentrated under reduced pressure. Flash chromatography (toluene→19:1, toluene/EtOAc) was followed by reprecipitation from toluene/hexane to obtain 24 mg of PLC-24 (40% yield) as an orange solid. ¹ H NMR (400 MHz, chloroform- d ) δ 8.70-8.63 (m, 2H), 8.49 (dd, J = 8.6, 1.2 Hz, 1H), 7.79-7.72 (m, 2H), 7.46-7.26 (m, 16H), 7.19-7.09 (m, 10H), 6.97 (s, 2H), 5.27 (s, 4H), 2.92-2.78 (m, 8H), 2.67 (t, J = 7.4 Hz, 2H), 2.35 (s , 6H), 2.22-2.08 (m, 8H), 1.72 (s, 6H).

PLC-25 [10-(4-((4-(4-(6-(4-( 二苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁醯基 ) 氧 )-2,6- 二甲氧基苯基 )-5,5- 二氟 -1,3,7,9- 四甲基 -5H -4λ⁴ ,5λ⁴ - 二吡咯并 [1,2-c :2',1'-f ][1,3,2] 二氮雜環己硼烷 -2,8- 二甲酸二苯甲酯 ] ： 向2,4-二甲基-1H -吡咯-3-甲酸苯甲酯(0.210 mmol，48 mg)和化合物19.1 (0.100 mmol，77 mg)在CH₂ Cl₂ (2.10 mL)中的溶液中添加p TsOH·H₂ O (0.010 mmol，1.20 mg)，並將反應混合物在室溫下攪拌1小時。接著添加DDQ (0.120 mmol，27 mg)，並將混合物在室溫下攪拌2小時。添加三乙胺(0.600 mmol，83 µL)，將混合物在室溫下攪拌30分鐘，接著添加BF₃ ·OEt₂ (0.900 mmol，111 µL)，並將混合物在室溫下攪拌1小時。添加更多三乙胺(0.300 mmol，42 µL)，並且在室溫下攪拌10分鐘後，添加BF₃ ·OEt₂ (0.450 mmol，55 µL)，並將混合物在室溫下再攪拌3小時。接著將該混合物用EtOAc (15.0 mL)稀釋，用3M HCl (3×15.0 mL)洗滌，乾燥(MgSO₄ )並減壓濃縮。快速層析法(甲苯→19:1，甲苯/EtOAc)得到60 mg的PLC-25 (產率為48%)，為橙色固體。¹ H NMR (400 MHz, 氯仿-d ) δ 8.68 (dd,J = 7.4, 2.6 Hz, 2H), 8.48 (d,J = 8.5 Hz, 1H), 7.77 (dd,J = 9.3, 7.4 Hz, 2H), 7.45-7.28 (m, 19H), 7.25-7.18 (m, 6H), 7.11 (表觀t,J = 7.3 Hz, 2H), 6.49 (s, 2H), 5.27 (s, 4H), 3.71 (s, 6H), 2.87 (t,J = 7.5 Hz, 2H), 2.81 (s, 6H), 2.68 (t,J = 7.5 Hz, 2H), 2.18 (表觀p,J = 7.5 Hz, 2H), 1.87 (s, 6H)；¹⁹ F NMR (376 MHz, 氯仿-d ) δ -142.70 - -143.10 (m)。 Example 2.25 : PLC-25

PLC-25 [10-(4-((4-(4-(6-(4-( diphenylamino ) phenyl )-1,3 -di-side oxy -1 H -benzo [ de ] Isoquinoline -2( 3H ) -yl ) phenyl ) butyryl ) oxy )-2,6 -dimethoxyphenyl )-5,5 -difluoro- 1,3,7,9 -tetramethyl -5 H -4λ ^4, 5λ ⁴ - two-pyrrolo [1,2- c: 2 ', 1'- f] [1,3,2] diazepin-cyclohexyl-2,8-dimethyl borane Benzyl ester ] : Add 2,4-dimethyl-1 H -pyrrole-3-carboxylic acid benzyl ester (0.210 mmol, 48 mg) and compound 19.1 (0.100 mmol, 77 mg) in CH ₂ Cl ₂ (2.10 mL To the solution in) was added p TsOH·H ₂ O (0.010 mmol, 1.20 mg), and the reaction mixture was stirred at room temperature for 1 hour. Then DDQ (0.120 mmol, 27 mg) was added, and the mixture was stirred at room temperature for 2 hours. Triethylamine (0.600 mmol, 83 µL) was added, the mixture was stirred at room temperature for 30 minutes, then BF ₃ ·OEt ₂ (0.900 mmol, 111 µL) was added, and the mixture was stirred at room temperature for 1 hour. More triethylamine (0.300 mmol, 42 µL) was added, and after stirring at room temperature for 10 minutes, BF ₃ ·OEt ₂ (0.450 mmol, 55 µL) was added, and the mixture was stirred at room temperature for another 3 hours. The mixture was then diluted with EtOAc (15.0 mL), washed with 3M HCl (3×15.0 mL), dried (MgSO ₄ ) and concentrated under reduced pressure. Flash chromatography (toluene→19:1, toluene/EtOAc) gave 60 mg of PLC-25 (48% yield) as an orange solid. ¹ H NMR (400 MHz, chloroform- d ) δ 8.68 (dd, J = 7.4, 2.6 Hz, 2H), 8.48 (d, J = 8.5 Hz, 1H), 7.77 (dd, J = 9.3, 7.4 Hz, 2H ), 7.45-7.28 (m, 19H), 7.25-7.18 (m, 6H), 7.11 (apparent t, J = 7.3 Hz, 2H), 6.49 (s, 2H), 5.27 (s, 4H), 3.71 ( s, 6H), 2.87 (t, J = 7.5 Hz, 2H), 2.81 (s, 6H), 2.68 (t, J = 7.5 Hz, 2H), 2.18 (apparent p, J = 7.5 Hz, 2H), 1.87 (s, 6H); ¹⁹ F NMR (376 MHz, chloroform- d ) δ -142.70--143.10 (m).

化合物 26.1 ： 第1步驟：將2,4-二甲基-1H-吡咯-3-甲酸乙酯(1.0 g，6.0 mmol)、4-羥基-2,6-二甲基苯甲醛(0.449 g，3.0 mmol)和p-TsOH (50 mg，0.29 mmol)在50 mL DCE中的混合物除氣，並在室溫下攪拌隔夜。LCMS分析表明，主洩漏為m/e⁺ =467時，反應完成。 第2步驟：向上述所得混合物中添加DDQ (0.817 g，3.6 mmol)，並將整體在室溫下攪拌30分鐘。LCMS分析表明，主峰為m/e⁺ =465時，反應完成。 第3步驟：在使用冰浴冷卻時，向上述所得混合物中添加三乙胺(1.7 mL，19 mmol)和BF₃ -二乙醚(2.2 mL，18 mmol)，並將所得混合物在50℃攪拌1小時。添加額外的1 mL三乙胺和1 mL BF₃ -二乙醚，並將整體加熱另外1小時。LCMS分析表明，所有的二吡咯甲烷起始材料皆轉化為m/e⁺ =513的BODIPY產物。冷卻至室溫後，將反應混合物提交至矽膠，並藉由使用己烷/乙酸乙酯(0%à30%乙酸乙酯)溶離劑進行快速層析法來純化。收集所需溶離份。在移除溶劑後，獲得呈橙色固體狀的所需產物(1.0 g，產率為65%)。¹ H NMR (400 MHz, 氯仿-d ) δ 6.68 (s, 2H), 4.29 (q,J = 7.1 Hz, 4H), 2.84 (s, 6H), 2.05 (s, 6H), 1.34 (t,J = 7.1 Hz, 6H)。LCMS (APCI+)：C₂₇ H₃₂ BF₂ N₂ O₅ (M+H)的計算值：513.2；實測值：513。PLC-26 ： 將化合物26.1 (100 mg，0.195 mmol)、化合物13.3.2 [4-(4-(6-(4-(二苯基胺基)苯基)-1,3-二側氧基-1H-苯并[de]異喹啉-2(3H)-基)苯基)丁酸](132 mg，0.22 mmol)、DIC (0.1 mL，0.63 mmol)和DMAP/p-TsOH (118 mg，0.4 mmol)在DCM (6 mL)中的混合物在室溫下攪拌隔夜，接著裝載到矽膠上，並藉由使用DCM/乙酸乙酯(0%à5%乙酸乙酯)溶離劑進行快速層析法來純化。收集所需的主要橙色溶離份。移除溶劑後，將所得固體在DCM/MeOH中再沈澱。過濾後獲得所需產物PLC-26，並將其風乾，為橙色固體(145 mg，產率為68%)。¹ H NMR (400 MHz, d2-TCE) δ 8.56 (dd,J = 7.4, 4.7 Hz, 2H), 8.43 (d,J = 8.3 Hz, 1H), 7.79-7.64 (m, 2H), 7.41-7.18 (m, 10H), 7.18-7.12 (m, 6H), 7.03 (t,J = 7.3 Hz, 2H), 6.93 (s, 2H), 4.19 (q,J = 7.1 Hz, 4H), 2.81 (t,J = 7.6 Hz, 2H), 2.75 (s, 6H), 2.62 (t,J = 7.4 Hz, 2H), 2.11 (t,J = 7.5 Hz, 2H), 2.06 (s, 6H), 1.65 (s, 6H), 1.25 (t,J = 7.1 Hz, 6H)。LCMS (APCI-)：C₆₇ H₅₉ BF₂ N₄ O₈ (M-)的計算值=1096.4；實測值：1096。 Example 2.26 : PLC-26

Compound 26.1 : Step 1: Combine 2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (1.0 g, 6.0 mmol), 4-hydroxy-2,6-dimethylbenzaldehyde (0.449 g, A mixture of 3.0 mmol) and p-TsOH (50 mg, 0.29 mmol) in 50 mL DCE was degassed and stirred at room temperature overnight. The LCMS analysis indicated that the reaction was completed when the ^{main leakage was m/e + =467.} Step 2: Add DDQ (0.817 g, 3.6 mmol) to the mixture obtained above, and stir the whole at room temperature for 30 minutes. LCMS analysis indicated that the reaction was completed when the main peak was m/e ^{+ =465.} Step 3: While using an ice bath for cooling, add triethylamine (1.7 mL, 19 mmol) and BF ₃ -diethyl ether (2.2 mL, 18 mmol) to the above-obtained mixture, and stir the obtained mixture at 50°C for 1 Hour. An additional 1 mL of triethylamine and 1 mL of BF ₃ -diethyl ether were added, and the whole was heated for another 1 hour. LCMS analysis showed that all the dipyrromethene starting materials were converted into BODIPY products with ^{m/e + =513.} After cooling to room temperature, the reaction mixture was submitted to silica gel and purified by flash chromatography using hexane/ethyl acetate (0%→30% ethyl acetate) eluent. Collect the required fractions. After removing the solvent, the desired product (1.0 g, 65% yield) was obtained as an orange solid. ¹ H NMR (400 MHz, chloroform- d ) δ 6.68 (s, 2H), 4.29 (q, J = 7.1 Hz, 4H), 2.84 (s, 6H), 2.05 (s, 6H), 1.34 (t, J = 7.1 Hz, 6H). LCMS (APCI+): _{calculated value for C 27} H ₃₂ BF ₂ N ₂ O ₅ (M+H): 513.2; found value: 513. PLC-26 : Compound 26.1 (100 mg, 0.195 mmol), compound 13.3.2 [4-(4-(6-(4-(diphenylamino)phenyl)-1,3-di-side oxy -1H-benzo[de]isoquinoline-2(3H)-yl)phenyl)butyric acid] (132 mg, 0.22 mmol), DIC (0.1 mL, 0.63 mmol) and DMAP/p-TsOH (118 mg , 0.4 mmol) in DCM (6 mL) was stirred overnight at room temperature, then loaded on silica gel, and flash chromatographed by using DCM/ethyl acetate (0%→5% ethyl acetate) eluent Method to purify. Collect the required main orange eluates. After removing the solvent, the resulting solid was reprecipitated in DCM/MeOH. After filtration, the desired product PLC-26 was obtained, and it was air-dried to be an orange solid (145 mg, 68% yield). ¹ H NMR (400 MHz, d2-TCE) δ 8.56 (dd, J = 7.4, 4.7 Hz, 2H), 8.43 (d, J = 8.3 Hz, 1H), 7.79-7.64 (m, 2H), 7.41-7.18 (m, 10H), 7.18-7.12 (m, 6H), 7.03 (t, J = 7.3 Hz, 2H), 6.93 (s, 2H), 4.19 (q, J = 7.1 Hz, 4H), 2.81 (t, J = 7.6 Hz, 2H), 2.75 (s, 6H), 2.62 (t, J = 7.4 Hz, 2H), 2.11 (t, J = 7.5 Hz, 2H), 2.06 (s, 6H), 1.65 (s, 6H), 1.25 (t, J = 7.1 Hz, 6H). LCMS ( _{APCI-): calculated value of C 67} H ₅₉ BF ₂ N ₄ O ₈ (M-)=1096.4; found value: 1096.

1,4,5,6- 四氫苯并 [6,7] 環庚并 [1,2-b ] 吡咯 ( 化合物 27.1) 在室溫下向1-苯并環庚酮(10.0 mmol，1.46 mL)在3:1的H₂ O/EtOH (32.5 mL)中的溶液中添加NH₂ OH·HCl (15.0 mmol，1.04 g)和乙酸鈉(25.0 mmol，2.05 g)，並將該反應混合物在95℃下攪拌1小時。接著將其冷卻至室溫，過濾，用水(150 mL)洗滌並冷凍乾燥16小時，得到1.64 g的6,7,8,9-四氫-5H-苯并[7]環庚烯-5-酮肟(產率為94%)，為無色固體，該固體不經進一步純化即用於後續合成步驟中。 在室溫下向6,7,8,9-四氫-5H-苯并[7]環庚烯-5-酮肟(5.71 mmol，1.00 g)在DMSO(9.00 mL)中的溶液中添加KOH (17.1 mmol，959 mg)，並將反應混合物加熱至140℃，接著在3小時內經由注射器泵添加DMSO (2.00 mL)中的1,2-二氯乙烷(11.4 mmol，897 µL)。接著將混合物冷卻至室溫，用1 M NH₄ Cl水溶液(30.0 mL)淬滅並用CH₂ Cl₂ (3×30.0 mL)萃取。將合併的有機物乾燥(MgSO₄ )，並減壓濃縮。快速層析法(己烷→9:1，己烷/EtOAc)得到262 mg的化合物27.1 (產率為25%)，為黃色固體。¹ H NMR (400 MHz，氯仿-d ) δ 8.18 (br s, 1H), 7.34 (dd,J = 7.8, 1.3 Hz, 1H), 7.25-7.19 (m, 1H), 7.16 (dd,J = 7.6, 1.6 Hz, 1H), 7.13-7.07 (m, 1H), 6.84 (t,J = 2.8 Hz, 1H), 6.17 (t,J = 2.8 Hz, 1H), 2.91 (t,J = 6.8 Hz, 2H), 2.86-2.80 (m, 2H), 2.07-1.98 (m, 2H)；¹³ C NMR (101 MHz，氯仿-d ) δ 140.4, 131.8, 129.3, 126.8, 125.9, 125.2, 123.2, 121.8, 118.3, 111.1, 34.9, 27.8, 26.7。4-(19,19- 二氟 -6,7,11,12,13,19- 六氫 -5H -18λ⁴ ,19λ⁴ - 苯并 [3',4'] 環庚烷并 [1',2':4,5] 吡咯并 [1,2-c ] 苯并 [3',4'] 環庚烷并 [1',2':4,5] 吡咯并 [2,1-f ][1,3,2] 二氮雜環己硼烷 -9- 基 )-3,5- 二氟苯酚 ( 化合物 27.2) 向化合物27.1 (1.36 mmol，250 mg)和2,6-二氟-4-羥基苯甲醛(0.650 mmol，103 mg)在CH₂ Cl₂ (13.5 mL)中的溶液中添加p TsOH·H₂ O (0.065 mmol，8 mg)，並將反應混合物在室溫下攪拌1小時。接著添加DDQ (0.780 mmol，177 mg)，並將該混合物在室溫下攪拌1小時。添加三乙胺(3.90 mmol，542 µL)，將混合物在室溫下攪拌1小時，接著添加BF₃ ·OEt₂ (5.85 mmol，722 µL)，並將混合物在室溫下攪拌1小時。添加更多三乙胺(3.90 mmol，542 µL)，並且在室溫下攪拌30分鐘後，添加BF₃ ·OEt₂ (5.85 mmol，722 µL)，並將該混合物在室溫下攪拌另外1小時。接著將該混合物用EtOAc (30.0mL)稀釋，用3M HCl (3×30.0 mL)洗滌，乾燥(MgSO₄ )並減壓濃縮。快速層析法(甲苯→19:1的甲苯/EtOAc)得到149 mg的化合物17.2(產率為42%)，為藍色固體。¹ H NMR (400 MHz, DMSO-d ₆ ) δ 7.73 (d,J = 7.4 Hz, 1H), 7.31-7.14 (m, 4H), 6.71 (s, 1H), 6.62 (d,J = 10.0 Hz, 1H), 2.47-2.40 (m, 2H), 2.28-2.04 (m, 2H), 1.90-1.83 (m, 3H)。4-(4-(6-(4-( 二苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁酸 4-(19,19- 二氟 -6,7,11,12,13,19- 六氫 -5H -18λ⁴ ,19λ⁴ - 苯并 [3',4'] 環庚烷并 [1',2':4,5] 吡咯并 [1,2-c ] 苯并 [3',4'] 環庚烷并 [1',2':4,5] 吡咯并 [2,1-f ][1,3,2] 二氮雜環己硼烷 -9- 基 )-3,5- 二氟苯酯 (PLC-27) 向化合物27.2 (0.091 mmol，50 mg)、化合物13.3.2 (0.099 mmol，60 mg)和DMAP·p TsOH鹽(0.091 mmol，27 mg)在CH₂ Cl₂ (0.50 mL)中的溶液中添加DIC (0.364 mmol，57 µL)，並將反應混合物在室溫下攪拌1小時。接著將反應混合物濾過矽藻土並減壓濃縮。快速層析法(甲苯)得到78 mg的PLC-27 (產率為76%)，為暗紫色固體。¹ H NMR (400 MHz, 氯仿-d ) δ 8.68-8.57 (m, 2H), 8.41 (dd,J = 8.5, 1.2 Hz, 1H), 8.08-7.88 (m, 2H), 7.72-7.64 (m, 2H), 7.39-7.30 (m, 4H), 7.29-7.22 (m, 8H), 7.18-7.13 (m, 6H), 7.06-7.01 (m, 2H), 6.89 (d,J = 7.9 Hz, 2H), 6.51 (s, 2H), 2.85-2.77 (m, 2H), 2.65 (t,J = 7.4 Hz, 2H), 2.56 (t,J = 6.8 Hz, 4H), 2.35-2.18 (m, 4H), 2.18-2.09 (m, 2H), 2.01-1.91 (m, 4H), 1.22-1.13 (m, 4H)。 Example 2.27 : PLC-27

1,4,5,6 -Tetrahydrobenzo [6,7] cyclohepta [1,2- b ] pyrrole ( compound 27.1) to 1-benzocycloheptanone (10.0 mmol, 1.46 mL) at room temperature _{) Add NH 2} OH·HCl (15.0 mmol, 1.04 g) and sodium acetate (25.0 mmol, 2.05 g) to a solution of 3:1 H ₂ O/EtOH (32.5 mL), and add the reaction mixture to 95 Stir at °C for 1 hour. Then it was cooled to room temperature, filtered, washed with water (150 mL) and freeze-dried for 16 hours to obtain 1.64 g of 6,7,8,9-tetrahydro-5H-benzo[7]cycloheptene-5- Ketone oxime (94% yield) is a colorless solid, and the solid is used in subsequent synthesis steps without further purification. Add KOH to a solution of 6,7,8,9-tetrahydro-5H-benzo[7]cyclohepten-5-one oxime (5.71 mmol, 1.00 g) in DMSO (9.00 mL) at room temperature (17.1 mmol, 959 mg), and heat the reaction mixture to 140°C, then add 1,2-dichloroethane (11.4 mmol, 897 µL) in DMSO (2.00 mL) via a syringe pump within 3 hours. Then the mixture was cooled to room temperature, quenched with 1 M _{aqueous NH 4} Cl (30.0 mL) and extracted with CH ₂ Cl ₂ (3×30.0 mL). The combined organics were dried (MgSO ₄ ) and concentrated under reduced pressure. Flash chromatography (hexane→9:1, hexane/EtOAc) gave 262 mg of compound 27.1 (yield 25%) as a yellow solid. ¹ H NMR (400 MHz, chloroform- d ) δ 8.18 (br s, 1H), 7.34 (dd, J = 7.8, 1.3 Hz, 1H), 7.25-7.19 (m, 1H), 7.16 (dd, J = 7.6 , 1.6 Hz, 1H), 7.13-7.07 (m, 1H), 6.84 (t, J = 2.8 Hz, 1H), 6.17 (t, J = 2.8 Hz, 1H), 2.91 (t, J = 6.8 Hz, 2H ), 2.86-2.80 (m, 2H), 2.07-1.98 (m, 2H); ¹³ C NMR (101 MHz, chloroform- d ) δ 140.4, 131.8, 129.3, 126.8, 125.9, 125.2, 123.2, 121.8, 118.3, 111.1, 34.9, 27.8, 26.7. 4-(19,19 -Difluoro- 6,7,11,12,13,19 -hexahydro- 5 H -18λ ⁴ ,19λ ⁴ -benzo [3',4'] cycloheptano [1',2':4,5] pyrrolo [1,2- c ] benzo [3',4'] cycloheptano [1',2':4,5] pyrrolo [2,1- f ] [1,3,2] diazepine- 9- yl )-3,5 -difluorophenol ( compound 27.2) to compound 27.1 (1.36 mmol, 250 mg) and 2,6-difluoro-4 -Hydroxybenzaldehyde (0.650 mmol, 103 mg) in CH ₂ Cl ₂ (13.5 mL) was added p TsOH·H ₂ O (0.065 mmol, 8 mg), and the reaction mixture was stirred at room temperature for 1 hour . Then DDQ (0.780 mmol, 177 mg) was added, and the mixture was stirred at room temperature for 1 hour. Triethylamine (3.90 mmol, 542 µL) was added, the mixture was stirred at room temperature for 1 hour, then BF ₃ ·OEt ₂ (5.85 mmol, 722 µL) was added, and the mixture was stirred at room temperature for 1 hour. More triethylamine (3.90 mmol, 542 µL) was added, and after stirring for 30 minutes at room temperature, BF ₃ ·OEt ₂ (5.85 mmol, 722 µL) was added, and the mixture was stirred at room temperature for another 1 hour . The mixture was then diluted with EtOAc (30.0 mL), washed with 3M HCl (3×30.0 mL), dried (MgSO ₄ ) and concentrated under reduced pressure. Flash chromatography (toluene→19:1 toluene/EtOAc) gave 149 mg of compound 17.2 (42% yield) as a blue solid. ¹ H NMR (400 MHz, DMSO- d ₆ ) δ 7.73 (d, J = 7.4 Hz, 1H), 7.31-7.14 (m, 4H), 6.71 (s, 1H), 6.62 (d, J = 10.0 Hz, 1H), 2.47-2.40 (m, 2H), 2.28-2.04 (m, 2H), 1.90-1.83 (m, 3H). 4-(4-(6-(4-( Diphenylamino ) phenyl )-1,3 -di-side oxy -1 H -benzo [ de ] isoquinoline- 2(3 H ) -yl ) Phenyl ) butyric acid 4-(19,19 -difluoro- 6,7,11,12,13,19 -hexahydro- 5 H -18λ ⁴ ,19λ ⁴ -benzo [3',4'] ring Heptano [1',2':4,5] pyrrolo [1,2- c ] benzo [3',4'] cycloheptano [1',2':4,5] pyrrolo [ 2,1- f ][1,3,2] diazepine- 9- yl )-3,5 -difluorophenyl ester (PLC-27) to compound 27.2 (0.091 mmol, 50 mg), Compound 13.3.2 (0.099 mmol, 60 mg) and DMAP· p TsOH salt (0.091 mmol, 27 mg) in CH ₂ Cl ₂ (0.50 mL) were added DIC (0.364 mmol, 57 µL), and the reaction The mixture was stirred at room temperature for 1 hour. Then the reaction mixture was filtered through Celite and concentrated under reduced pressure. Flash chromatography (toluene) gave 78 mg of PLC-27 (76% yield) as a dark purple solid. ¹ H NMR (400 MHz, chloroform- d ) δ 8.68-8.57 (m, 2H), 8.41 (dd, J = 8.5, 1.2 Hz, 1H), 8.08-7.88 (m, 2H), 7.72-7.64 (m, 2H), 7.39-7.30 (m, 4H), 7.29-7.22 (m, 8H), 7.18-7.13 (m, 6H), 7.06-7.01 (m, 2H), 6.89 (d, J = 7.9 Hz, 2H) , 6.51 (s, 2H), 2.85-2.77 (m, 2H), 2.65 (t, J = 7.4 Hz, 2H), 2.56 (t, J = 6.8 Hz, 4H), 2.35-2.18 (m, 4H), 2.18-2.09 (m, 2H), 2.01-1.91 (m, 4H), 1.22-1.13 (m, 4H).

4-(4-(6-(4-( 二苯基胺基 ) 苯基 )-1,3- 二側氧基 -1H - 苯并 [de ] 異喹啉 -2(3H )- 基 ) 苯基 ) 丁醯氯 ( 化合物 28.1) 向化合物13.3.2 (0.500 mmol，300 mg)在CH₂ Cl₂ (2.50 mL)中的懸浮液中添加DMF (1滴)和草醯氯(1.00 mmol，86 µL)，並將反應混合物在室溫下攪拌2.5小時。減壓移除所有揮發物，得到315 mg化合物28.1 (產率＞99%)，為黃色/棕色固體。這種材料具有足直接用於後續合成步驟中的純度。¹ H NMR (400 MHz, 二氯甲烷-d ₂ ) δ 8.63 (dd,J = 7.5, 1.6 Hz, 2H), 8.49 (dd,J = 8.6, 1.2 Hz, 1H), 7.80-7.73 (m, 2H), 7.45-7.29 (m, 9H), 7.29-7.16 (m, 9H), 7.13-7.06 (m, 2H), 3.03 (t,J = 7.2 Hz, 2H), 2.84-2.76 (m, 3H), 2.17-2.09 (m, 2H)；¹³ C NMR (101 MHz, 二氯甲烷-d ₂ ) δ 174.3, 165.0, 164.8, 149.0, 148.0, 147.7, 141.7, 134.7, 133.7, 132.6, 131.8, 131.5, 131.4, 130.8, 130.0, 129.9, 129.8, 129.4, 129.3, 128.3, 127.3, 125.6, 124.2, 123.7, 123.1, 122.0, 47.0, 34.6, 27.1。2-(4-(3-(6,6- 二氟 -13,15- 二甲基 -12,16- 二氫 -6H -5λ⁴ ,6λ⁴ - 茚并 [2',1':4,5] 吡咯并 [1,2-c] 茚并 [2',1':4,5] 吡咯并 [2,1-f ][1,3,2] 二氮雜環己硼烷 -14- 基 ) 丙基 ) 苯基 )-6-(4-( 二苯胺基 ) 苯基 )-1H - 苯并 [de ] 異喹啉 -1,3(2H )- 二酮 (PLC-28) 在室溫下向化合物28.1 (0.200 mmol，124 mg)在DCE (2.20 mL)中的溶液中添加3-甲基-1,4-二氫茚并[1,2-b]吡咯(0.440 mmol，74 mg)在DCE (2.20 mL)中的溶液，並將反應混合物加熱至回流達16小時，在此之後將其冷卻至室溫。添加三乙胺(1.20 mmol，166 µL)，將混合物在室溫下攪拌1小時，接著添加BF₃ ·OEt₂ (1.80 mmol，222 µL)，並將混合物在室溫下攪拌3.5小時。接著將該混合物用EtOAc (30.0mL)稀釋，用3M HCl (3×30.0 mL)洗滌，乾燥(MgSO₄ )並減壓濃縮。快速層析法(3:2的己烷/EtOAc，接著1:1的甲苯/CH₂ Cl₂ )得到13 mg的PLC-28 (產率為7%)，為紫色固體。¹ H NMR (400 MHz, 二氯甲烷-d ₂ ) δ 8.6 (d,J = 7.5 Hz, 2H), 8.5 (d,J = 8.5 Hz, 1H), 8.3 (d,J = 7.7 Hz, 2H), 7.8-7.7 (m, 2H), 7.5 (d,J = 7.6 Hz, 2H), 7.5-7.4 (m, 6H), 7.4-7.3 (m, 10H), 7.2-7.2 (m, 6H), 7.1-7.1 (m, 2H), 3.6 (s, 2H), 3.2-3.1 (m, 2H), 3.0 (t,J = 7.2 Hz, 2H), 2.4 (s, 6H), 2.2-2.1 (m, 2H)。 Example 2.28 : PLC-28

4-(4-(6-(4-( Diphenylamino ) phenyl )-1,3 -di-side oxy -1 H -benzo [ de ] isoquinoline- 2(3 H ) -yl ) Phenyl ) butyryl chloride ( compound 28.1) To a suspension of compound 13.3.2 (0.500 mmol, 300 mg) in CH ₂ Cl ₂ (2.50 mL) was added DMF (1 drop) and oxalate chloride (1.00 mmol , 86 µL), and the reaction mixture was stirred at room temperature for 2.5 hours. All volatiles were removed under reduced pressure to obtain 315 mg of compound 28.1 (yield>99%) as a yellow/brown solid. This material has sufficient purity to be directly used in subsequent synthesis steps. ¹ H NMR (400 MHz, dichloromethane- d ₂ ) δ 8.63 (dd, J = 7.5, 1.6 Hz, 2H), 8.49 (dd, J = 8.6, 1.2 Hz, 1H), 7.80-7.73 (m, 2H ), 7.45-7.29 (m, 9H), 7.29-7.16 (m, 9H), 7.13-7.06 (m, 2H), 3.03 (t, J = 7.2 Hz, 2H), 2.84-2.76 (m, 3H), 2.17-2.09 (m, 2H); ¹³ C NMR (101 MHz, dichloromethane- d ₂ ) δ 174.3, 165.0, 164.8, 149.0, 148.0, 147.7, 141.7, 134.7, 133.7, 132.6, 131.8, 131.5, 131.4, 130.8, 130.0, 129.9, 129.8, 129.4, 129.3, 128.3, 127.3, 125.6, 124.2, 123.7, 123.1, 122.0, 47.0, 34.6, 27.1. 2- (4- (3- (6,6-difluoro--13,15- dimethyl -12,16- dihydro -6 H -5λ ^4, 6λ ⁴ - indeno [2 ', 1': 4 ,5] pyrrolo [1,2-c] indeno [2',1':4,5] pyrrolo [2,1- f ][1,3,2] diazepine- 14 - yl) propyl) phenyl) -6- (4- (diphenylamino) phenyl) -1 H - benzo [de] isoquinoline -1,3 (2 H) - dione (PLC-28 ) To a solution of compound 28.1 (0.200 mmol, 124 mg) in DCE (2.20 mL) was added 3-methyl-1,4-dihydroindeno[1,2-b]pyrrole (0.440 mmol , 74 mg) in DCE (2.20 mL), and the reaction mixture was heated to reflux for 16 hours, after which it was cooled to room temperature. Triethylamine (1.20 mmol, 166 µL) was added, the mixture was stirred at room temperature for 1 hour, then BF ₃ ·OEt ₂ (1.80 mmol, 222 µL) was added, and the mixture was stirred at room temperature for 3.5 hours. The mixture was then diluted with EtOAc (30.0 mL), washed with 3M HCl (3×30.0 mL), dried (MgSO ₄ ) and concentrated under reduced pressure. Flash chromatography (3:2 hexane/EtOAc followed by 1:1 toluene/CH ₂ Cl ₂ ) gave 13 mg of PLC-28 (7% yield) as a purple solid. ¹ H NMR (400 MHz, dichloromethane- d ₂ ) δ 8.6 (d, J = 7.5 Hz, 2H), 8.5 (d, J = 8.5 Hz, 1H), 8.3 (d, J = 7.7 Hz, 2H) , 7.8-7.7 (m, 2H), 7.5 (d, J = 7.6 Hz, 2H), 7.5-7.4 (m, 6H), 7.4-7.3 (m, 10H), 7.2-7.2 (m, 6H), 7.1 -7.1 (m, 2H), 3.6 (s, 2H), 3.2-3.1 (m, 2H), 3.0 (t, J = 7.2 Hz, 2H), 2.4 (s, 6H), 2.2-2.1 (m, 2H) ).

3,5- 二氯 -4-(19,19- 二氟 -6,7,11,12,13,19- 六氫 -5H-18l4,19l4- 苯并 [3',4'] 環庚烷并 [1',2':4,5] 吡咯并 [1,2-c] 苯并 [3',4'] 環庚烷并 [1',2':4,5] 吡咯并 [2,1-f][1,3,2] 二氮雜環己硼烷 -9- 基 ) 苯酚 ( 化合物 29.1) ： 將100 mL的2頸圓底燒瓶裝配空氣冷凝器和攪拌棒。向該燒瓶中添加化合物1,4,5,6-四氫苯并[6,7]環庚烷并[1,2-b]吡咯(化合物27.1，220 mg，1.20 mmol)和4-羥基-2,6-二氯苯甲醛(115 mg，0.61 mmol)，之後添加無水二氯乙烷(15 ml)。將該反應混合物用氬氣鼓泡30分鐘，接著添加三氟乙酸(TFA)(3滴)。將反應溶液加熱至45℃隔夜。在冰水浴中將反應冷卻至0℃後，添加四氯對苯醌(200 mg，0.81 mmol)。將反應保持在0℃持續20分鐘。接著在0℃添加BF₃ ·OEt₂ (0.8 mL，6.5 mmol)和Et₃ N (0.5 mL，3.6 mmol)。將反應混合物加熱至50℃達1小時。將反應混合物用矽膠裝載，並藉由使用己烷的DCM溶液(0-70%)作為溶離劑進行快速層析法來純化，以提供純BODIPY化合物29.1，為金棕色固體，115 mg，產率為33%。MS (APCI)：C₃₃ H₂₄ BCl₂ F₂ N₂ O ([M-H]⁺ )的計算值=584；實測值：584。¹ H NMR (400 MHz, CDCl₃ ) 8.09 (dd, J = 4.0 Hz, 2.0 Hz, 2H), 7.32 (dddd, J = 13.2 Hz, 7.2 Hz, 7.2 Hz, 2.0 Hz, 4H), 7.22 (dd, J = 6.4 Hz, 2.0 Hz, 2H), 6.99 (s, 2H), 6.43 (s, 2H)c, 5.77 (bs, 1H), 2.63 (dd, J = 6.8 Hz, 6.8 Hz, 4H), 2.32 (bs, 4H), 2.03 (ddd, J = 14.0 Hz, 6.8 Hz, 6.8 Hz, 4H)。PLC-29 將3,5-二氯-4-(19,19-二氟-6,7,11,12,13,19-六氫-5H-18l4,19l4-苯并[3',4']c環庚烷并[1',2':4,5]吡咯并[1,2-c]苯并[3',4']環庚烷并[1',2':4,5]吡咯并[2,1-f][1,3,2]二氮雜環己硼烷-9-基)苯酚(化合物29.1，29 mg，0.0495 mmol)、4-(4-(6-(4-(二苯基胺基)苯基)-1,3-二側氧基-1H-苯并[de]異喹啉-2(3H)-基)苯基)丁酸(化合物13.3.2，48 mg，0.08 mmol)、DIC(0.1 mL，0.63 mmol)、DMAP/TsOH鹽(29 mg，0.1 mmol)在無水二氯甲烷(5 mL)中的混合物在室溫下攪拌48小時。將所得混合物裝載到矽膠上，並藉由使用己烷/二氯甲烷(40%à100%二氯甲烷)溶離劑進行快速層析法來純化。收集所需溶離份。在移除溶劑並用甲醇洗滌之後，在過濾獲得了暗紅色固體並風乾(PLC-29 ，43 mg，產率為74%)。LCMS (APCI)：C₇₃ H₅₃ BCl₂ F₂ N₄ O₄ 的計算值：1168.3；實測值：1168。¹ H NMR (400 MHz, TCE-d2) δ 8.60-8.53 (m, 2H), 8.43 (dd,J = 8.6, 1.1 Hz, 1H), 7.97 (t,J = 4.6 Hz, 2H), 7.76-7.68 (m, 2H), 7.39 (d,J = 8.2 Hz, 2H), 7.36-7.19 (m, 16H), 7.15 (d,J = 8.0 Hz, 6H), 7.03 (t,J = 7.3 Hz, 2H), 6.40 (s, 2H), 2.83 (t,J = 7.5 Hz, 2H), 2.68 (t,J = 7.4 Hz, 2H), 2.60-2.50 (m, 4H), 2.24 (bs, 4H), 2.14 (q,J = 7.6 Hz, 2H), 1.96 (t,J = 7.1 Hz, 4H)。 Example 2.29 : PLC-29

3,5- Dichloro- 4-(19,19 -difluoro- 6,7,11,12,13,19 -hexahydro- 5H-18l4,19l4 -benzo [3',4'] cycloheptane And [1',2':4,5] pyrrolo [1,2-c] benzo [3',4'] cycloheptano [1',2':4,5] pyrrolo [2, 1-f][1,3,2] diazepine- 9- yl ) phenol ( Compound 29.1) : A 100 mL 2-neck round bottom flask was equipped with an air condenser and a stir bar. The compound 1,4,5,6-tetrahydrobenzo[6,7]cycloheptano[1,2-b]pyrrole (compound 27.1, 220 mg, 1.20 mmol) and 4-hydroxy- 2,6-Dichlorobenzaldehyde (115 mg, 0.61 mmol), followed by anhydrous dichloroethane (15 ml). The reaction mixture was bubbled with argon for 30 minutes, and then trifluoroacetic acid (TFA) (3 drops) was added. The reaction solution was heated to 45°C overnight. After cooling the reaction to 0°C in an ice water bath, tetrachloro-p-benzoquinone (200 mg, 0.81 mmol) was added. The reaction was kept at 0°C for 20 minutes. _{Then BF 3} ·OEt ₂ (0.8 mL, 6.5 mmol) and Et ₃ N (0.5 mL, 3.6 mmol) were added at 0°C. The reaction mixture was heated to 50°C for 1 hour. The reaction mixture was loaded with silica gel and purified by flash chromatography using hexane in DCM (0-70%) as the eluent to provide pure BODIPY compound 29.1 as a golden brown solid, 115 mg, yield Is 33%. MS (APCI): _{calculated value of C 33} H ₂₄ BCl ₂ F ₂ N ₂ O ([MH] ⁺ )=584; actually measured value: 584. ¹ H NMR (400 MHz, CDCl ₃ ) 8.09 (dd, J = 4.0 Hz, 2.0 Hz, 2H), 7.32 (dddd, J = 13.2 Hz, 7.2 Hz, 7.2 Hz, 2.0 Hz, 4H), 7.22 (dd, J = 6.4 Hz, 2.0 Hz, 2H), 6.99 (s, 2H), 6.43 (s, 2H)c, 5.77 (bs, 1H), 2.63 (dd, J = 6.8 Hz, 6.8 Hz, 4H), 2.32 ( bs, 4H), 2.03 (ddd, J = 14.0 Hz, 6.8 Hz, 6.8 Hz, 4H). PLC-29 will 3,5-dichloro-4-(19,19-difluoro-6,7,11,12,13,19-hexahydro-5H-18l4,19l4-benzo[3',4']ccycloheptano[1',2':4,5]pyrrolo[1,2-c]benzo[3',4']cycloheptano[1',2':4,5] Pyrrolo[2,1-f][1,3,2]diazepine-9-yl)phenol (compound 29.1, 29 mg, 0.0495 mmol), 4-(4-(6-(4 -(Diphenylamino)phenyl)-1,3-di-side oxy-1H-benzo[de]isoquinolin-2(3H)-yl)phenyl)butyric acid (compound 13.3.2, A mixture of 48 mg, 0.08 mmol), DIC (0.1 mL, 0.63 mmol), DMAP/TsOH salt (29 mg, 0.1 mmol) in dry dichloromethane (5 mL) was stirred at room temperature for 48 hours. The resulting mixture was loaded on silica gel and purified by flash chromatography using hexane/dichloromethane (40%→100% dichloromethane) eluent. Collect the required fractions. After removing the solvent and washing with methanol, a dark red solid was obtained after filtration and air-dried ( PLC-29 , 43 mg, 74% yield). LCMS (APCI): _{calculated value for C 73} H ₅₃ BCl ₂ F ₂ N ₄ O ₄ : 1168.3; found value: 1168. ¹ H NMR (400 MHz, TCE-d2) δ 8.60-8.53 (m, 2H), 8.43 (dd, J = 8.6, 1.1 Hz, 1H), 7.97 (t, J = 4.6 Hz, 2H), 7.76-7.68 (m, 2H), 7.39 (d, J = 8.2 Hz, 2H), 7.36-7.19 (m, 16H), 7.15 (d, J = 8.0 Hz, 6H), 7.03 (t, J = 7.3 Hz, 2H) , 6.40 (s, 2H), 2.83 (t, J = 7.5 Hz, 2H), 2.68 (t, J = 7.4 Hz, 2H), 2.60-2.50 (m, 4H), 2.24 (bs, 4H), 2.14 ( q, J = 7.6 Hz, 2H), 1.96 (t, J = 7.1 Hz, 4H).

Example 3 Production of color conversion film A glass substrate was basically prepared in the following manner. A 1.1 mm thick glass substrate measuring 1 inch × 1 inch was cut into a certain size. Then the glass substrate was washed with detergent and deionized (DI) water, rinsed with fresh deionized water, and ultrasonically treated for about 1 hour. The glass was then immersed in isopropyl alcohol (IPA) and ultrasonicated for about 1 hour. Next, the glass substrate was immersed in acetone and ultrasonically processed for about 1 hour. The glass was then removed from the acetone bath and dried with nitrogen at room temperature.

Preparation of poly(methyl methacrylate) (PMMA) (the average molecular weight measured by GPC purchased from MilliporeSigma, Burlington, MA, USA is 120,000) 20 weight of copolymer in cyclopentanone (purity of 99.9%) % Solution. The prepared copolymer was stirred at 40°C overnight. [PMMA] CAS: 9011-14-7; [Cyclopentanone] CAS: 120-92-3

The 20% PMMA solution (4 g) prepared above was added to 3 mg of the photoluminescent composite prepared as described above in a sealed container, and mixed for about 30 minutes. Next, the PMMA/phosphor solution was spin-coated on the prepared glass substrate at 1000 RPM for 20 seconds, and then spin-coated on the prepared glass substrate at 500 RPM for 5 seconds. The thickness of the resulting wet coating was about 10 μm. Before spin coating, the sample was covered with aluminum foil to prevent exposure of the sample to light. In this way, three samples were prepared for each of emission/FWHM and quantum yield, respectively. The spin-coated sample was baked in a vacuum oven at 80°C for 3 hours to evaporate the remaining solvent.

The 1 inch x 1 inch sample was inserted into a Shimadzu UV-3600 UV-VIS-NIR spectrophotometer (Shimadzu Instruments, Inc., Columbia, MD, USA). All equipment operations are performed in a nitrogen-filled glove box. The obtained absorption/emission spectrum of PC-8 is shown in Figure 1, and the obtained absorption/emission spectrum of PC-33 is shown in Figure 2.

Use a Fluorolog spectrofluorometer (Horiba Scientific, Edison, NJ, USA) to measure the fluorescence spectrum of the 1 inch × 1 inch film sample prepared as described above. The excitation wavelength of the Fluorolog spectrofluorometer is set to the corresponding maximum absorption wavelength . The maximum emission and FWHM are shown in Table 1.

Quantarus-QY spectrophotometer (Hamamatsu Inc., Campbell CA, USA) was used to measure the quantum yield of the 1 inch × 1 inch sample prepared as described above. The Quantarus-QY spectrophotometer was excited at the corresponding maximum absorption wavelength. of. The results are reported in Table 1.

The results of film characterization (absorption peak wavelength, FWHM and quantum yield) are shown in Table 1 below. Table 1.

Fig. 1 is a graph depicting the absorption spectrum and the emission spectrum of an embodiment of the photoluminescent composite. Fig. 2 is a graph depicting the absorption spectrum and the emission spectrum of an embodiment of the photoluminescent composite.

Claims (21)

A photoluminescence composite comprising: a blue light-absorbing naphthalenedicarboxylic acid derivative; a BODIPY moiety; and a linking group, wherein the linking group covalently links the naphthalenedicarboxylic acid derivative To the BODIPY part; wherein the blue light-absorbing naphthalenedicarboxylic acid derivative is represented by the following chemical formula:

; Wherein X is NR ⁹ or O; Wherein R ⁹ is H, substituted aryl, or the linking group; Wherein n is 0 or 1; Wherein R ¹⁰ is H, methyl, connected to adjacent benzene ring A direct bond forming a carbazole or the linking group; wherein R ¹¹ is H or a methyl group; wherein the linking group is a substituted ester group or a substituted aralkyl group; wherein the naphthalenedicarboxylic acid is derived The substance absorbs the light energy of the first excitation wavelength and transfers the energy to the BODIPY portion, wherein the BODIPY portion absorbs the energy from the naphthalenedicarboxylic acid derivative and emits light energy of a second higher wavelength; and wherein the photoluminescence The emission quantum yield of the composite is greater than 80%. Such as the photoluminescence composite of claim 1, wherein the BODIPY part is represented by the following chemical formula:

, Wherein R ¹ and R ^{6 are} independently H, alkyl, alkenyl, or alkynyl; wherein R ³ and R ^{4 are} independently H, or C ₁ -C ₂ alkyl; wherein R ² and R ^{5 are} independently It is H, alkyl, alkenyl, alkynyl, cyano (-CN), alkyl ester, or aryl ester; wherein R ¹ and R ² can be connected together to form another cyclic hydrocarbon ring structure or a polycyclic hydrocarbon ring Structure; Wherein R ⁵ and R ⁶ can be connected together to form another monocyclic hydrocarbon ring structure or polycyclic hydrocarbon ring structure; Wherein G ⁷ is L or:

; Wherein R ⁷ and R ^{8 are} independently H, methyl, fluorine, chlorine, or alkoxy; and wherein L represents the linking group. The photoluminescent composite of claim 1 or 2, wherein X is NR ⁹ , n is 0, R ⁹ is a substituted aryl group, R ¹⁰ is a substituted ester linker, and R ¹¹ is H. Such as the photoluminescent composite of claim 3, wherein R ⁹ is

. The photoluminescent composite of claim 1, wherein X is NR ⁹ , n is 0 or 1, R ^{9 is} the linking group, R ¹⁰ is H, and R ¹¹ is H. The photoluminescent composite of claim 1, wherein X is NR ⁹ , n is 0 or 1, R ^{9 is} the linking group, R ¹⁰ is a methyl group, and R ¹¹ is a methyl group. The photoluminescent composite of claim 1, wherein X is NR ⁹ , n is 1, R ^{9 is} the linking group, R ¹⁰ is a direct bond to the adjacent benzene ring to form a carbazole, and R ¹¹ is H. The photoluminescent composite of claim 1, wherein X is O, n is 1, R ^{10 is} the linking group, and R ¹¹ is H. For example, the photoluminescent composite of claim 2, wherein R ¹ , R ³ , R ⁴ and R ⁶ are all methyl groups, R ² and R ⁵ are both alkyl esters or aryl esters, and R ⁷ and R ⁸ are both Methyl group, and L is the linking group. Such as the photoluminescent composite of claim 2, wherein R ¹ , R ³ , R ⁴ and R ⁶ are all methyl groups, R ² and R ⁵ are both cyano ^{groups, R 7} and R ⁸ are both methyl groups, and L Is the linking group. Such as the photoluminescent composite of claim 2, wherein R ¹ , R ³ , R ⁴ and R ⁶ are all methyl groups, R ² and R ⁵ are all aryl esters, and R ⁷ and R ^{8 are} independently methyl groups, Fluorine, chlorine or methoxy, and L is the linking group. The photoluminescent composite of claim 2, wherein R ¹ and R ^{2 are} connected together to form a polycyclic hydrocarbon ring structure, R ³ and R ⁴ are both H or methyl, and R ⁵ and R ^{6 are} connected together to form In a polycyclic hydrocarbon ring structure, R ⁷ and R ⁸ are H, methyl, halo, or methoxy, and L is the linking group. The photoluminescent composite of claim 1 or 2, wherein the linking group is:

. The photoluminescent composite of claim 1 or 2, wherein the linking group is

. The photoluminescent composite of claim 1 or 2, wherein the composite is one of the following structures:

. A color conversion film, which includes: Transparent substrate layer; A color conversion layer, wherein the color conversion layer includes a resin matrix, and For the photoluminescent compound of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15, the photoluminescent compound is dispersed in the resin matrix. The color conversion film of claim 16, wherein the color conversion film also contains a singlet oxygen quencher or a radical scavenger. Such as the color conversion film of claim 16 or 17, wherein the thickness of the film is between 10 μm and 200 μm. The color conversion film of claim 16 or 17, wherein the film absorbs light in the wavelength range of about 400 nm to about 480 nm, and emits light in the wavelength range of 510 nm to about 560 nm, or 575 nm to about 645 nm Light in the wavelength range. A backlight unit including the color conversion film as claimed in claim 16 or 17. A display device including a backlight unit as claimed in claim 20.

Images